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Summary 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1, gene name HSD11B1) is a 
ubiquitously expressed enzyme that converts glucocorticoid receptor-inert cortisone to 
receptor-active cortisol. HSD11B1 expression is regulated in a highly tissue-specific manner 
by immunomodulatory and metabolic regulators. Multiple evidences support a causal role for 
11β-HSD1 in the current obesity epidemic. In obese people, HSD11B1 expression is increased 
in adipose tissue, but typically decreased in liver, and the underlying tissue-specific 
mechanisms are largely unknown.  
 
In this context, a potential role of microRNAs (miRNAs) was investigated. Four different 
miRNA target prediction tools were used to choose possible candidates and a publicly 
available miRNA expression atlas to further select candidates expressed in hepatocytes. Using 
a luciferase reporter assay, where the complete 3’UTR of HSD11B1 mRNA was inserted 
downstream of the gene for firefly luciferase, three potential miRNAs, hsa-miR-561, -579 and 
-340 were identified as potential negative regulators of HSD11B1 expression. Moreover, 
disruption of the corresponding microRNA response elements (MREs) abolished repression 
of luciferase activity for hsa-miR-561 and -579, but not completely for hsa-miR-340. 
Therefore, hsa-miR-561 and hsa-miR-579-mediated downregulation of HSD11B1 expression 
are strictly dependent on the binding of miR-561- and miR-579-MRE in the 3’UTR of 
HSD11B1 mRNA. Levels of firefly luciferase mRNA were not changed by miR-561 and -
579; and levels of endogenous HSD11B1 mRNA were as well unchanged by miR-561 and -
579, indicating a mechanism based on translational repression rather than on mRNA 
degradation. Interestingly, hsa-miR-579 was still performing downregulation of HSD11B1 
expression after treatment with glucocorticoids to induce HSD11B1 expression, due to 
different regulatory mechanisms for HSD11B1 expression by glucocorticoids and miRNAs in 
a dual luciferase assay system. The function of miR-561 and -579 could be blocked by anti-
microRNA oligonucleotides (AMOs). MiR-561 and -579 were amplified by specific stem-
loop reverse transcription primers and specific PCR primers from human hepatocytes and 
HepG2 cells. Although their relative contribution to HSD11B1 expression remains unclear, 
literature findings and a pathway enrichment analysis of miR-561 and -579 target mRNAs 
support a role of these miRNAs in glucocorticoid metabolism/signalling and associated 
diseases.  
 
 
                                                                                                                                                                                                     V 
Zusammenfassung 
Die 11β-Hydroxysteroid-Dehydrogenase Typ 1 (11β-HSD1, Gen HSD11B1) ist ein 
ubiquitäres Enzym, welches Glucocorticoidrezeptor-inaktives Cortison in Rezeptor-aktives 
Cortisol umwandelt. Die Expression von HSD11B1 wird höchst gewebespezifisch von 
immunomodulatorischen und metabolischen Regulatoren beeinflusst. Zahlreiche Befunde 
sprechen für eine kausale Rolle der 11β-HSD1 in der aktuellen Übergewichtsepidemie. 
Übergewichtige Patienten weisen erhöhte HSD11B1-Expression in Fettgewebe auf, die 
typischerweise mit erniedrigten Levels in der Leber einhergeht. Die diesem Phänomen 
zugrundeliegenden gewebespezifischen Mechanismen sind weitgehend unverstanden.  
In diesem Zusammenhang wurde in der vorliegenden Arbeit eine potentielle Rolle von 
microRNAs (miRNAs) untersucht. Vier unterschiedliche miRNA-Vorhersageprogramme 
wurden verwendet, um mögliche Kandidaten zu identifizieren sowie ein öffentlich 
zugänglicher miRNA-Expressionsatlas, um die Auswahl auf in der Leber exprimierte 
Kandidaten einzuschränken. Mit Hilfe eines Luciferase-Reporter-Assays, in dem die 
komplette 3‘-UTR der HSD11B1 mRNA an das Gen für Glühwürmchen-Luciferase gekoppelt 
war, identifizierten wir schließlich drei miRNAs, nämlich hsa-miR-561, -579 und -340, als 
potentielle negative Regulatoren der HSD11B1-Expression. Mutation oder Deletion der 
entsprechenden miRNA-Response-Elemente (MRE) hob die Repression der Luciferase-
Aktivität für hsa-miR-561 and -579 vollständig auf, aber nicht für hsa-miR-340. Daraus folgt, 
dass die hsa-miR-561- und hsa-miR-579-vermittelte Herunterregulation der HSD11B1- 
Expression streng abhängig von der Bindung an die entsprechenden MREs in der 3’-UTR der 
HSD11B1-mRNA ist. Hsa-miR-561 und hsa-miR-579 veränderten dabei aber weder die 
Glühwürmchen-Luciferase-Transkriptspiegel noch die Levels der endogenen HSD11B1-
mRNA, was auf translationelle Repression statt mRNA-Abbau als Mechanismus hinweist. 
Außerdem wurde beobachtet, dass im Luciferase-Assay-System hsa-miR-579 auch nach 
glucocorticoid-induzierter HSD11B1-Expression noch in der Lage ist, die selbige 
herunterzuregulieren, aufgrund der Regulation auf unterschiedlichen Ebenen der 
Proteinbiosynthese. Weiterhin konnten miRNA-561 und -579 unter Verwendung von 
spezifischen Haarnadelstruktur-Primern für die Reverse Transkription und spezifischen 
Primern für die PCR aus normalen und malignen humanen Hepatozyten amplifiziert werden. 
Obwohl ihr relativer Beitrag zur Regulation der HSD11B1-Expression unklar bleibt, sprechen 
sowohl Literaturbefunde als auch eine Stoffwechselweg-Enrichment-Analyse ihrer Zielgene 
für eine Rolle dieser miRNAs in Glucocorticoid-Metabolismus/Signaltransduktion und damit 
assoziierten Krankheiten. 
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Abbreviations 
11β-HSD1                             11β-Hydroxysteroid dehydrogenase type 1 
μg                                           microgram 
μl                                            microliter 
aa                                            amino acid 
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1 Introduction 
1.1 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1, gene name HSD11B1) belongs to the 
short-chain dehydrogenase/reductase (SDR) superfamily. 11β-HSD1 is a microsomal enzyme 
responsible for the reversible interconversion of active 11β-hydroxyglucocorticoids into 
inactive 11-ketosteroids and, by this mechanism, regulates access of glucocorticoids to the 
glucocorticoid receptor (Blum et al., 2000). Although bidirectional in vitro, in vivo it is 
believed to function as a reductase generating active glucocorticoid at a prereceptor level, 
enhancing glucocorticoid receptor activation (Tomlinson et al., 2004). 11β-HSD1 is a 
ubiquitously expressed enzyme, but occurs at highest levels in glucocorticoid target tissues. 
Moreover, HSD11B1 expression is regulated in a highly tissue-specific manner by 
immunomodulatory and metabolic regulators. 11β-HSD1 is responsible for intracellular 
glucocorticoid activation and appears to play a central role in obesity (Rask et al., 2001; 
Tiosano et al., 2003) and the associated metabolic syndrome (Tomlinson et al., 2001a; 
Andrews et al., 2003; Duplomb et al., 2004; Bays et al., 2007). Over the past ten years, 11β-
HSD1 has emerged as a major potential drug target in the prevention of obesity (Livingstone 
et al., 2003), type 2 diabetes (Andrews et al., 2003) or other metabolic syndrome symptoms 
(Nuotio-Antar et al., 2007). 
 
1.1.1 The 11β-Hydroxysteroid dehydrogenase (11β-HSD) system 
11β-Hydroxysteroid dehydrogenase (11β-HSD) was designated the number EC1.1.1.146 by 
the Nomenclature Committee of the International Union of Biochemistry. Two isozymes of 
11β-HSD, 11β-HSD1 and 11β-HSD2, catalyse the interconversion of hormonally active 
cortisol and inactive cortisone in human (Figure 1.1). The type 1 or ‘liver’ isozyme was the 
first to be characterized (Amelung et al., 1953) about 50 years ago, whereas the type 2 or 
‘kidney’ isozyme was discovered in the late 1980s to mid-1990s (Edwards et al., 1988; 
Castello et al., 1989; Rundle et al., 1989). Both isozymes belong to the short-chain 
dehydrogenase/reductase (SDR) superfamily. The identity of 11β-HSD1 and 11β-HSD2 on 
the amino acid level is approximately 25%, and both enzymes are anchored in the 
endoplasmic reticulum (ER) with hydrophobic domains (Tsigelny et al., 1995). The tissue-
specific expression of the isozymes plays a crucial role in regulating glucocorticoid and 
mineralocorticoid receptor activation. 11β-HSD1 was shown to act as a low-affinity 
NADP(H)-dependent enzyme. 11β-HSD1 displays reductase and dehydrogenase activities in 
vitro, but the dominant reaction direction in vivo is reduction, thus generating receptor-active 
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cortisol from inactive cortisone. Hence, in glucocorticoid target tissues, such as liver, lung, 
and adipose tissue, 11β-HSD1 regulates the exposure of active glucocorticoids to the 
glucocorticoid receptor. In contrast, 11β-HSD2 is a high-affinity NAD-dependent enzyme 
which shows almost no reductase activity (Walker et al., 1992), suggesting that the enzyme is 
a unidirectional dehydrogenase. 11β-HSD2 is found principally in mineralocorticoid target 
tissues, such as kidney, colon, and placenta, where it protects the mineralocorticoid receptor 
from cortisol excess. The characteristics of 11β-HSD1 and 11β-HSD2 isozymes are 
summarized in Table 1.1. However, the work in this thesis focuses on 11β-HSD1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Predominant reaction directions of 11β-HSD1 and 11β-HSD2 in vivo. 
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                                               11β-HSD1                              11β-HSD2 
Chromosomal location           1q32.2                                     16q22 
Size                                        Gene: 30 kb, 6 exons               6.2 kb, 5 exons 
                                               Protein: 292 aa, 34 kD             405 aa, 44 kD 
Enzyme family                       SDR superfamily                    SDR superfamily 
Distribution                            Ubiquitous (liver, adipose       Aldosterone target tissue 
                                               tissue, lung, brain)                    (kidney, colon, placenta) 
Cofactor                                  NADP(H)                                 NAD 
Enzyme kinetics                     In vitro bidirectional                Only dehydrogenase 
                                               In vivo mainly reductase,          High affinity 
                                               Low affinity (Km∼μM)              (Km∼nM) 
Physiological role                  Regulates cortisol to                 Protects mineralocorticoid 
                                               glucocorticoid receptor              receptor from cortisol  
 
 
1.1.2 Human HSD11B1 gene and alternative promoter usage 
1.1.2.1 Human HSD11B1 gene 
The human HSD11B1 gene was firstly cloned and isolated from a human testis cDNA library 
by hybridization with a previously isolated rat 11β-HSD1 cDNA clone (Tannin et al., 1991). 
Hybridization of the human 11β-HSD1 cDNA to a human-hamster hybrid cell panel localized 
the single corresponding HSD11B1 gene to chromosome 1 (1q32-41). Human HSD11B1 gene 
consists of six exons (182 bp, 130 bp, 111 bp, 185 bp, 143 bp and 617 bp, respectively) and 
five introns (776 bp, 767 bp, 120 bp, 25,300 bp and 1,700 bp, respectively) (Figure 1.2). The 
human 11β-HSD1 cDNA predicted a protein of 292 amino acids and was 77% identical at the 
amino acid level to the rat 11β-HSD1 cDNA (Tannin et al., 1991). Originally, the human 
HSD11B1 gene was thought to be approximately 9 kb in size; however, subsequent studies 
revealed a much larger than previously recognized intron 4 of approximately 25 kb, 
expanding the size of the HSD11B1 gene to approximately 30 kb (Draper et al., 2002). 
 
 
 
Table 1.1 Direct comparisons between the characteristics of 11β-HSD1 and 11β-HSD2 
isozymes. (Blum et al., 2003; Draper et al., 2005)
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There are few reports describing polymorphisms in and around the HSD11B1 gene locus and 
few polymorphisms have been identified in the HSD11B1 gene. To date, 39 polymorphisms 
are documented in the GenBank single nucleotide polymorphisms (SNP) database (dbSNP at 
http://www.ncbi.nim.nih.gov/SNP/). All but one polymorphism is located in non-coding 
regions of the gene; 31 SNPs are within intron 4, one SNP is located in the 3’-untranslated 
region, and seven SNPs are located within 2 kb of the mRNA transcript (three in 5’ regions of 
the gene and four in 3’ regions of  the gene).  
 
1.1.2.2 Alternative promoter usage 
Expression of human HSD11B1 is highly tissue-specific and controlled by two distinct 
promoters, an aspect which to date has been studied very little. However, studies in the mouse 
have shown that both promoters are active in liver, lung, adipose tissue and brain (Bruley et 
al., 2006). Alternative promoter usage in expression of murine Hsd11b1 and human 
HSD11B1, as transcription from the distal promoter P1 or the proximal promoter P2,  results 
in distinct transcript variants differing in the 5’-untranslated region (UTR), which are 
translated to the same protein. A schematic illustration depicting the two distinct transcript 
variants is shown in Figure 1.3. Little work on alternative promoter usage has been published 
for the human HSD11B1 gene, but the evidence for corresponding alternative transcripts can 
be found in public databases (NCBI, http://www.ncbi.nlm.nih.gov/; Ensembl Genome 
Browser, http://www.ensembl.org/).  In our lab, Staab et al. (2011) used 5’UTR-specific 
primers for their detection by semi-quantitative PCR and also established a quantitative real-
time PCR method using 5’UTR-specific fluorescent probes in combination with 5’-UTR-
specific primers for absolute quantification of the two human transcripts in a duplex approach. 
The combined results demonstrated that transcription from P1 (transcript from the distal 
promoter P1) predominated in the human tumor cell lines A431 and HT-29 and contributed 
significantly to overall HSD11B1 expression in human lung (Staab et al., 2011). Transcription 
Figure 1.2 Organization of the human HSD11B1 gene. Gray boxes indicate the 5’- and 3’-UTR, Open 
boxes indicate coding exons (1-6), and intervening solid lines indicate introns (the dashed line of intron 4, 
corresponding to 25.3 kb, is not to scale).  
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from P2 (transcript from the proximal promoter P2) predominated in most tissues and cell 
lines assessed, including human liver, human lung, human subcutaneous adipose tissue, and 
the cell lines A549, Caco-2, C2C12 and 3T3-L1 (Staab et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.3 11β-HSD1 and glucocorticoid action 
Glucocorticoids (GCs) are a vital class of steroid hormones that are secreted by the adrenal 
cortex. The secretion is regulated by adrenocorticotrophic hormone (ACTH) under the control 
of the hypothalamic-pituitary-adrenal axis (HPA). Glucocorticoids play a key role in the 
modulation of immune and inflammatory processes, in the regulation of energy metabolism, 
in cardiovascular homeostasis, and in the body’s response to stress. Multiple factors regulate 
glucocorticoid secretion, such as the abundance of plasma binding proteins and glucocorticoid 
receptor (GR). 11β-HSD1 has been identified as tissue-specific glucocorticoid activating 
enzyme and thus as an additional intracellular determinant in the glucocorticoid signaling 
pathways. Within the cell, 11β-HSD1 functions as an important pre-receptor regulator by 
converting the inert 11-ketoforms 11-dehydrocorticosterone in rodents and cortisone in 
human to the receptor-active hydroxyforms corticosterone and cortisol, respectively. When 
not activated by ligand, the GR is retained in the cytoplasm by the association with 
chaperones (Yudt et al., 2002). Once activated by the ligand, the GR-chaperone complex 
dissociates and the GR is translocated rapidly into the nucleus where it binds to the promoter 
region of glucocorticoid–responsive genes and leads to induction or repression of gene 
transcription. Hence, 11β-HSD1 regulates glucocorticoid access to the glucocorticoid receptor 
Figure 1.3 Schematic illustration of the two distinct transcripts of human HSD11B1. The HSD11B1 is 
regulated by two different promoters, leading to two distinct transcript variants that differ in the 5’-UTR. Both 
transcripts have the same coding sequence and 3’-UTR. Hence both transcripts code for the same 11β-HSD1 
protein. 
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and can thus be considered an enzymatic pre-receptor regulator in the signaling pathway of 
glucocorticoid hormones. 
 
1.1.4 Localization of 11β-HSD1 
Numerous studies have assessed HSD11B1 expression using different methodologies that 
include PCR, RNase protection assays, Western blotting, immunohistochemistry, 
immunocytochemistry, Northern blotting and specific enzyme assays. Table 1.2 gives a 
comprehensive list of the tissue-specific distribution of 11β-HSD1 in different species. It 
seems that 11β-HSD1 is expressed in many tissues throughout the body. 11β-HSD1 is highly 
expressed in glucocorticoid target tissues including liver and lung, at modest levels expressed 
in adipose tissue and brain, and also found in a number of other tissues, including heart, eye, 
bone and ovary. 
 
 
 
Tissue (11β-HSD1)                                           References 
Hepatobiliary system 
    Human liver (centripetal distribution)           Ricketts et al., 1998; Brereton et al., 2001   
    Human pancreatic islets                                 Brereton et al., 2001 
    Rodent pancreatic islets                                 Davani et al., 2000 
    Rat liver                                                          Nwe et al., 2000 
Adrenal 
Human adrenal cortex                                    Ricketts et al.,1998; Brereton et al., 2001 
Lung 
    Lung (rodent)                                                 Bruley et al., 2006 
Heart 
Rat cardiac myocytes                                     Sheppard et al., 2002 
    Rat cardiac fibroblasts                                    Sheppard et al., 2002 
Kidney 
    Human kidney medulla                                   Whorwood et al., 1995 
Central nervous system 
    Human cerebellum                                          Whorwood et al., 1995 
Table 1.2 Tissue- and species-specific expression of 11β-HSD1 (Tomlinson et al., 2004). 
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    Rodent hippocampus, brain stem                    Jellinck et al., 1999 
    Rat spinal cord                                                Moisan et al., 1990 
    Human microglia                                            Gorrfried-Blackmore et al., 2010 
Gonad 
Rat epididymis                                                Waddell et al., 2003 
Human granulosa-lutein cells                         Michael et al., 1993 
Human testis                                                   Tannin et al., 1991 
Rat Leydig cells                                              Leckie et al., 1998 
Rat testis                                                         Nwe et al., 2000 
Bone 
Human osteoblasts                                          Cooper et al., 2000 
Human osteoclasts                                          Cooper et al., 2000 
Connective tissues 
Human adipose tissue                                     Bujalska et al., 1997 
    Human skeletal myoblasts                              Whorwood et al., 2002 
Human skin fibroblasts                                  Hammami and Siiteri, 1991 
Lymphoid tissue 
Human spleen                                                 Hennebold et al., 1996 
Human macrophage                                        Thieringer et al., 2001 
Human thymus                                               Whorwood et al., 1995 
Human lymph nodes                                      Whorwood et al., 1995 
Colon 
Human lamina propria and the                       Whorwood et al., 1994 
    surface epithelium 
Eye 
Rat nonpigmented ciliary epithelium             Stokes et al., 2000 
Rat trabecular meshwork                                Stokes et al., 2000 
Rat corneal epithelium                                   Stokes et al., 2000 
Human corneal epithelium                             Rauz et al., 2001 
Human nonpigmented epithelium                  Rauz et al., 2001 
Uterus 
Human ovary                                                  Smith et al., 1997 
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Rat endometrial stroma  and                          Burton et al., 1998 
myometrium 
Murine uterus                                                 Thompson et al., 2002 
Pituitary 
Rat anterior pituitary                                      Moisan et al., 1990 
Human lactotrophs                                         Korbonits et al., 2001    
Placenta 
Human placenta and fetal membranes           Sun et al., 1997 
Murine placenta                                              Thompson et al., 2002 
Human syncytiotrophoblast                            Pepe et al., 1999 
Ear 
Rat inner ear                                                   Terakado et al., 2011 
Skin 
Human skin                                                    Tiganescu et al., 2011 
 
 
1.1.5 Regulation of HSD11B1 expression 
Expression of HSD11B1 is regulated by many regulatory factors including some 
proinflammatory cytokines (TNF-α and IL-1β), glucocorticoids (cortisol and dexamethasone), 
insulin, growth hormone, CCATT/enhancer binding proteins (C/EBPs), peroxisome 
proliferator-activated receptor (PPAR) agonists, leptin, sex hormones, thyroid hormone and 
other nuclear receptors. The regulation of HSD11B1 expression is highly tissue-specific 
manner (Tomlinson et al., 2004). For instance, the proinflammatory cytokines, TNF-α and IL-
1β induce HSD11B1 expression in smooth muscle cells and adipocytes, but not in human 
monocytes and primary hepatocytes (Cai et al., 2001; Tsuqita et al., 2008; Tomlinson et al., 
2001; Friedberg et al., 2003; Handoko et al., 2000; Thieringer et al., 2001). A comprehensive 
list of to date published studies on regulation of HSD11B1 expression in different tissues after 
induction and species is given in Table 1.3.  
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                                                                                               HSD11B1 
Regulatory factor                   Tissue/cell type                   expression                 References 
and/or activity 
Glucocorticoid receptor 
(GR) agonists 
Cortisol                            Human skeletal muscle cells                                Whorwood et al., 2002 
                                             Human omental adipose cells                               Bujaska et al., 1997 
                                             Human osteoblasts                                                Cooper et al., 2002 
                                             Human fetal lung                                                  Yang et al., 2009 
                                             Fetal ovine liver                                                    Gupta et al., 2003 
 
Corticosterone                 Rat liver                                                                 Nwe et al., 2000 
                                             Rat testis                                                                Nwe et al., 2000 
                                             Rat Leydig cells                                                    Sankar et al., 2000 
 
Dexamethasone               Rat hepatocytes                                                     Liu et al., 1996 
                                             Rat hippocampus                                                  Moisan et al., 1990 
                                             Human skin fibroblasts                                         Hammami et al., 1991 
                                             Rat liver                                                                 Jamieson et al., 1999 
                                             Rat 2S FAZA hepatoma cells                               Voice et al., 1996 
 
Betamethasone                Baboon placenta                                                    Ma et al., 2003 
Cytokines 
Interleukin (IL) 
IL-1β                                Human smooth muscle cells                                 Cai et al., 2001 
                                             Human osteoblasts                                                Cooper et al., 2001 
                                             Human adipose stromal cells                                Tomlinson et al., 2001 
                                             Rat glomerular mesangial cells                             Escher et al., 1997 
                                             Human adipocytes                                                 Friedberg et al., 2003 
                                             Human HuH7 cells                                                Iwasaki et al., 2008 
Table 1.3 Regulation of HSD11B1 expression by regulatory factors in different tissues and cell types. 
Upward arrows, downward arrows and horizontal arrows depict upregulated, downregulated and unchanged 
HSD11B1expression and/or activity, respectively (Tomlinson et al., 2004; Wamil et al., 2007; Staab et al., 2010). 
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                                             Human fibroblasts                                                 Hardy et al., 2006 
 
IL-2                                  Human granulosa-lutein cells                               Evagelatou et al., 1997 
 
IL-4                                  Human monocytes                                                Thieringer et al., 2001 
                                             Human granulosa-lutein cells                               Evagelatou et al., 1997 
                                             (leukocyte depleted)  
                                             Human ASM cells                                                 Hu et al., 2009 
 
IL-5                                  Human granulosa-lutein cells                               Evagelatou et al., 1997 
 
IL-6                                  Human adipose stromal cells                                Tomlinson et al., 2001  
                                             Human granulosa-lutein cells                               Evagelatou et al., 1997 
 
IL-13                                Human monocytes                                                Thieringer et al., 2001 
                                             Human ASM cells                                                 Hu et al., 2009 
 
Tumor Necrosis               Rat glomerular mesangial cells                             Escher et al., 1997 
Factor α (TNFα)             Human adipocytes                                                 Friedberg et al., 2003 
                                             Human HuH7 cells                                                Iwasaki et al., 2008 
                                             Human fibroblasts                                                 Hardy et al., 2006 
                                             Human adipose stromal cells                                Tomlinson et al., 2001 
                                             Human osteoblasts                                                Cooper et al., 2001 
                                             Human monocytes                                                Thieringer et al., 2001 
 
Interferon γ (IFNγ)          Human granulosa-lutein cells                                Evagelatou et al., 1997 
(leukocyte depleted) 
 
Insulin-like growth          Human adipose stromal cells                                Tomlinson et al., 2001 
factor I (IGF-I)                 HEK 293 cells                                                       Moore et al., 1999 
                                             Human hepatocytes                                               Tomlinson et al., 2001 
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                                             3T3-L1 cells                                                          Moore et al., 1999 
                                             Rat 2S FAZA hepatoma cells                                Voice et al., 1996 
                                             Mouse liver                                                           Huang et al., 2010 
 
Growth hormone             HEK 293 cells                                                        Moore et al., 1999 
(GH)                                Rat hepatocytes                                                      Liu et al., 1996  
                                             Human adipocytes                                                 Friedberg et al., 2003 
                                             Rat liver                                                                 Low et al., 1994 
 
Insulin                              3T3-F442A and 3T3-L1                                        Napolitano et al., 1998 
                                             Human adipose stromal cell                                  Bujaska et al., 1999 
                                             Rat hepatocytes                                                     Liu et al., 1996 
                                             Rat 2S FAZA hepatoma cells                               Voice et al., 1996 
 
Leptin                               Mouse hepatocytes                                               Liu et al., 2003 
                                             Mouse liver                                                           Liu et al., 2003 
                                             Human hepatocytes                                              Tomlinson et al., 2001 
 
Liver X receptor              Mouse 3T3-L1 cells                                              Stulnig et al., 2002 
(LXR) agonist                  Mouse embryonic fibroblasts                               Stulnig et al., 2002 
Adrenergic receptor agonists 
Salbutamol                       Human subcutaneous adipocytes                          Friedberg et al., 2003 
 
    Clonidine                         Human subcutaneous adipocytes                           Friedberg et al., 2003 
PPARα agonists 
    Fenofibrate                       KKAy mice (hepatic and adipose)                       Srivastava, 2009 
 
Bezafibrate                       Murine adipose tissue                                           Nakano et al., 2007 
                                             3T3-L1 adipocytes                                                Nakano et al., 2007 
 
WY14643                        Murine liver                                                           Hermanowski-Vosatka 
et al., 2000 
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PPARγ agonists 
    Rosiglitazone                   3T3-L1 adipocytes                                                Berger et al., 2001 
    TZD2                               3T3-L1 adipocytes                                                Berger et al., 2001 
COOH                             Rat adipose                                                            Laplante et al., 2003 
Protein kinase A (PKA) 
activators 
Forskolin                          Rat 2S FAZA hepatoma cells                               Voice et al., 1996 
                                             Rat granulosa cells                                                Tetsuka et al., 1999 
 
8-bromo-cAMP               Human skin fibroblasts                                          Hammami et al., 1991 
   
Dibutyryl-cAMP              Rat granulosa cells                                                Tetsuka et al., 1999 
Protein kinase C (PKC) 
activators 
Phorbol ester                    Rat granulosa cells                                                Tetsuka et al., 1999 
                                             Human skin fibroblasts                                         Hammami et al., 1991 
 
Retinoic acid                        Mouse 3T3-L1 cells                                              Stulnig et al., 2002 
                                             Mouse C2C12 myotubes                                       Aubry et al., 2009 
 
(1, 25-Dihydroxy-)              Human monocytes                                                Thieringer et al., 2001 
Vitamin D3                          Human adipocytes                                                 Morris et al., 2005 
                                             THP-1 cells                                                           Thieringer et al., 2001 
 
Vitamin A                            Rat liver                                                                 Sakamuri et al., 2011 
Eicosanoids  
15-Deoxy12,14-               Human adipose stromal cells                                Tomlinson et al., 2001 
prostaglandin J2 
 
     Prostaglandin F2α           Human chorionic trophoblast cells                       Alfaidy et al., 2001 
Bovine endometrial stromal cells                         Lee et al., 2009 
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Sex steroids 
Estradiol                         Rat uterus                                                              Ho et al., 1999 
                                             Rat kidney                                                             Low et al., 1993 
                                             Human endometrial decidual cell                         Arcuri et al., 1997 
                                             Rat liver                                                                 Nwe et al., 2000 
                                             Rat testis                                                                Nwe et al., 2000 
 
Testosterone                    Rat liver                                                                 Nwe et al., 2000 
                                             Rat testis                                                                Nwe et al., 2000 
CCATT/enhancer binding 
Protein (C/EBP) 
C/EBPα                           Human HepG2 cells                                              Williams et al., 2000 
C/EBPβ                            Human HepG2 cells                                              Williams et al., 2000 
 
Protease inhibitor                Human omental and subcutaneous                        Moore et al., 1999 
 preadipocytes 
 
Thyroid hormone (T3)         Rat liver                                                                 Whorwood et al., 1993 
                                             Rat pituitary                                                           Whorwood et al., 1993 
                                             Rat kidney                                                              Whorwood et al., 1993
 
 
1.1.6 11β-HSD1 and obesity/type 2 diabetes 
1.1.6.1 11β-HSD1 and obesity 
Obesity has become an epidemic in the western world and is tightly associated with type 2 
diabetes and other symptoms of the metabolic syndrome (DeFronzo et al., 1991; Stulnig et 
al., 2004). Excess glucocorticoids produce visceral obesity and diabetes, but circulating 
glucocorticoid levels are normal in typical obesity. The enzyme 11β-HSD1 plays a pivotal 
role in determining intracellular glucocorticoid concentrations by regenerating the active 
glucocorticoids cortisol in human and corticosterone in mice from inert glucocorticoids 
cortisone in human and 11-dehydrocorticosterone in mice, hence amplifying active 
glucocorticoids in key metabolic tissues including adipose tissue and liver. Transgenic mice 
overexpressed 11β-HSD1 selectively in adipose tissue and increased adipose levels of 
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corticosterone, thus developing visceral obesity (Masuzaki et al., 2001). Other data provide 
evidence for a role of 11β-HSD1 in the development of visceral obesity. In leptin-resistant 
fatty ‘Zucker’ rats, obesity comes along with decreased 11β-HSD1 activity in liver, but 
increased 11β-HSD1 activity in adipose tissue, notably in visceral fat (Livingstone et al., 
2000). Similar changes have been reported in leptin-deficient ob/ob mice (Liu et al., 2003; 
Wamil et al., 2007). Furthermore, several research groups have reported that obese patients 
show selective downregulation of 11β-HSD1 in liver and upregulation in adipose tissue, but 
the underlying tissue-specific mechanisms are still unknown (Stewart et al., 1999; Rask et al., 
2001; Tiosano et al., 2003).  
 
1.1.6.2 11β-HSD1 and type 2 diabetes 
Type 2 diabetes is a metabolic disorder characterized by insulin resistance, hyperglycemia and 
relative insulin deficiency. National health surveys estimated that more than 80% of patients 
with type 2 diabetes are either obese or overweight in the USA (Bays et al., 2007), but that 
does not mean that everyone with obesity is equally at risk to develop type 2 diabetes (Brochu 
et al., 2001). Indeed, the majority of patients with obesity do not develop diabetes (Felber et 
al., 2002). Type 2 diabetes is mainly characterized by disturbed insulin secretion in addition 
to decreased insulin sensitivity. 11β-HSD1 is expressed in islets of Langerhans isolated from 
ob/ob mice and also from human pancreas (Davani et al., 2000). 11β-HSD1 is increased in 
islets of diabetes but not pre-diabetes ‘Zucker’ rats (Duplomb et al., 2004). High levels of 
HSD11B1 mRNA and enzyme activity have been correlated with the appearance of diabetes 
(Duplomb et al., 2004). Moreover, treatment with glucocorticoids decreases insulin sensitivity 
and accelerates to the development of diabetes (Stunlnig et al., 2004). Fewer studies of 11β-
HSD1 have been conducted in type 2 diabetes (Valsamakis et al., 2004). Although hepatic 
11β-HSD1 activity is mild impaired, adipose tissue 11β-HSD1 activity appears to be normal 
in lean patients with type 2 diabetes (Andrews et al., 2002). However, in obese type 2 
diabetes patients, 11β-HSD1 expression is increased in skeletal muscle myotubes (Abdallah et 
al., 2005), which may contribute to the pathogenesis of insulin resistance (Abdallah et al., 
2005). 
 
 
 
 
 
Introduction 
 15
1.1.7 Inhibition of 11β-HSD1 as a therapeutic target 
Glucocorticoids such as cortisol are important regulators of fuel metabolism during stress and 
starvation. Chronic glucocorticoids excess induce all features of the metabolic syndrome 
including obesity, type 2 diabetes and hypertension as well as neurological disorders such as 
memory impairments and mood disorders. 11β-Hydroxysteroid dehydrogenase type 1 (11β-
HSD1) amplifies glucocorticoid concentrations in key metabolic tissues including liver and 
adipose tissue (Seckl et al., 2001). Inhibition of 11β-HSD1 shows considerable promise as a 
therapeutic target for the treatment of obesity, type 2 diabetes and other aspects of the 
metabolic syndrome (Stulnig et al., 2004; Hughes et al., 2008). Two principal therapeutic 
strategies to diminish the exaggerated activation of a receptor are thinkable: antagonism of the 
receptor and /or its signaling pathway or reducing ligand availability, systemically or locally. 
 
In current therapies available for treatment of Cushing’s syndrome, obesity and type 2 
diabetes, cortisol antagonism might be a therapeutic target for all of the major features of the 
metabolic syndrome. Several approaches have been proposed (Hughes et al., 2008). One 
example is inhibition of steroid biosynthesis in the adrenal to decrease glucocorticoid activity 
(Hughes et al., 2008). For instance, metyrapone and ketoconazole are traditionally used for 
the treatment of Cushing’s syndrome, as they reduce the cortisol level in plasma by inhibiting 
key enzymes in adrenal steroidogenesis (Wolkowitz et al., 1999). Other studies have focused 
on GR antagonists such as RU38484, which is known as a glucocorticoid and progestin 
receptor antagonist. In Cushing’s syndrome, administration of RU38484 shows such marked 
improvements in glycemic control, demonstrating the beneficial metabolic effects of reducing 
glucocorticoid activity (Chu et al., 2001). Administration of RU38484 also improved plasma 
glucose level in diabetic mice (Gettys et al., 1997).  
 
Inhibition of 11β-HSD1 is used as a therapeutic target for obesity and type 2 diabetes. Up to 
date, more than twenty-five companies have involved in the development of 11β-HSD1 
inhibitor drugs, several 11β-HSD1 inhibitors are in late preclinical or early clinical 
development as therapeutic target for obesity or type 2 diabetes, for instance, carbenoxolone 
(Livingstone et al., 2003; Andrews et al., 2003; Nuotio-Antar et al., 2007; Tomlinson et al., 
2007), derivatives of 18β-glycyrrhetinic acid (Su et al., 2007), adamantane sulfone (Sorensen 
et al., 2007), and beta-keto sulfones (Xiang et al., 2007). Recently, several new 11β-HSD1 
inhibitors have been reported as therapeutic target for obesity or type 2 diabetes, like 
BVT.2733 (Liu et al., 2011), HSD-016 (Wan et al., 2011), dipeptidyl peptidase-IV inhibitors 
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(DPP-IV, Sun et al., 2011), MK-0916 (Feig et al., 2011) and INCB-13739 (Tiwair, 2010). 
However, advances in the treatment of obesity and the metabolic syndrome have been limited 
with the availability of very few drugs on the market (Kolonin et al., 2004). Moreover, known 
drugs have many limitations and side effects, for instance, thiazolidinediones may cause an 
increase in the risk of death from cardiovascular events (Nissen et al., 2007), insulin and 
many other antidiabetic treatments are associated with weight gain (Verspohl et al., 2009). 
Therefore, it will be a more promising perspective to explore less toxic and side effect 11β-
HSD1 inhibitors for the treatment of obesity and type 2 diabetes in the future. 
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1.2 MicroRNAs  
MicroRNAs (miRNAs) are short, single-stranded, evolutionarily conserved noncoding RNAs 
with an average length of 22 nucleotides (Ambros, 2003). MiRNAs regulate gene expression 
by translational repression or degradation of target mRNAs, depending on the level of 
complementarity between the miRNAs and the target mRNAs. In plants, miRNAs-target 
mRNAs complementarity is perfect or near perfect and the target mRNA is degraded (Rhades 
et al., 2002). In animals, in general, miRNAs-target mRNAs complementarity is imperfect 
(Lai, 2004), but partial complementarity is sufficient to trigger target mRNA degradation 
(Bagga et al., 2005; Du et al., 2005; Lim et al., 2005) or translational repression, while in 
mammals translational repression seems to be the key approach (Bartel, 2004). The 
interaction of miRNAs and target genes is intricately regulated, in that one miRNA may 
modulate multiple target genes whereas one target gene may be regulated by various 
miRNAs. Although the first miRNA was identified over 10 years, it is only recently that 
people began to understand the scope and the diversity of these regulatory molecules. 
MiRNAs comprise one of more abundant classes of gene regulatory molecules in 
multicellular organisms and likely influence the output of many protein-coding genes. 
Computational analyses predict the presence of up to 50,000 different miRNAs in a 
mammalian cell, each with hundreds to thousands of potential mRNA targets regulating 
approximately 30% of protein-coding genes (Berezikov et al., 2005). 
 
1.2.1 Discovery of miRNAs 
In 1993, Lee et al. discovered that lin-4 in C.elegans did not code for a protein but instead 
produced a pair of short RNA transcripts that regulate the timing of larval development by 
translational repression of lin-14. Lin-4 acts by negatively regulating the level of lin-14 
protein, creating a temporal decrease in lin-14 protein starting in the first larval stage. They 
postulated that the regulation was due to in part sequence complementarity between lin-4 and 
unique repeats within the 3’ untranslated region (UTR) of the lin-14 mRNA (Lee et al., 1993). 
For seven years after the discovery of the lin-4 RNA, Reinhart et al. (2000) discovered the 
second miRNA, let-7. The let-7 miRNA, similarly to lin-4, regulates developmental timing in 
C. elegans and acts to promote the transition from late-larval to adult cell fates in the same 
way that the lin-4 RNA acts earlier in development to promote the progression from the first 
larval stage to the second (Reinhart et al., 2000). Up to date, thousands of miRNAs have been 
identified in organisms as diverse as human, rat, mouse, worm, and Drosophila. The 
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identified miRNAs are currently annotated at miRBase, as a publicy available repository 
(http://microrna.sanger.ac.uk/). 
 
1.2.2 Biogenesis of miRNAs 
Most miRNAs reside in intergenic or intronic regions, which are transcribed as a part of a 
long transcript through RNA polymerase II (Esquela-Kerscher et al., 2006). The current 
model for maturation of the mammalian miRNAs is shown in Figure 1.4. In mammalian cells, 
the miRNA pathway begins with the transcription of a primary miRNA from a miRNA gene. 
The primary miRNA is processed in the nucleus by the microprocessor machinery, which 
contains the Drosha RNase and the double-stranded RNA binding protein DGCR8 (Han et al., 
2006). The nuclear cleavage of the primary miRNA by the Drosha RNase III endonucleases 
liberates a 60-70 nt stem-loop intermediate, termed precursor miRNA. Precursor miRNA is 
actively transported from the nucleus to the cytoplasm by the export receptor Exportin-5 
(Lund et al., 2004; Yi et al., 2003), where it is further processed by a protein complex that 
includes DICER, AGO1, AGO2 and TRBP, leading to the production of ~21 bp miRNA 
duplexes (Yue, 2006; Chendrimada et al., 2005). Generally, the strand with the 5’ terminus 
located at the thermodynamically less-stable end of the duplex is selected to function as a 
mature miRNA, while the other strand is degraded (Du et al., 2005; Kim et al., 2006). 
Following processing, to perform regulatory functions, miRNAs are assembled into 
ribonucleoprotein (RNP) complexes called micro-RNPs (miRNPs) or miRNA-induced 
silencing complexes (miRISCs) or RNA-induced silencing complexes (RISCs). The key 
components of miRNPs are proteins of the Argonaute (AGO) family. In mammals, four AGO 
proteins (AGO 1 to AGO4) function in the miRNAs repression. With these complexes, 
miRNAs lead Argonaute proteins to fully or partially complementary mRNA targets, which 
are then silenced posttranscriptionally (Bushati and Cohen, 2007). 
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1.2.3 Mechanisms of miRNA-mediated gene silencing  
According to our current understanding, the mature miRNAs are assembled into 
ribonucleoprotein (RNP) complexes called micro-RNPs (miRNPs). Subsequently, miRNAs 
could lead the miRNPs to downregulate gene expression by one of two posttranscriptional 
mechanisms: mRNA cleavage or translational repression.  
 
1.2.3.1 Mechanism: mRNA cleavage  
MiRNAs interact with their target mRNAs by base pairing. In plants, miRNAs generally bind 
to mRNAs with almost perfect complementarity and trigger endonucleolytic mRNA cleavage 
by an RNAi-like mechanism (Jones-Rhoades et al., 2006). The mRNA is cleaved 
endonucleolytically in the middle of the miRNA-mRNA duplex by miRNPs (Figure 1.5A). 
Figure 1.4 Biogenesis of miRNAs. 1: miRNA gene is transcribed into a primary miRNA (pri-miRNA). 2: Pri-
miRNA is cleaved by Drosha to a pre-miRNA. 3: Pre-miRNA is transported out of the nucleus by exportin-5. 4: 
Pre-miRNA is cleaved by Dicer to form a short double-stranded miRNA duplex. 5: miRNA duplex separates 
into single-stranded mature miRNA. 6: miRNAs are assembled into ribonucleoprotein (RNP) complexes called 
micro-RNPs (miRNPs). 
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After cleavage of the mRNA, the miRNA remains intact and can guide the recognition and 
destruction of additional messages (Tang et al., 2003). In contrast, with few exceptions, 
metazoan miRNA is imperfect base pairing with their target mRNAs. The most stringent 
requirement is a contiguous and perfect base pairing of the miRNA nucleotides 2-8, 
representing the ‘seed’ region, which is mainly binding sites for the miRNA-mRNA 
association. Usually, miRNA-binding sites in metazoan mRNAs lie in the 3’UTR, but partial 
complementarity is sufficient to trigger target mRNA cleavage (Figure 1.5B, Lewis et al., 
2005; Grimson et al., 2007; Nielsen et al., 2007). For example, in zebrafish embryos at the 
onset of zygotic transcription, the dramatic increase of miR-430 expression correlates with the 
degradation of a large number of maternal mRNAs containing miR-430 binding sites in their 
3’UTRs (Giraldez et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Modes of mRNA cleavage by miRNA. A: In plants B: In metazoans (Filipowicz et al., 2008). 
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1.2.3.2 Mechanism: translational repression 
In animals, miRNAs regulate gene expression by imperfect base pairing with the 3’-
untranslated region (3’UTR) of target mRNAs, and repressing protein synthesis. According to 
the published studies, miRNAs can repress protein expression in all steps of mRNA 
translation, namely by inhibition of translational initiation, by inhibition of translational 
elongation, by premature termination of translation (like ribosome drop-off) or by proteolysis 
(degradation of nascent peptide) (Figure 1.6; Eulalio et al., 2008; Filipowicz et al., 2008). The 
key components of miRNPs are proteins of the Argonaute (AGO) family. Kiriakidou et al. 
(2007) reported an unexpected observation, the central domain of Argonaute proteins exhibits 
sequence similarities to the cytoplasmic cap-binding protein elF4E (eukaryotic translation 
initiation factor 4E), which is essential for cap-dependent translation initiation. MiRNAs 
inhibit translation at cap-recognition step by displacing elF4E from the cap structure (Figure 
1.6A; Kiriakidou et al., 2007). Chendrimada et al. (2007) showed that human Argonaute 2 
(AGO2) associates with both eukaryotic translation initiation factor 6 (elF6) and large 
ribosomal subunit in human cells. ElF6 prevents the large ribosomal subunit from binding to 
the small ribosomal subunit. Therefore, if AGO2 recruits elF6, then the large and small 
ribosomal subunits might not be associated, leading to translational repression (Figure 1.6B; 
Chendrimada et al., 2007). Studies by Petersen et al. have identified that repression by 
miRNA mimics increased rate of termination at the stop codon, leading the authors to propose 
that miRNAs promote premature termination and ribosome drop-off (Figure 1.6C; Petersen et 
al., 2006). The paradoxical observation that the targets of mRNAs appear to be actively 
translated while the corresponding protein product remains undetectable prompted the 
proposal that the nascent polypeptide chain might be degraded (Figure 1.6D; Nottrott et al., 
2006). However, this proposal is based on negative rather than direct positive evidence. In 
summary, translational repression by miRNAs probably occurs via multiple mechanisms in all 
different steps of mRNA translation. 
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Figure 1.6 Possible mechanisms of the miRNA-mediated translational repression in animals. 
(Eulatio et al., 2008; Filipowicz et al., 2008). 
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1.2.4 MiRNAs and diseases 
MiRNAs have been implicated in a wide diversity of basic cellular functions, such as insulin 
secretion (Poy et al., 2004), cardiac regulation (Care et al., 2007), organ development (Schratt 
et al., 2006), immune response (Li et al., 2007), and muscle differentiation (Chen et al., 
2006). Therefore, mutation of miRNAs, dysfunction of miRNAs biogenesis and dysregulation 
of miRNAs and their targets may result in various diseases. Currently, approximately 150 
different diseases including obesity and type 2 diabetes which are associated with miRNAs 
have been reported (Esau et al., 2004; He et al., 2007; Herrera et al., 2009; Herrera et al., 
2010; Lovis et al., 2008; Takanabe et al., 2008). In 2008, Lu et al. performed a 
comprehensive analysis of the literature on human microRNA-disease associations and built 
the human microRNA disease database (HMDD) (Lu et al., 2008; see database 
http://cmbi.bjmu.edu.cn/hmdd). Recently, it has been reported that miRNAs are used for rapid 
and accurate diagnosis of cancers (Martens-Uzunova et al., 2011) and as novel epigenetic 
biomarkers for human cancers (Cortes-Sempere et al., 2011). Moreover, miRNAs are special 
because they are stable, tissue-specific, and dysregulated in the diseased organs and cancers. 
These characteristics make them potential biomarkers in prognostic and predictive purposes 
(Lin et al., 2011).  
 
1.2.4.1 MiRNAs and obesity 
Obesity is characterized by increased fat mass and energy storage in adipose tissues (Lean et 
al., 1998). Fat mass can be grown by increasing in the size of adipocytes, or expanding the 
numbers of adipocytes (Rosen and MacDougald, 2006). Recently, evidences of miRNA 
dysregulation have been reported in human obesity (Martinelli et al., 2010). Several miRNA 
profiling studies have identified miRNAs associated with obesity in adipose tissues from 
obese mouse models and obese people (Klöting et al., 2009; Xie et al., 2009; Martinelli et al., 
2010; Ortega et al., 2010). The findings of these studies are summarized in Table 1.4. Two 
miRNAs, miR-21 and miR-143, were profiled in subcutaneous adipose tissues from healthy 
humans with varying degrees of obesity. MiR-21 showed higher expression in persons with a 
BMI >30, while miR-143 showed lower expression in human adipose tissue with BMI >30 
(Keller et al., 2011). In the ob/ob mouse, which develops obesity and type 2 diabetes-like 
symptoms, expression of miR-21 is downregulated in liver suggesting that miR-21 may have 
different roles depending on the cell types (Keller et al., 2011). Increased miR-143 expression 
in adipose tissue of obese mice is associated with parallel alterations in PPARγ and aP24 
which are markers of adipocyte differentiation (Takanabe et al., 2008). MiR-27 gene family is 
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downregulated during adipogenic differentiation (Lin et al., 2009). Overexpression of miR-27 
specifically inhibited adipocyte formation, without affecting myogenic differentiation (Lin et 
al., 2009). Expression of miR-27 resulted in blockade of expression of PPARγ and C/EBPα, 
the two master regulators of adipogenesis (Lin et al., 2009; Table 1.4). The levels of miR-335 
expression in liver and white adipose tissue were upregulated in murine models of obesity, 
including KKAy44 mice, leptin deficient ob/ob mice, leptin receptor deficient db/db mice 
(Nakanishi et al., 2009). Increased miR-335 expression was associated with an elevated body, 
liver and white adipose tissue weight, and hepatic triglyceride and cholesterol (Nakanishi et 
al., 2009). In 3T3-L1 adipocyte, the induction of miR-335 expression was accompanied by 
that of the adipogenic genes including PPARγ and aP24 after induction of differentiation. 
These results indicated that miR-335 might be involved in the adipoyte differentiation and 
lipid accumulation (Nakanishi et al., 2009). Overexpression of miR-519d was reported to be 
associated with severe obesity in human subcutaneous adipose tissue (Martinelli et al., 2010). 
MiR-519d has been identified to bind to the 3’UTR of PPARα. The level of PPARα mRNA 
was highly expressed in obese subjects, while PPARα protein was undetectable compared to 
the controls (Martinelli et al., 2010). It indicated that a post-transcriptional mechanism may 
be involved to downregulate PPARα protein. Several studies have reported that miR-519d is 
differentially expressed in obesity or during adipogenic differentiation (Table 1.4). 
 
 
 
MiRNA         Species                Function                 Targets          References 
miR-15a         Mouse                 Adipogenesis           DLK1             Kajimoto et al., 2006; 
                                                                                                           Andersen et al., 2010        
                       Human                Adipose tissue                                 Martinell et al., 2010 
miR-17/92      Mouse                 Adipogenesis           RB2; p130      Lin et al., 2009 
                                                                                                           Wang et al., 2008 
miR-21           Human/Mouse    Adipogenesis           TGFBR2        Gerin et al., 2010 
                                                                                                           Kim et al., 2009 
                                                                                                           Sun et al., 2009 
miR-24           Mouse                 Adipogenesis                                  Sun F et al., 2009     
miR-27           Human/Mouse    Adipogenesis           PPARγ           Lin et al., 2009 
                                                                                                           Karbiener et al., 2009 
                                                                                                           Qin et al., 2010 
Table 1.4 MiRNAs associated with adipogenesis and obesity 
(http://cmbi.bjmu.edu.cn/hmdd; McGregor and Choi, 2011) 
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                       Human/Mouse    Adipose tissue                                 Kim SY et al., 2010      
Lin et al., 2009 
                                                                                                           Karbiener et al., 2009 
miR-31           Human/Mouse    Adipogenesis           CEBPA          Gerin et al., 2010 
                                                                                                           Sun et al., 2009 
                                                                                                           Tang et al., 2009 
                                                   Adipose tissue                                 Ortega et al., 2010 
miR-103         Human/Mouse    Adipogenesis            PDK1            Esau et al., 2004 
                                                                                                           Kajimoto et al., 2006 
                                                                                                           Oskowitz et al., 2008 
                                                                                                           Qin et al., 2010 
                                                                                                           Sun et al., 2009 
                       Mouse      Adipose tissue         WNT3A         Xie et al., 2009 
miR-107         Human/Mouse    Adipogenesis                                  Esau et al., 2004 
                                                                                                           Oskowitz et al., 2008 
                                                                                                           Gerin et al., 2010 
                                                                                                           Qin et al., 2010 
                       Mouse                 Adipose tissue                                Xie et al., 2009 
miR-125b       Human/Mouse    Adipogenesis                                  Gerin et al., 2010 
                                                                                                           Ortega et al., 2010 
                       Human/Mouse    Adipose tissue                                 Xie et al., 2009 
                                                                                                           Ortega et al., 2010 
miR-132         Human                Adipose tissue                                 Heneghan et al., 2011 
miR-138         Human                Adipogenesis           EID1              Yang et al., 2011 
miR-143         Human/Mouse    Adipogenesis           ERK5              Esau et al., 2004 
                                                                                                           Kajimoto et al., 2006 
                                                                                                           Sun et al., 2009 
                                                                                                           Oskowitz et al., 2008 
                       Human/Mouse    Adipose tissue                                 Xie et al., 2009 
                                                                                                           Takanabe et al., 2008 
miR-150         Mouse                 Adipogenesis                                  Gerin et al., 2010 
                       Human                Adipose tissue                                 Martinell et al., 2010 
miR-200         Mouse                 Adipogenesis                                  Kennell et al., 2008 
miR-210         Mouse                 Adipogenesis           TCF7L2         Gerin et al., 2010 
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                                                                                                           Qin et al., 2010 
                                                                                                           Sun et al., 2009 
                       Human                Adipose tissue                                Ortega et al., 2010 
miR-221         Mouse                 Adipogenesis                                  Xie et al., 2009 
                       Human/Mouse    Adipose tissue                                 Ortega et al., 2010    
                                                                                                            Xie et al., 2009                
miR-222         Mouse                 Adipogenesis                                  Xie et al., 2009 
                       Mouse                 Adipose tissue                                 Xie et al., 2009 
miR-326         Human                Adipose tissue                                Ortega et al., 2010            
miR-335         Human/Mouse    Adipogenesis                                  Oskowitz et al., 2008 
                                                                                                           Nakanishi et al., 2009 
                                                                                                           Qin et al., 2010 
                       Mouse                 Adipose tissue                                 Nakanishi et al., 2009      
miR-378         Mouse                 Adipogenesis                                  Gerin et al., 2010 
miR-448         Mouse                 Adipogenesis           KLF5              Kinoshita et al., 2010 
miR-519d       Human                Adipose tissue          PPARα          Martinell et al., 2010 
 
 
1.2.4.2 MiRNAs and type 2 diabetes 
Type 2 diabetes is a progressive metabolic disorder characterized by reduced insulin 
sensitivity, insulin resistance in tissues such as adipose tissue, liver and skeletal muscle, and 
combined with pancreatic β-cell dysfunction. However, the major mechanisms underlying the 
pathogenesis of diabetes remain obscure. The various miRNAs have been identified as being 
potentially involved in type 2 diabetes, which are mainly expressed in adipose tissue, liver, 
skeletal muscle and pancreatic β-cells, shown in Table 1.5. MiR-24 is downregulated in the 
diabetic rat skeletal muscle and is shown to target directly p38 mitogen-activated protein 
kinase (MAPK) (Huang et al., 2009). Based on microarray technology, miR-27b and miR-335 
have been identified to contribute to fatty liver and associated pathologies. Furthermore, miR-
27b expression is downregulated in the liver of type 2 diabetes rats (Herrera et al., 2010). 
MiR-27b can bind to 3’UTR of PPARγ mRNA and induce its degradation (Jennewein et al., 
2010; Table 1.5). The destabilization of PPARγ in 3T3-L1 adipocytes by miR-27b blocks 
their differentiation into lipid-storing adipocytes (Karbiener et al., 2009). As mentioned above, 
miR-335 is involved in lipid metabolism and upregulated not only in the liver of type 2 
diabetes (Table 1.5), but also in the liver of obese mice (Nakanishi et al., 2009). MiR-125a is 
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up-regulated in the white adipose tissue of type 2 diabetes rats as well as in insulin-resistant 
3T3-L1 adipocytes (Ling et al., 2009; Table 1.5). In vivo or in vitro, although none of the 
miR-125a target has been identified, bioinformatics analysis revealed that several predicted 
target mRNAs were involved in glucose metabolism (Herrera et al., 2009). MiR-375 is 
essential for pancreatic β-cell development and function. MiR-375 knock-out mice show a 
lowered pancreatic α- and β-cell mass and reduced insulin secretion (Poy et al., 2009). The 
level of miR-375 in pancreatic islets has been found to be decreased in diabetic rats as well as 
in obese mice (Zhao et al., 2009), suggesting that miR-375 down-regulation plays a major 
role in the pathogenesis of type 2 diabetes in islet (EI Ouaamari et al., 2008). 
 
 
 
MiRNA           Species           Tissue/Cell               Expression              References 
miR-15a           Human            Skeletal muscle            down             Gallagher et al., 2010 
                         Human            Plasma                          down             Zampetaki et al., 2010 
miR-15b           Human            Skeletal muscle            up                  Gallagher et al., 2010       
miR-21             Rat                  Adipose tissue              up                  Herrera et al., 2010   
miR-24             Rat                  Skeletal muscle            down             Huang et al., 2009        
miR-27b           Rat                  Liver                             down             Herrera et al., 2010 
miR-29a           Rat                  Adipose tissue              up                  Karolina et al., 2011 
miR-30a*         Human            Adipose tissue              down             Ortega et al., 2010           
miR-103           Rat                  Liver                             up                 Herrera et al., 2010   
                         Mouse             Liver                             up                 Trajkovski et al., 2011 
miR-107           Mouse             Liver                            up                  Trajkovski et al., 2011    
miR-125a         Rat                  Adipose tissue              up                  Ling et al., 2009 
                                                                                                            Herrera et al., 2009 
miR-126           Human            Plasma                         down              Zampetaki et al., 2010 
miR-140*         Rat                  Liver                             up                  Herrera et al., 2010 
miR-143           Human            Skeletal muscle            up                  Gallagher et al., 2010 
miR-144           Rat                  Pancreas                       down              Karolina et al., 2011 
miR-146           Mouse            Pancreatic β-cell           up                  Lovis et al., 2008 
miR-146a         Human            Peripheral blood           down             Balasubramanyam M et  
                                                 mononuclear cell                                al., 2011 
miR-150           Rat                  Liver                            up                   Karolina et al., 2011 
Table 1.5 The involvement of miRNAs in type 2 diabetes 
(http://cmbi.bjmu.edu.cn/hmdd; Ferland-McCollough et al., 2010)
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miR-182           Rat                  Skeletal muscle            down             Karolina et al., 2011 
miR-190           Human            Skeletal muscle            up                 Gallagher et al., 2010        
miR-191           Rat                  Liver                             up                  Herrera et al., 2010   
                         Human            Plasma                          down             Zampetaki et al., 2010 
miR-197           Human            Plasma                         down              Zampetaki et al., 2010 
miR-223           Rat                  Liver                            up                  Herrera et al., 2009 
                         Human            Plasma                          down             Zampetaki et al., 2010 
miR-320a         Human            Plasma                          down             Zampetaki et al., 2010 
miR-335           Rat                  Liver                             up                 Herrera et al., 2010 
miR-375           Mouse             Pancreatic β-cell          down             EI Ouaamari et al., 2008
miR-486           Human            Plasma                          down             Zampetaki et al., 2010 
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2 Aim of this study 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1, gene name HSD11B1) is responsible 
for intracellular glucocorticoid activation and plays an important role in obesity and the 
associated metabolic syndrome. During the last ten years, 11β-HSD1 has emerged as a major 
potential drug target in the prevention of obesity, type 2 diabetes and other symptoms of the 
metabolic syndrome. Regulation of HSD11B1 expression is multifactorial and highly tissue-
specific manner. Interestingly, increased 11β-HSD1 levels in adipose tissue typically parallel 
unchanged or decreased 11β-HSD1 levels in liver of obese patients, and the underlying tissue-
specific mechanisms remain obscure.  
 
The aim of the present study is to investigate the potential impact of miRNAs in HSD11B1 
expression.  
• to identify potential miRNA candidates by bioinformatic miRNA prediction tools  
• to perform functional analysis in human cell culture with interesting candidates 
• to assess the mechanism of the miRNA-mediated suppression 
• to investigate promoter and miRNAs in regulation of HSD11B1 expression 
• to explore alternative promoter usages by induction with regulatory factors 
• to detect potential miRNAs that are present in human liver cells 
• to evaluate potential miRNAs expression in hepatocytes of normal, overweight and 
obese people 
• to analyze potential miRNAs that are involved in regulation of HSD11B1 expression 
in obesity, type 2 diabetes or other symptoms of the metabolic syndrome 
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3 Materials and Methods  
3.1 Materials  
3.1.1 Chemicals 
β-mercaptoethanol                                      BIOMOL, Germany 
Acetic acid                                                  Carl Roth GmbH, Karlsruhe, Germany 
Adiponectin                                                Alexis Biochemicals, United States 
Agarose                                                       Carl Roth GmbH, Karlsruhe, Germany 
Ammonium persulfate (APS)                     SERVA, Germany 
Ampicillin                                                   AppliChem, Germany 
Blocking reagent                                         Carl Roth GmbH, Karlsruhe, Germany  
Bovine serum albumin (BSA)                    Behringwerke AG, Germany 
Bradford reagent                                         Sigma-Aldrich Chemie GmbH, Germany 
Bromophenol blue                                      Sigma-Aldrich Chemie GmbH, Germany 
Chloroform                                                 Carl Roth GmbH, Karlsruhe, Germany 
Ciglitazone                                                  Enzo Life Sciences, Germany 
Cortisol                                                        Sigma-Aldrich Chemie GmbH, Germany 
dNTPs                                                         Fermentas GmbH, Germany 
Dexamethasone                                           Sigma-Aldrich Chemie GmbH, Germany 
EDTA                                                          Sigma-Aldrich Chemie GmbH, Germany 
Estradiol                                                      Sigma-Aldrich Chemie GmbH, Germany 
Ethanol                                                        Carl Roth GmbH, Karlsruhe, Germany 
Ethidium bromide                                       Sigma-Aldrich Chemie GmbH, Germany  
Formaldehyde                                             Merck KGaA, Germany 
Formamide                                                  Sigma-Aldrich Chemie GmbH, Germany 
Gel 40                                                          Carl Roth GmbH, Karlsruhe, Germany 
GelRed                                                        Biotium, Inc., Germany 
Glycerin                                                      Merck KGaA, Germany 
Glycine                                                        Carl Roth GmbH, Karlsruhe, Germany 
Hydrochloric acid (HCl)                             Carl Roth GmbH, Karlsruhe, Germany     
Insulin                                                         Sigma-Aldrich Chemie GmbH, Germany                  
Isopropanol                                                 Merck KGaA, Germany 
Kanamycin                                                  CALBIOCHEM, Germany 
KAc                                                             Merck KGaA, Germany 
KCl                                                              Merck KGaA, Germany 
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KH2PO4                                                                                  Merck KGaA, Germany 
Leptin                                                          Enzo Life Sciences, Germany 
Loading dye solution 6×                             Fermentas GmbH, Germany 
Maleic acid                                                  Merck KGaA, Germany 
Methanol                                                     Merck KGaA, Germany 
MgCl2 (25mM)                                            Fermentas GmbH, Germany 
Milk powder Blotting grade                        Carl Roth GmbH, Karlsruhe, Germany 
MOPS                                                         Sigma-Aldrich Chemie GmbH, Germany 
NaCl                                                            Merck KGaA, Germany 
NaOH                                                          Merck KGaA, Germany 
Na2HPO4                                                      Merck KGaA, Germany  
N-lauroylsarcosine                                      Merck KGaA, Germany 
NuPage MES SDS Transfer buffer 10×      Invitrogen Co., Germany   
NuPage Runing buffer 20×                         Invitrogen Co., Germany   
Oligo (dT) 15 primer                                   Promega GmbH, Germany 
Oligo (dT) 18 primer                                   Fermentas GmbH, Germany 
Phenol                                                         Carl Roth GmbH, Karlsruhe, Germany 
Protease Inhibitor Cocktail Tablet              Roche GmbH, Germany 
Reducing Agent                                          Invitrogen Co., Germany   
Resistin                                                       Alexis Biochemicals, United States 
Retinoic acid                                               Sigma-Aldrich Chemie GmbH, Germany 
RNase A                                                      Carl Roth GmbH, Karlsruhe, Germany 
Salmon sperm DNA                                    Invitrogen Co., Germany   
Sodium dodecyl sulfate (SDS)                    Carl Roth GmbH, Karlsruhe, Germany 
Sodium acetate                                            Sigma-Aldrich Chemie GmbH, Germany 
Sodium citrate                                             Sigma-Aldrich Chemie GmbH, Germany 
Sucrose                                                        Sigma-Aldrich Chemie GmbH, Germany 
T4 Polynucleotide Kinase buffer                BioLabs, Frankfurt, Germany 
TEMED                                                       Sigma-Aldrich Chemie GmbH, Germany  
TNFα                                                          Enzo Life Sciences, Germany 
Trichostatin A                                             Enzo Life Sciences, Germany 
Tris base                                                      Merck KGaA, Germany 
Tween-20                                                    Sigma-Aldrich Chemie GmbH, Germany 
Vitamin D3                                                  Sigma-Aldrich Chemie GmbH, Germany 
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WY14643                                                    Sigma-Aldrich Chemie GmbH, Germany 
Xylene cyanol                                              Sigma-Aldrich Chemie GmbH, Germany 
 
3.1.2 Enzymes 
Restriction enzymes, Taq-polymerase, Revert Aid M-MuLV Reverse Transcriptase, T4-DNA 
Ligase, and Shrimp Alkaline Phosphatase (SAP) were obtained from Fermentas (St. Leon-
Rot, Germany). Phire Hotstart DNA polymerase was from Finnzymes (Keilaranta, Finland). 
T4 Polynucleotide Kinase was purchased from BioLabs (Frankfurt, Germany). 
 
3.1.3 Molecular weight markers  
For DNA analysis, GeneRulerTM 1 kb DNA ladder (250-10000 bp) and GeneRulerTM 100 bp 
plus DNA ladder (100-3000 bp) were used. For protein analysis, PageRulerTM prestained 
protein ladder (10-170 kDa) was used. All molecular weight markers were obtained from 
Fermentas (St. Leon-Rot, Germany). 
 
3.1.4 Kits 
All kits used are listed in the table 3.1 below including their applications and suppliers. 
 
 
Kit name                             Application                              Supplier 
QIAGEN Plasmid Midi Kit          Plamid midi preparation        QIAGEN, Hilden, Germany 
QIAEX II Gel Extraction Kit       Purification of DNA               QIAGEN, Hilden, Germany 
                                                      fragments from gels 
TOPO TA Cloning Kits                PCR fragments Cloning         Invitrogen GmbH, 
Karlsruhe，Germany 
Master Pure RNA                         RNA preparation                    Epicentre Biotechnologies, 
Purification Kit                                                                             Madison, USA 
Amersham ECL and                     Western Blotting Detection    GE Healthcare, Munich, 
Amersham ECL Advance                                                             Germany 
Western Blotting Detection  
Reagents 
LipofectamineTM 2000                  Transfection Reagent              Invitrogen GmbH, 
                                                      (Mammalian cells)                  Darmstadt, Germany 
Dual-GloTM Luciferase                 Measuring firfly and Renilla   Promega, Mannheim, 
Table 3.1 List of all kits used in this work 
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Assay System                               luciferase activities                  Germany 
TaqMan® MicroRNA Assays      miRNA-specific primers for    Applied Biosystems,   
                                                      RT-PCR                                   Darmstadt, Germany 
TaqMan® MicroRNA                   Reverse transcription               Applied Biosystems, 
Reverse Transcription Kit                                                              Darmstadt, Germany 
TaqMan® Universal PCR             Polymerase Chain Reaction     Applied Biosystems, 
Master Mix II, with UNG                                                              Darmstadt, Germany 
Bis-Tris Gel: NuPAGE                Protein analysis                        Invitrogen GmbH, 
Novex 4-12% Bis-Tris Gel                                                            Darmstadt, Germany 
1.0 mm, 10 well  
Cortisol Assay                             Cortisol measurement               R&D, Administration and  
                                                                                                       Europe Office, Cisbio  
                                                                                                       Bioassay, France 
 
 
3.1.5 Plasmids 
 
pCR2.1-TOPO                Cloning of Taq polymerase-amplified PCR products;                                                  
                                         ampicillin/kanamycin resistance (Invitrogen GmbH, Karlsruhe,                                 
                                         Germany); plasmid map in Appendix 7.1.1 
 
pmir-GLO                        pmir-GLO Dual-luciferase miRNA target expression vector,  
                                         mammalian expression vector for transient transfection; 
                                         ampicillin-resistance (Promega, Mannheim, Germany); 
                                         plasmid map in Appendix 7.1.2 
 
3.1.6 MicroRNAs 
All microRNA precursors were purchased from Applied Biosystems/Ambion (Darmstadt, 
Germany). All microRNAs used are listed in Table 3.2.  
 
 
 
 
 
Table 3.2 List of all miRNA precursors used in this work. Also two negative control precursors (Negative 
control miRNA#1 and #2) were purchased. Their sequences are not disclosed by the manufacturer, but they 
are supposed not to bind to any mRNA. 
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MiRNA name               Sequence of the mature miRNA 
hsa-miR-561                  5’-CAAAGUUUAAGAUCCUUGAAGU-3’ 
hsa-miR-579                  5’-UUCAUUUGGUAUAAACCGCGAUU-3’ 
hsa-miR-340                  5’-UUAUAAAGCAAUGAGACUGAUU-3’ 
hsa-miR-181b                5’-AACAUUCAUUGCUGUCGGUGGGU-3’ 
Negative control#1 
Negative control#2 
 
3.1.7 Primers 
All primers were purchased from Eurofins MWG Operon (Ebersberg, Germany) and are listed 
in Table 3.3. Forward primers are named fd, reverse primers are named re. Bold letters 
indicate restriction enzyme sites; Lowercases indicate mismatch mutations. 
 
 
 
Name                                Type                             Sequence 
HSD11B1-3’UTR-fd        PCR forward primer     5’-CTCGAGGAACTCCCTGAGGGC 
 TGGGCATGCTGAGGGATTTTG-3’ 
HSD11B1-3’UTR-re        PCR reverse primer       5’-GTCGACTAAGAAACAAATATT 
GAAAAATTTCATTTGTACAG-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-CAATATTAATTATAAATTCATAA 
561-del-fd                                                                     CTGGTAGCTATAACT-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-CTACCAGTTATGAATTTATAAT 
561-del-re                                                                     TAATATTGTATTAATC-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-AAGGTCACATAtAgTcTATAAA 
561-mut-fd                                                                    TTCATAACTGGTAG-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-TATGAATTTATAgAcTaTATGTGA 
561-mut-re                                                                   CCTTTATTATAAT-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-CTCGAGGAACTCCCTGAGGGCT 
579-del-fd                                                                     GGGCATGCTGAGGGATTTTG-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-GTCGACTAAGAAACAAATATTG 
579-del-re                                                                 AAAAATTAAAGAAACCATCCTG-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-CTCGAGGAACTCCCTGAGGGCT 
579-mut-fd                                                                   GGGCATGCTGAGGGATTTTG-3’ 
Table 3.3 List of all primers used in this work
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HSD11B1-3’UTR-           Mutagenesis primer       5’-GTCGACTAAGAAACAAATATTG 
579-mut-re                                                                 AAAAATTTgAcTaGTACAGTTTA-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-CAATATTAATTATAAATTCATAA 
340-del-fd                                                                    CTGGTAG-3’ 
HSD11B1-3’UTR-           Mutagenesis primer       5’-GGTCACATAAACgTgAgAAATTC 
340-mut-fd                                                                    ATAACTGG-3’ 
HSD11B1-P1-fd               PCR forward primer      5'-CAGATTTGTTCGAAATC 
                                                                                     TTGAGG-3' 
HSD11B1-P2-fd               PCR forward primer      5'-CTGCCTGCTTAGGAGGTTGT-3' 
HSD11B1-all-fd                PCR forward primer      5'-ACCAGAGATGCTCCAAGGAA-3' 
HSD11B1-all-re                PCR reverse primer       5'-CAAGGCAGCTACAGTCAGGA-3' 
GAPDH-fd                        PCR forward primer      5'-TGGAAGGCTCATGACCACA-3' 
GAPDH-re                        PCR reverse primer        5'-TTCTAGACGGCAGGTCAGGT-3' 
Firefly-fd                           PCR forward primer     5'-CACCTTCGTGACTTCCCATT-3' 
Firefly-re                           PCR reverse primer      5'-CCTCACCTACCTCCTTGCTG-3' 
Renilla-fd                          PCR forward primer     5'-CCGAGTTCGTGAAGGTGAAG-3' 
Renilla-re                          PCR reverse primer       5'-ACAACGTCGAGCACAGCTGC-3' 
P-deletion PGk-fd             PCR forward primer      5’-AGATCTCCCGGGAAGCTTGG 
CAATCCGGTA-3’ 
P-deletion PGk-re              PCR reverse primer      5’-CTCGAGGCTAGCGAGCTCGTT 
TAA-3’ 
HSD11B1-P1-fd                PCR forward primer     5’-CCCGGGGCCCAGAAAAATTAG 
                                           (cloning)                             GAG-3’ 
HSD11B1-P1-re                PCR reverse primer      5’-CCCGGGAGATTTCGAACAAA  
(cloning)                             TCTG-3’ 
HSD11B1-P2-fd               PCR forward primer      5’-CCCGGGGAGAACCAGC CATG 
(cloning)                              TAAA-3’ 
HSD11B1-P2-re               PCR reverse primer        5’-CCCGGGCCGACAGGGAGCTG 
(cloning)                              GCCT-3’ 
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3.1.8 Oligonucleotides 
All oligonucleotides were purchased from Eurofins MWG Operon (Ebersberg, Germany). All 
oligonucleotides used are listed in Table 3.4. 
 
 
Name                        Sequence  
DNA-579                  5’-TTCATTTGGTATAAACCGCGATT-3’   
AMO-579                 5’-AATCGCGGTTTATACCAAATGAA-3’ 
DNA-561                  5’-CAAAGTTTAAGATCCTTGAAGT-3’   
AMO-561                 5’-ACTTCAAGGATCTTAAACTTTG-3’ 
 
3.1.9 Cell lines 
A549 cells (passages 3-9)                                        DSMZ-Deutsche Sammlung von  
(human lung adenocarcinoma cell line)                   Mikroorganismen und Zellkulturen 
                                                                                 GmbH, Germany 
 
HepG2 (passages 19-21)                                          CLS-Cell Line Service, Germany 
(human hepatoma cell line) 
 
3T3-L1 (passages 23-24)                                          Health Protection Agency’s Culture  
 (Mouse embryonic fibroblast                                   Collection, Salisbury, UK 
-adipose like cell line) 
 
3.1.10 Cell culture media, solution and materials 
Dulbecco’s Modified Eagle Medium                       PAA laboratories GmbH, Gölbe, Germany 
(DMEM): high glucose   
Dulbecco’s Modified Eagle Medium                       PAA laboratories GmbH, Gölbe, Germany 
(DMEM) Ham’s F-12   
Foetal bovine serum                                                 PAA laboratories GmbH, Gölbe, Germany 
OPTI-MEM I Reduced Serum Medium                   Invitrogen GmbH, Karlsruhe, Germany 
modification of MEM (Eagle's)                             
Trypsin/EDTA                                                          PAA laboratories GmbH, Gölbe, Germany 
Penicillin/Streptomycin (100×)                                PAA laboratories GmbH, Gölbe, Germany 
L-Glutamine 200 mM (100×)                                   PAA laboratories GmbH, Gölbe, Germany 
Table 3.4 List of all oligonucleotides used in this work 
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Cell culture materials were obtained from Sarstedt AG & Co (Nümbrecht, Germany). 
 
3.1.11 Hepatocyte Total RNAs 
Human Hepatocyte Total RNA, BMI 14.9               BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte Total RNA, BMI 29.9               BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte Total RNA, BMI 35.4               BioCat GmbH, Heidelberg, Germany 
 
3.1.12 Frozen Hepatocytes 
Human Hepatocyte, BMI 23.5                                  BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte, BMI 23.8                                  BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte, BMI 26.1                                  BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte, BMI 38                                     BioCat GmbH, Heidelberg, Germany 
Human Hepatocyte, BMI 38.2                                  BioCat GmbH, Heidelberg, Germany 
 
3.1.13 Antibodies 
Primary Antibodies: 
11β-HSD1 antibody                                                    
(Raised in: Rabbit; Polyclonal antibody)                  Abcam GmbH, Cambridge, UK 
 
β-Actin                                                                        
(Raised in: Rabbit; Polyclonal antibody)                   Neomarkers Inc, Fremont, CA 
 
Secondary antibody: 
ECL peroxidase labelled anti-rabbit antibody           GE Healthcare, Munich, Germany  
 
3.1.14 Bacterial media 
Standard I Nutrient Broth                                          25 g Standard I Nutrient Broth/liter,            
(SIN)                                                                                   autoclave (15 min at 121 ˚C) 
 
Standard I Nutrient Broth plate                                 25 g Standard I Nutrient Broth/liter,            
                                                                                  20 g agar, autoclave (15 min at 121 ˚C) 
Media were autoclaved, and 100 mg/l ampicillin or 25 mg/l kanamycin was supplemented 
prior to use. 
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3.1.15 Radiochemical 
ATP, [γ32P]-3000Ci/mmol                                  PerkinElmer, Rodgau, Germany 
 
3.1.16 Buffers and solutions 
DNA loading dye (6×)                                        0.1% bromophenol blue  
(Agarose gel)                                                       0.1% xylene cyanol 
                                                                           10 mM EDTA 
                                                                            40% glycerol 
 
TAE (50×)                                                          242 g Tris base 
                                                                           57.1 ml Acetic Acid 
                                                                           100 ml 0.5 M EDTA  
                                                                           Add deionized water to 1 liter and adjust pH to   
                                                                           8.0 using NaOH 
 
TAE (1×)                                                            20 ml TAE (50×) 
(Agarose gels)                                                     in 980 ml deionized water                                             
 
SDS running buffer                                            25 mM Tris-HCl, pH 8.3 
(SDS-PAGE)                                                     192 mM glycine 
                                                                           0.1% (w/v) SDS 
 
15% Resolving gel                                             5.5 ml 40% gel (the molar ratio of acrylamide:  
 (SDS-PAGE)                                                     bisacrylamide is 37.5: 1)        
                                                                            3.8 ml 1.5 M Tris-HCl (pH 8.8)  
                                                                           150 μl 10% SDS                       
                                                                           150 μl 10% APS                       
                                                                            6 μl TEMED                             
                                                                           5.5 ml deionized water              
 
5% Stacking gel                                                 1.25 ml 40% gel (the molar ratio of  
 (SDS-PAGE)                                                     acrylamide: bisacrylamide is 37.5: 1)        
                                                                           1.25 ml 1 M Tris-HCl (pH 6.8)     
                                                                           100 μl 10% SDS                       
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                                                                           100 μl 10% APS       
                                                                           10 μl TEMED                             
                                                                           2.3 ml deionized water      
  
Protein loading buffer (5×)                                10% (w/v) SDS 
(SDS-PAGE)                                                      5% (w/v) β-mercaptoethanol 
                                                                           50% (w/v) glycerol 
                                                                           0.13% (w/v) bromophenol blue  
                                                                           312 mM Tris-HCl (pH 6.8)     
 
Coomassie brilliant blue solution                      0.1% (w/v) coomassie brilliant blue R250 
                                                                           40% (v/v) ethanol  
                                                                           10% (v/v) acetic acid 
 
Destaining solution                                            40% (v/v) methanol                                     
                                                                           10% (v/v) acetic acid 
 
P1 Buffer                                                            50 mM Tris-HCl, pH 8.0 
(Miniprep plasmid)                                            10 mM EDTA 
                                                                           100 μg/ml RNase A 
 
P2 Buffer                                                            200 mM NaOH 
(Miniprep plasmid)                                            1% SDS 
 
P3 Buffer                                                            2.8 M KAc, pH 5.1 
(Miniprep plasmid)        
 
Cell lysis buffer                                                 10 mM Tris-HCl pH 8.0 
                                                                           1 mM EDTA  
                                                                           0.1% (w/v) SDS 
 
Homogenization buffer                                      20 mM Tris-HCl pH 7.4 
(Microsomal preparation)                                  0.25 M sucrose 
                                                                           1 mM EDTA                                                                              
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Protease-inhibitors                                             Resuspending 1 pill in 2 ml PBS results 
                                                                            in a 25× stock solution   
                                                                           (COMPLETETM pills, Roche  
                                                                            Mannheim, Germany). 
 
Phosphate buffered saline                                  137 mM NaCl 
(PBS 1×)                                                             2.7 mM KCl 
                                                                            4.3 mM Na2HPO4 
                                                                           1.47 mM KH2PO4 
                                                                            pH 7.6 
 
PBS-T                                                                 0.1% (v/v) Tween-20 in PBS 
 
Blocking buffer                                                  5% milk powder in PBS-T 
(Western blot)                                                                                                                                                 
 
Transfer buffer                                                   25 mM Tris base 
(Western blot)                                                    0.2 M glycine 
                                                                           20% methanol 
                                                                            pH 8.5   
 
Stripping buffer                                                 100 mM glycine  
                                                                            pH 2.5 
 
RNA loading buffer (5×)                                   16 μl saturated aqueous bromophenol blue 
                                                                            solution    
                                                                           80 μl 500 mM EDTA, pH 8.0 
                                                                           720 μl 37% (12.3M) formaldehyde 
                                                                           2 ml 100% glycerol 
                                                                           3.084 ml formamide 
                                                                           4 ml 10 × Formaldehyde agarose gel buffer       
 
10 × Formaldehyde agarose gel buffer              200 mM MOPS 
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                                                                           50 mM sodium acetate 
                                                                           10 mM EDTA 
                                                                            pH 7.0 
 
SSC (20×)                                                          175.3 g NaCl 
                                                                           88.2 g sodium citrate 
                                                                           Add deionized water to 1 liter and adjust to 
                                                                            pH 7.0 
 
10% SDS solution                                              10 g SDS   
                                                                            Dissolve in 100 ml deionized water         
 
Blocking stock solution                                     10% (w/v) Blocking reagent        
(Northern blot)                                                    dissolve in 0.1 M Maleic acid  
                                                                            0.15 M NaCl 
                                                                             pH 7.5 
 
Prehybridization buffer                                      5 × SSC 
 (Northern blot)                                                  0 .1% N-lauroylsarcosine   
                                                                           0 .02% SDS       
                                                                           1% Blocking reagent      
                                                                           100 μg/ml Salmon sperm DNA       
 
Hybridization buffer                                          10 ml prehybridization buffer                                      
(Northern blot)                                                   150 μl γ-32P-labelled DNA probe                                               
 
Washing solution I                                            100 ml 20×SSC                             
2× SSC buffer, 0.1% SDS                                 10 ml 10% SDS solution 
(Northern blot)                                                   Add deionized water to1 liter                                                   
 
Washing solution II                                           10 ml 20×SSC                             
0.2× SSC buffer, 0.1% SDS                              10 ml 10% SDS solution 
(Northern blot)                                                   Add deionized water to1 liter                                                     
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TE buffer                                                           10 mM Tris-Cl, pH 7.5 
                                                                           1 mM EDTA 
 
3.1.17 Equipments 
Centrifuge Biofuge                                              Schnakenberg GmbH, Germany 
GeneQuant II Photometer                                    Pharmacia Biotech, Germany 
Gel iX Imager                                                      Intas GmbH, Germany 
Homogenizator                                                   Corlora Messtechnik GmbH, Germany                                    
Optima L90k Ultracentrifuge                              Beckman Coulter, Germany 
Scanner PowerLook III                                       Umax Digital, Germany 
SDS-PAGE electrophoresis apparatus                Roche Diagnostics, Germany 
T Profession Thermocycler                                 Biometra GmbH, Germany 
T1 Thermocycler                                                 Biometra GmbH, Germany 
Tecan Photometer                                                Tecan Trading AG, Switzerland 
Thermal Imaging System FTI-500                      Pharmacia Biotech, Germany 
XCell II Blot Module                                           Invitrogen Co., Germany 
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3.2 Methods 
3.2.1 Molecular biology 
3.2.1.1 Polymerase chain reaction (PCR) 
To amplify DNA fragments for cloning or detection, PCR was used. Taq polymerase was 
used for amplification of DNA fragments for subsequent cloning, while Phire Hotstart DNA 
polymerase was used for detection of specific DNA sequences. The following reaction 
mixture was used for the different applications: 
 
Reaction mixture for a PCR with Taq polymerase             
            MgCl2 (25 mM)                              10 μl  
            PCR buffer (10×)                            5 μl 
            dNTPs (10 mM)                             1 μl  
            Template                                         10-100 ng plasmid or 1 μl of cDNA 
            Forward primer                               10 μM 
            Reverse primer                               10 μM 
            Taq polymerase                              1 U 
           ddH2O                                              add to 50 μl 
 
Reaction mixture for a PCR with Phire Hotstart DNA polymerase 
           Phire Reaction buffer (5×)                4 μl 
           dNTPs (10 mM)                               0.4 μl  
           Forward primer                                10 μM 
           Reverse primer                                 10 μM 
           cDNA template                                 2 μl 
           Phire Hotstart DNA polymerase      0.4 U 
           ddH2O                                              add to 20 μl 
 
The PCR was performed with the following step gradient: 
                  95 ˚C    3 min                                initial denaturation step 
                  95 ˚C   30 sec                                denaturation 
                  45 ˚C   30 sec          × 30-40         annealing 
                  72 ˚C   30 sec                                elongation (1 min/1kb) 
                  72 ˚C   10 min                               final elongation step   
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                    4 ˚C                                             hold        
                (Taq polymerase) 
 
                  98 ˚C   30 sec                                initial denaturation step 
                  98 ˚C   10 sec                                denaturation 
                  60 ˚C   15 sec          × 30-40         annealing 
                  72 ˚C   15 sec                                elongation (20 sec/1kb) 
                  72 ˚C    1 min                                final elongation step         
                    4 ˚C                                             hold                                                       
                (Phire Hotstart DNA polymerase) 
 
3.2.1.2 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR is a PCR amplification of a product from the reverse transcription (RT) reaction, 
where all messenger RNAs (mRNAs) are reverse transcribed into single-stranded 
complementary DNA (cDNA). This is followed by a PCR reaction for amplification of a 
specific cDNA using Phire Hotstart DNA polymerase as specified above. Reverse 
transcriptase was used according to the manufacturer’s instructions. Reverse transcription was 
performed using oligo (dT) primer targeting the 3’ poly (A) mRNA tail. The following RT 
reaction mixture was used:    
                RevertAidTM buffer (5×)              6.9 μl 
                RNA                                               2 μg 
                dNTPs (10 mM)                             3 μl 
                Oligo(dT) 15 primer                       1 μl 
                RvertAid M-MuLV                        1 μl 
                (Reverse Transcriptase)    
                RNase inhibitor                              1 μl 
                ddH2O                                             add to 34.4 μl 
The reaction mixture was incubated at 42 ˚C for 60 min and then the enzyme was inactivated 
at 70 ˚C for 10 min. 2 μl of the cDNA was used directly for the subsequent PCR or cDNA 
samples were stored at -80 ˚C until use. 
 
3.2.1.3 DNA Gel-electrophoresis 
DNA fragments were separated in horizontal electrophoresis chambers using agarose gels. 
Agarose gels were prepared by heating 0.8-2% (w/v) agarose in 1× TAE buffer, depending on 
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the size of the DNA fragments. The samples were mixed with an appropriate amount of 6 × 
DNA loading dye and loaded on the agarose gel. The gels were run at constant current (100 
mA). The gels were stained in ethidium bromide (EB) solution (5 min, room temperature) 
with constant agitation. The gels were then placed in water for 5 min. Finally, the gels were 
documented using the Gel UV-light documentation system. For semi-quantitative RT-PCR, 
gel electrophoresis of PCR samples was performd using 1% agarose gels. 0.5 g of agarose 
was suspended in 50 ml of 1× TAE buffer and melted in a microwave. After cooling to 
approximately 50 ˚C, 5 μl of GelRed was added and the solution was poured into a casting 
tray. After half an hour the gel was solidified and then submerged into 1× TAE running 
buffer. The 20 μl of PCR sample was mixed with 6× DNA loading dye and loaded on the 
agarose gel. DNA fragments were separated at 100 V for 40 min. The DNA fragments were 
visualized under UV-light (Gel iX Imager). 
 
3.2.1.4 Digestion of plasmid 
The plasmid was incubated with an appropriate amount of restriction enzymes in the 
recommended buffer in a final volume of 20 μl in a 1.5 ml Eppendorf tube for 1-2 hours at 37 
˚C. The digestion was terminated by heating 80 ˚C for 20 min. Then, the tube was placed on 
ice for 5 min. Finally, the digested DNA was applied to an agarose gel.  
 
3.2.1.5 Dephosphorylation of plasmid DNA 
After digestion, the plasmid DNA was dephosphorylated by direct addition 1 U of Shrimp 
Alkaline Phosphatase (SAP) and 4 μl of SAP buffer (Fermentas, St. Leon-Rot, Germany) to 
the restriction reaction in a final volume of 60 μl. The dephosphorylation was carried out at 
37 ˚C for 15-20 min. 
 
3.2.1.6 Extraction of DNA fragments  
For isolation and purification of DNA fragments from agarose gels, ethidium bromide stained 
gels were illuminated with UV-light and the appropriate DNA band was excised from the gel 
with a clean scalpel and transferred into an Eppendorf tube. The fragment was mostly isolated 
using QIAEX II Gel Extraction Kit (QIAGEN, Hilden, Germany) following the 
manufacturer’s instructions. In some cases, isolation and purification of DNA fragments were 
used by phenol/chloroform: After digestion of DNA, ddH2O was added up to 200 μl, followed 
by 100 μl of phenol. The reaction mixture was shaken and incubated at room temperature for 
5 min, followed by centrifugation at 13,000 rpm for 5 min. Then, the upper phase was 
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transferred to a new tube, 100 μl of chloroform was added and after vortexing, the mixture 
was again centrifuged at 13,000 rpm for 1 min (twice). The upper phase was transferred to a 
new tube and two volumes of 100% ethanol and 1/20 volume of 5 M NaCl were added, 
followed by centrifugation at 13,000 rpm for 10 min. The DNA pellet was washed with 200 
μl of 70% ethanol, and then centrifuged at 13,000 rpm for 10 min. Finally, the pellet was 
dried at room temperature for 5 min and dissolved in 10 μl ddH2O. 
 
3.2.1.7 Ligation of DNA fragment 
Ligation of DNA fragment was performed by mixing 10-100 ng of plasmid DNA with the 
insert DNA. The reaction mixture was supplemented with 1 U of T4-DNA Ligase (Fermentas, 
St. Leon-Rot, Germany), 1 μl of ligation buffer (10×) and filled up to a final volume of 10 μl 
ddH2O. The reaction was incubated at room temperature for 1-2 hours or at 4 ˚C overnight, 
which was used directly for transformation in competent E.coli bacteria. 
 
3.2.1.8 Transformation of bacteria 
To 100 μl of competent E.coli HB101 either 50-100 ng of plasmid DNA or 10 μl of ligation 
mixture were added and incubated for 30 min on ice. After a heat shock at 42 ˚C for 90 sec 
and successive incubation on ice for 5 min, 400 μl of SIN medium was added to the bacteria 
and the bacterial suspension was shaken at 37 ˚C and 110 rpm for 60 min. After that, bacteria 
were spreaded on SIN-agar plates containing the appropriate antibiotics. Plates were 
incubated at 37 ˚C overnight. 
 
3.2.1.9 Plasmid isolation from 1 ml of bacterial cultures (Minipreps) 
A single colony was inoculated into 0.5-1 ml of SIN medium supplemented with the 
appropriate antibiotic and incubated at 37 ˚C with constant agitation for 5 hours. Bacterial 
cultures were pelleted by centrifugation (13,000 rpm, 20 sec.) and the bacterial pellet was 
resuspended in 50 μl of P1 buffer. For bacterial lysis, 50 μl of P2 buffer was added to the 
suspension which was then mixed thoroughly by vigorously inverting 4-6 times and incubated 
at room temperature for 5 min. Then, 50 μl of P3 buffer was added and the mixture was 
inverted until a homogenous suspension containing a white flocculate was formed. The 
bacterial lysate was cleared by centrifugation (13,000 rpm, 10 min) and the supernatant was 
transferred to a new eppendorf tube and two times the supernatant volume of 100% ethanol 
was added. The plasmid DNA was precipitated by centrifugation (13,000 rpm, 10 min). 
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Finally, the pellet was dried at room temperature for 5 min and dissolved in 10 μl of TE 
buffer. 
 
3.2.1.10 Plasmid isolation from 50 ml of bacterial cultures (Midipreps) 
For preparation of large quantities of high- or low-copy plasmid DNA, the QIAGEN Plasmid 
MIDI Kit was used. First, the bacterial cells were harvested by centrifugation at 6000× g for 
10 min at 4 ˚C. The bacterial pellet was resuspended in 4 ml of P1 buffer, then 4 ml of P2 
buffer was added, and the suspension was thoroughly mixed by vigorously inverting the 
sealed tube 4-6 times and incubated at room temperature for 5 min. 4 ml of chilled P3 buffer 
was added, and the suspension was thoroughly mixed by vigorously inverting 4-6 times and 
incubated on ice for 15 min, followed by centrifugation at 13,000× g for 10 min at 4 ˚C. The 
QIAGEN-tip was equilibrated by applying 3 ml of QBT buffer, and the column was allowed 
to empty by gravity flow. The supernatant was applied from last centrifugation to the 
QIAGEN-tip with filter paper and allowed to enter the resin by gravity flow. The QIAGEN-
tip was washed with 2× 10 ml of wash buffer. The DNA was eluted with 5 ml of elution 
buffer and precipitated by adding 5 ml of room temperature isopropanol to the eluted DNA, 
followed by centrifugation immediately at 13,000× g for 10 min at 4 ˚C. The supernatant was 
carefully decanted. The DNA pellet was washed with 2 ml of room temperature 70% ethanol, 
followed by centrifugation at 13,000× g for 5 min. The supernatant was carefully decanted 
without disturbing the pellet. The pellet was dried for 5-10 min.  Finally, the plasmid pellet 
was dissolved in 500 μl of TE buffer and the plasmid concentration was determined by UV-
spectrophotometry. 
 
3.2.1.11 DNA sequencing 
DNA sequencing was performed by the company Eurofins MWG Operon (Ebersberg, 
Germany). For sequencing 0.7 μg of plasmid DNA was diluted in 15 μl of TE buffer. 
 
3.2.1.12 Isolation of genomic DNA from A549 cells  
A549 cells were harvested from the flask surface by mechanical scraping with cell scraper. 
After that, A549 cells were resuspended in 1 ml of cell lysis buffer and transferred into a new 
tube. Isolation of genomic DNA was used by phenol/chloroform: The suspension was added 1 
ml of phenol and mixed by vortexing for 1 min. Then the suspension was incubated at room 
temperature for 5 min, followed by centrifugation at 13,000 rpm for 5 min. Then, the upper 
phase was transferred to a new tube, 1 ml of chloroform was added and after vortexing, the 
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mixture was again centrifuged at 13,000 rpm for 1 min (twice). The upper phase was 
transferred to a new tube and two volumes of 100% ethanol were added, followed by 
centrifugation at 13,000 rpm for 10 min. The DNA pellet was washed with 2 ml of 70% 
ethanol, and then centrifuged at 13,000 rpm for 5 min. Finally, the pellet was dried at room 
temperature for 5 min and dissolved in 500 μl of TE buffer. 
 
3.2.1.13 Determination of DNA or RNA concentration 
DNA or RNA concentration was determined using GeneQuant II Photometer (Pharmacia, 
Germany). The DNA or RNA samples were normally diluted in ratio of 1: 10, 10 μl of sample 
was used for every determination.  
 
3.2.1.14 RNA Isolation 
The cells were harvested from the flask surface by mechanical scraping with cell scraper. 
After that, total RNA was isolated from the A549 or HepG2 cells using the Master Pure RNA 
Purification Kit according to the manufacturer’s instructions. RNA concentration was 
determined by UV-spectrophotometry. 2 μg of isolated total RNA was used as template for 
RT-PCR reaction, as described in 3.2.1.2. 
 
3.2.1.15 Northern blot 
3.2.1.15.1 Preparation of RNA samples 
First, the HepG2 cells were harvested from the flask surface by mechanical scraping with cell 
scraper. After that, total RNA was isolated from HepG2 cells with RNA Purification Kit 
according to the manufacturer’s instructions. The human hepatocyte total RNA samples were 
obtained from BioCat GmbH (Heidelberg, Germany). 
 
3.2.1.15.2 RNA electrophoresis 
Total RNA was separated by electrophoresis under denaturing conditions on a 2% agarose gel 
containing 2.2 M formaldehyde. 10 μg of RNA mixed with 6 μl of 5× RNA loading buffer 
was loaded. The gel was run in RNA electrophoresis buffer at 80 mA constant current. 
 
3.2.1.15.3 Transfer and fixation of RNA to membrane 
Capillary transfer of RNA from an agarose gel to nylon membrane (Amershen Biosciences, 
Germany) was carried out at neutral pH in 20× SSC buffer (pH 7.0) overnight. For fixation of 
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RNA to the membrane, the membrane was placed between two dry filter papers (Whatman, 
Germany) and baked at 100 ˚C for 1 hour. 
 
3.2.1.15.4 Preparation of γ-32P-labelled DNA probe 
1 μl of DNA oligonucleotide probe (100 pmol/μl), 2 μl of 10× T4 Polynucleotide Kinase 
buffer, 1 μl of γ-32P-ATP, 1 μl of T4 Polynucleotide Kinase, and 15 μl of distilled water were 
mixed and incubated at 37 ˚C for 1 hour. The labelled DNA probe was extracted with 
phenol/chloroform and precipitated with ethanol. Finally, the labelled DNA probe was 
dissolved in 150 μl of TE buffer. 
 
3.2.1.15.5 Hybridization, washing and exposure to X-ray film 
The membrane was put into a hybridization bottle and incubated in prehybridization buffer at 
37 ˚C for 30 min under rotation. Hybridization buffer with labelled DNA probe was boiled at 
95 ˚C for 10 min and chilled on ice for 10 min. The membrane was put into hybridization 
buffer and incubated at 37 ˚C overnight in the hybridization bottle under rotation. The 
membrane was washed twice with 2× SSC, 0.1% SDS for 5 min at room temperature and then 
washed twice with 0.2× SSC, 0.1% SDS for 15 min at 37 ˚C. The membrane was baked at 80 
˚C for 10 min, then wrapped in plastic and exposed to X-ray film. 
 
3.2.2 Cell culture and cell-based assays 
3.2.2.1 Cell cultivation 
All human cells were cultured at 37 ˚C with 5% CO2 in a 90% humified atmosphere. A549 
cells (human lung adenocarcinoma cell line) were usually grown in 75 cm2 flasks or 96-well 
plates in DMEM High Glucose (4.5 g/l) Medium with L-Glutamine supplemented with 10% 
FBS and 1% penicillin/streptomycin. HepG2 cells (human hepatoma cell line) were normally 
grown in 75 cm2 flasks or 96-well plates in DMEM Ham’s F-12 Medium with L-Glutamine 
supplemented with 10% FBS and 1% penicillin/streptomycin. For maintenance, medium was 
refreshed at least three times weekly. Cells were passaged at around 90% confluency. 
Adherent cells were detached by 2 ml of trypsin/EDTA for 3 min at 37 ˚C. After 
centrifugation (1000 rpm, 5 min), the cell pellet was gently resuspended in fresh medium. The 
split ratio was 1: 5 – 1: 10. 
 
3.2.2.2 Transfection of mammalian cells 
3.2.2.2.1 Plasmid DNA Transfection 
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To transfect mammalian cells with plasmid DNA in a 96-well plate, one day before 
transfection, the cells were changed with 200 μl of fresh growth medium without antibiotics 
so that cells will be 90-95% confluent at the time of transfection. For each transfection 
sample, complexes were prepared as follows: Plasmid DNA (10-50 ng) was diluted in 25 μl 
of Opti-MEM I Reduced Serum Medium without serum. After gently mixing the transfection 
reagent (LipofectamineTM 2000) before use, 0.3-0.6 μl (depending on different cell lines) of 
transfection reagent was diluted in 25 μl of Opti-MEM I Reduced Serum Medium and 
incubated at room temperature for 5 min. After 5 min of incubation, the diluted DNA and the 
diluted transfection reagent were combined and incubated at room temperature for 20 min. 
Before addition of complexes, the growth medium was removed from the cells and the cells 
were covered with 100 μl of fresh growth medium without antibiotics. Then, 50 μl of 
complexes were added to each well. The plate was gently rocked back and forth and 
incubated at 37 ˚C in a CO2 incubator for 48 hours. 
 
3.2.2.2.2 MicroRNA Transfection 
To transfect mammalian cells with microRNAs in a 6-well plate or 75 cm2 flask, one day 
before transfection, the cells were changed with 3 ml or 22 ml (6-well plate, 75 cm2 flask) of 
fresh growth medium without antibiotics so that cells will be 80-90% confluent at the time of 
transfection. For each transfection sample, complexes were prepared as follows: microRNA 
(150 pmol, 6-well plate; 600 pmol, 75 cm2 flask) was diluted in 250 μl or 1.5 ml (6-well plate, 
75 cm2 flask) of Opti-MEM I Reduced Serum Medium without serum. After gently mixing 
the transfection reagent (LipofectamineTM 2000) before use, 5 μl or 35 μl (6-well plate, 75 
cm2 flask) of transfection reagent was diluted in 250 μl or 1.5 ml (6-well plate, 75 cm2 flask) 
Opti-MEM I Reduced Serum Medium and incubated at room temperature for 5 min. After 5 
min of incubation, the diluted microRNA and the diluted transfection reagent were combined 
and incubated at room temperature for 20 min. Before addition of complexes, the cells were 
changed with 2 ml or 19 ml (6-well plate, 75 cm2 flask) of fresh growth medium without 
antibiotics. Then, complexes were added to cells. The plate or flask were gently rocked back 
and forth and incubated at 37 ˚C in a CO2 incubator for 48 hours. 
 
3.2.2.2.3 Cotransfection of mamalian cells with plasmid DNA and microRNA 
To cotransfect mammalian cells with plasmid DNA and microRNA in a 96-well plate, one 
day before cotransfection, the cells were changed with 200 μl of fresh growth medium 
without antibiotics such that cells will be 80-90% confluent at the time of transfection. For 
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each transfection sample, DNA-miRNA molecule-LipofectamineTM 2000 complexes were 
prepared as follows. The DNA (10 ng) and miRNA (3 pmol) were diluted in 25 μl of Opti-
MEM I Reduced Serum Medium without serum. The transfection reagent was diluted in 25 μl 
of Opti-MEM I Reduced Serum Medium without serum and incubated for 5 min at room 
temperature. After 5 min of incubation, the diluted DNA and miRNA molecule and the 
diluted transfection reagent were combined and incubated for 20 min at room temperature. 
Before addition of complexes, the growth medium was removed from the cells and the cells 
were covered with 100 μl of fresh growth medium without antibiotics. Then, 50 μl of 
complexes were added to each well. The plate was gently rocked back and forth and 
incubated at 37 ˚C in a CO2 incubator for 48 hours. 
 
3.2.2.2.4 Cotransfection of HepG2 cells with plasmid DNA and microRNA/AMOs 
To cotransfect HepG2 cells with plasmid DNA and microRNA/AMOs in a 96-well plate, one 
day before cotransfection, the cells were changed with 200 μl of fresh growth medium 
without antibiotics such that cells will be 80-90% confluent at the time of transfection. For 
each transfection sample, DNA-microRNA/AMOs-LipofectamineTM 2000 complexes were 
prepared as follows. The plasmid DNA (50 ng) and miRNA (3 pmol)/AMOs (15 pmol) were 
diluted in 25 μl of Opti-MEM I Reduced Serum Medium without serum. Then, the complexes 
were incubated at 70 ˚C for 3 min and cooled down around 30 ˚C. The transfection reagent 
was diluted in 25 μl of Opti-MEM I Reduced Serum Medium without serum and incubated 
for 5 min at room temperature. After 5 min of incubation, the diluted DNA and 
miRNA/AMOs and the diluted transfection reagent were combined and incubated for 20 min 
at room temperature. Before addition of complexes, the growth medium was removed from 
the cells and the cells were covered with 100 μl of fresh growth medium without antibiotics. 
Then, 50 μl of complexes were added to each well. The plate was gently rocked back and 
forth and incubated at 37 ˚C in a CO2 incubator for 48 hours. 
 
3.2.2.3 Luciferase reporter assay 
After transfection of plasmid DNA or cotransfection of plasmid DNA and miRNA for 48 
hours, a 96-well plate was removed from the incubator. The medium on the cells was 
removed and 75 μl of fresh growth medium was added to each well. For measuring firefly 
luciferase activity, 75 μl of Dual-GloTM Luciferase Reagent was added to each well. The plate 
was gently rocked back and forth for 10 min. Then, the cell lysates were transferred to a 96-
well white microplate (Greiner bio-one, BioScience, Germany). The firefly luminescence was 
Materials and Methods 
 52
measured using GENios Pro microplate reader (Tecan GmbH, Crailsheim, Germany). For 
measuring Renilla luciferase activity, 75 μl of Dual-GloTM Stop & Glo Reagent was added to 
each well and mixed gently. After 10 min, the Renilla luminescence was measured using 
GENios Pro microplate reader (Tecan GmbH, Crailsheim, Germany). Renilla luminescence 
should be measured in the same plate order as the firefly luminescence was measured using 
GENios Pro microplate reader (Tecan GmbH, Crailsheim, Germany).  
 
3.2.2.4 Calculation of relative luciferase activity 
After measurement of the firefly luciferase luminescence and Renilla luciferase luminescence, 
the ratio of luminescence from the experimental reporter (firefly luciferase) to luminescence 
from the control reporter (Renilla luciferase) was calculated as followed.  
Relative luciferase activity (%) = RLU firefly/ RLU Renilla (%) 
 
3.2.2.5 Induction cells with regulatory factors 
 Cells were maintained and transfected as described above. One day before induction, the 
cells (96-well plate) were changed with 200 μl of fresh growth medium. The regulatory factor 
was diluted with fresh medium. After 4 hours of transfection, the resulting solution was 
directly added onto the cells. The plate was gently rocked back and forth and incubated at 37 
˚C in a CO2 incubator for 48 hours. 
 
3.2.3 Protein biochemical methods 
3.2.3.1 Preparation of microsomes from human liver tissue (Maser et al., 2002) 
The homogenization buffer was supplemented with protease inhibitor solution before use. The 
complete procedure was performed on ice or at 4 ˚C. Human liver samples were obtained 
following routine surgical procedures and in accordance with German legislation. Samples 
were rinsed in an ice-cold isotonic solution of NaCl and homogenized in four volume of ice-
cold homogenization buffer with a homogenizator (Corlora Messtechnik GmbH, Germany). 
The homogenate was centrifuged at 600× g for 10 min and 10,000× g for 10 min to sediment 
nuclei, cell debris, and mitochondria. The supernatant at this stage was centrifuged at 
100,000× g for 1 h to sediment the microsomes. The microsomal pellet was resuspended and 
washed with 150 mM KCl to remove glycogen, then centrifuged at 100,000× g for 45 min. 
Finally, the pellet was resuspended in the homogenization buffer without protease inhibitor 
and stored at -80 ˚C. 
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3.2.3.2 Preparation of cell total protein 
The cells were harvested from the flask surface by mechanical scraping with cell scraper and 
washed with PBS buffer and centrifuged at 1000 rpm for 5 min. The homogenization buffer 
was supplemented with protease inhibitor solution before use. The cell pellets were 
resuspended in 1 ml of ice-cold homogenization buffer. Then, cells were repeatedly frozen 
and thawed for 10 times. The cell lysates were centrifuged at 13,000× g for 30 min. The 
supernatant containing total protein was transferred to a new tube and stored at -80 ˚C. 
 
3.2.3.3 Bradford assay for determination of protein concentration  
The concentration of protein sample was determined using the Bradford protein assay. Five 
standard solutions of BSA with concentration ranging from 0.1 to 1.4 mg/ml were prepared to 
generate a standard curve using the corresponding sample buffer. Protein sample was diluted 
1: 10 to get a concentration within the linear range of the standard protein. 5 μl of blank 
(buffer only), 5 μl of each standard solution and 5 μl of each sample were distributed in a 96-
well plate. Each measurement was performed at least in duplicates. 250 μl of Bradford 
reagent was added to each well, followed by 5 min of incubation at room temperature. 
Finally, absorbance at 595 nm was measured with GENios Pro microplate reader (Tecan 
GmbH, Crailsheim, Germany).  
 
3.2.3.4 SDS-polyacrylamid gel electrophoresis (SDS-PAGE) 
Separation of protein was performed with a discontinuous SDS-PAGE using the Mini-Protean 
III system (Bio-Rad Laboratories GmbH, Munich, Germany). The resolving and stacking gels 
were prepared as described in 3.1.16. After complete polymerization of the gel, the chamber 
was assembled as described by the manufacturer’s protocol. SDS running buffer was added. 
Protein sample was supplemented with protein loading buffer and heated at 95 ˚C for 5 min 
before loading to the gel. Up to 30 μl sample was loaded into the pockets and the gel was run 
at constant voltage at 80 V for 15 min and then at 140 V for the remainder. The gel run was 
stopped when the bromophenol blue line reached the end of the gel. Ater electrophoresis, the 
proteins were visualized by staining with Coomassie brilliant blue solution at room 
temperature for half an hour and destaining with destaining solution at room temperature for 
an hour.  
 
3.2.3.5 NuPAGE and Western blotting 
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The proteins were separated with a NuPAGE Novex Bis-Tris Mini Gels (Invitrogen GmbH, 
Darmstadt, Germany) using XCell SureLock Mini-Gel (Invitrogen GmbH, Darmstadt, 
Germany) according to manufacturer’s protocol. The proteins were transferred from the 
NuPAGE mini gel on a polyvinylidene difluoride (PVDF) membrane using the XCell II TM 
Blot Module (Invitrogen GmbH, Darmstadt, Germany). First the PVDF membrane was 
activated by methanol for 30 sec, and subsequently soaked with transfer buffer. Also the 
blotting pads and 2 pieces of Whatman filter papers were soaked with transfer buffer. The 
blotting sandwich was assembled according to manufacturer’s instructions. Proteins were 
transferred at 30 V constant for 1 hour. Afterwards the membrane was blocked in 5% milk 
powder in PBS-T for 1 hour at room temperature or overnight at 4 ˚C. The membrane was 
rinsed shortly two times with PBS-T. The membrane was incubated with primary antibody at 
room temperature for 1 hour with constant agitation. The membrane was washed three times 
with PBS-T for 10 min and the appropriate secondary antibody was probed at room 
temperature for 1 hour with constant agitation. After three washing steps, the membrane was 
incubated with ECL and Amersham ECL Advance Western Blotting Detection Reagents (GE 
Healthcare, Munich, Germany) according to manufacturer’s instructions. The membrane was 
exposed to X-ray film (GE Healthcare, Munich, Germany). 
 
3.2.3.6 Stripping of membrane 
After detection, the membrane was incubated in stripping buffer two times for 25 min. The 
membrane was washed 3× with PBS-T for 10 min. Then, the membrane was reactivated by 
dipping into methanol for 5 sec. After that, the membrane was washed 3× with PBS-T for 5 
min and then redone by Western blot analysis from blocking procedure.  
 
3.2.4 Web-based tools 
3.2.4.1 Prediction of miRNAs and web-based tissue profiling  
Four different miRNA target prediction tools were applied to search for microRNA response 
elements (MREs) in the 3’UTR of human HSD11B1 mRNA, namely Diana micro-T-ANN 
(http://diana.cslab.ece.ntua.gr/microT_ANN/, Maragkakis et al., 2009a; Maragkakis et al., 
2009b), TargetScan (http://www.targetscan.org, Lewis et al., 2005; Liu et al., 2003; Grimson 
et al., 2007; Lewis et al., 2003), microRNA (http://www.microrna.org, Betel et al., 2008), and 
MicroCosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/, 
Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008). Non-human miRNAs were removed 
from the results obtained by MicroCosm Targets. The miRNAs identified by at least three 
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prediction tools were pre-selected for web-based tissue profiling using the smiRNAdb 
miRNA expression atlas (www.mirz.unibas.ch, Landgraf et al., 2007; Hausser et al., 2009), 
choosing liver as target tissue including all subsamples, e.g. hepatoma samples and cell lines. 
The smiRNAdb miRNA expression atlas is based on relative cloning frequencies which 
represents a measure of miRNA expression (Landgraf et al., 2007). The relative cloning 
frequencies are expressed as log2 values, i.e. a value of e.g. -2 signifies a relative cloning 
frequency of 2-2 x 100% =25%. 
 
3.2.4.2 Pathway Enrichment Analysis using DIANA mirPATH 
Two miRNAs, hsa-miR-561 and hsa-miR-579 were subjected to a pathway enrichment 
analysis by DIANA-mirPATH (http://diana.cslab.ece.ntua.gr/pathways/, Papadopoulos et al., 
2009), using the online tool for multiple miRNAs analysis and the beta-version of the 
prediction software DIANA-microT-4.0. The enrichment analysis compares the set of 
predicted target genes for each miRNA with all biological pathways in the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (Papadopoulos et al., 2009; Kanehisa 
et al., 2000). Results are ranked by negative natural logarithm of the p-value. P-values < 0.01 
and < 0.05 correspond to –ln (p-value) > 4.6 and > 3.0, respectively. 
 
3.2.5 Statistical analysis 
Data are expressed as average ± SD (standard deviation). Statistical analysis was performed 
by using a Student’s t test. A p-value below 0.05 was considered statistically significant (* P 
< 0.05; ** P < 0.01; *** P < 0.001). 
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4 Results 
4.1 miRNA prediction  
To investigate the potential impact of miRNAs in HSD11B1 expression, four different 
miRNA target prediction tools were applied to predict miRNA response elements (MREs) in 
the 3’UTR of human HSD11B1 mRNA, yielding four different lists of miRNAs (Table 4.1). 
Diana microT suggested in total four miRNAs while the other three prediction tools proposed 
considerably more miRNAs, namely 50 (TargetScan), 46 (microRNA), 57 (MicroCosm 
Targets). Two miRNAs (hsa-miR-561 and hsa-miR-579) were predicted by all four different 
tools and thus directly selected for functional analysis. Twenty additional miRNAs were 
predicted by three of four tools (Table 4.1). Subjecting all twenty-two miRNA candidates to 
web-based tissue profiling using the smiRNAdb miRNA expression atlas 
(www.mirz.unibas.ch, Hausser et al., 2009; Landgraf et al., 2007) revealed that at least five 
miRNAs are expressed in hepatocytes including the above mentioned hsa-miR-579, but also 
hsa-miR-142-5p, hsa-miR-181a, hsa-miR-181b, and hsa-miR-340 (Figure 4.1). From the 
latter four miRNAs, two of them were selected with higher ranking in the various predictions, 
namely hsa-miR-181b and hsa-miR-340, as additional candidates for functional analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 MiRNA candidates for regulation of HSD11B1 expression. Four different miRNA target gene 
prediction tools (head row) were used to identify miRNA candidates for binding to the 3’UTR of HSD11B1 
mRNA. Only candidates identified independently by at least three different tools are shown with the ranks from 
the corresponding hit lists. For TargetScan, double ranks indicate two potential binding sites with different 
scores; for all other tools, the number of binding sites contributes to the score and thus to the ranking. All 
displayed miRNAs were selected for visualisation of miRNA profiles (http://www.mirz.unibas.ch, Figure 4.1). 
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prediction             Rank in                  Rank in               Rank in            Rank in 
tool          DIANA microT1      TargetScan2          microRNA3       MicroCosm    
hsa-miR-                                                                                                         Targets4,5 
132                             -                                6                        26                         25 
142-5p                       -                               45                        41                        35 
      181a                           -                               30                        31                        23 
      181b                           -                               28                         4                           4 
      181c                           -                               29                        42                        40 
      181d                           -                               27                         2                           1 
      212                             -                                5                        11                        14 
      330-5p                       -                             11 ,15                     3                          2                  
      340                             -                               46                         9                          9 
      376a                           -                                10                       17                          7 
      376b                           -                                 9                        18                        10 
410                             -                              37,40                    33                        36 
      450b-5p                     -                                21                         5                          6 
      513a-3p                     1                              39, 50                   16                         - 
      561                             2                                1                          8                         16 
      577                             -                               7,8                       22                        18 
      579                             4                                2                        20                         29 
      593                             -                               16                        24                          8 
605                             -                                 4                        14                          3 
      637                             -                               13                        29                        17 
      647                             -                               32                        25                        19 
      889                             3                              38                         40                         - 
 
 
 
 
 
 
 
1 http://diana.cslab.ece.ntua.gr/microT (Maragkakis et al., 2009a; Maragkakis et al., 2009b) 
2 http://www.targetscan.org (Lewis et al., 2005; Liu et al., 2003; Grimson et al., 2007; Lewis et al., 2003); the 
list includes miRNAs binding to poorly conserved sites. 3 http://www.microrna.org (Betel et al., 2008) 
4 http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/ (Griffiths-Jones et al., 2006; Griffiths-Jones et 
al., 2008); non-human miRNAs and miRNA* species were not considered 
5 Results for 3’-UTR of transcript ENST00000367028 
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Figure 4.1 Results of the web-based tissue profiling. Twenty-two miRNAs were suggested as potential 
regulators of HSD11B1 expression by at least three of four miRNA target prediction tools (see Table 4.1) and 
subjected to tissue profiling using the publicly available smiRNAdb miRNA expression atlas 
(http://www.mirz.unibas.ch/). Expression levels of miRNAs (rows) are estimated by relative cloning frequencies 
which are expressed as log2 values and displayed with a colour code according to the left panel. Yellow colour 
indicates high cloning frequency, blue colour indicates low cloning frequency and black colour indicates no 
detection. The columns represent different hierarchical categories and samples of the smiRNAdb miRNA 
expression atlas: 8.0.0.0: Liver represents all hepatocyte samples; 8.2.0.0: hepatoma cell represents the human 
HepG2 and PLC hepatoma cell lines; 8.1.0.0: hepatocellular carcinoma represents the HuH7 hepatoma cell line. 
‘Liver’ is a normal liver from a 43-year old female (Landgraf et al., 2007). 
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4.2 Construction of pmir-HSD11B1-3’UTR plasmid (dual-luciferase assay 
system) 
The pmir-GLO, dual-luciferase miRNA target expression vector, is designed to quantitatively 
evaluate miRNAs activity by the insertion of miRNA target sites on the downstream of the 
firefly luciferase gene. Firefly luciferase is the primary reporter gene; reduced firefly 
luciferase expression indicates the binding of endogenous or introduced miRNAs to the 
cloned miRNA target sequence. The map of pmir-GLO vector is shown in Appendix 7.1.2, 
firefly luciferase is used as the primary reporter to monitor mRNA regulation, and Renilla 
luciferase is acting as a control reporter for normalization and selection. Therefore, the pmir-
GLO vector was used to study miRNA function. The complete 3’UTR sequence of the 
HSD11B1 mRNA was cloned into pmir-GLO vector between the XhoI and SalI sites, 
immediately 3’ downstream in the firefly luciferase gene as follows: First, the complete 
3’UTR sequence of the HSD11B1 mRNA was amplified from a human liver cDNA library 
(UniZAP XR, Stratagene) using HSD11B1-3’UTR-primers (see Table 3.3). The desired 
3’UTR sequence of the HSD11B1 mRNA was designed 429 bp in length, the PCR product 
was visualized by agarose gel (Figure 4.2). Then, the fragment was inserted into the pCR2.1-
TOPO vector (Appendix 7.1.1). The sequencing result corresponded to the published one 
(http://www.ncbi.nlm.nih.gov/nuccore/NM_005525.3, 
http://www.ncbi.nlm.nih.gov/nuccore/NM_181755.2, see Appendix 7.2.1). Subsequently, the 
3’UTR sequence was released from the pCR2.1-TOPO vector by XhoI and SalI and ligated 
into pmir-GLO. The resulting plasmid was named pmir-HSD11B1-3’UTR (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.2 The PCR product from a human liver cDNA library.  
Lane 1: HSD11B1-3’UTR  Lane 2: 1 kb DNA ladder 
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4.3 Optimizing plasmid DNA (pmir-HSD11B1-3’UTR) transfection 
To obtain the highest transfection efficiency and low cytotoxicity, transfection conditions 
were optimized by DNA and LipofectamineTM 2000 (transfection reagent) concentrations in 
different cell lines, which are A549 (human lung adenocarcinoma cell line), HepG2 (human 
hepatoma cell line) and 3T3-L1 (Mouse embryonic fibroblast adipose like cell line) cell lines, 
respectively. One day before transfection, each well (96-well plate) was plated with 0.6-2× 
104 cells (depending on different cell lines) in 200 μl of growth medium without antibiotics so 
that cells would be greater than 90% confluent at the time of transfection and DNA (μg): 
LipofectamineTM 2000 (μl) ratios varied from 1: 0.5 to 1: 5 (Table 4.2). After 48 hours of 
transfection, the firefly luciferase and Renilla luciferase activities were measured using Dual-
GloTM Luciferase Reagent (see Method 3.2.2.3). 
 
 
 
Figure 4.3 Schematic overview of cloning of HSD11B1-3’UTR into pmir-GLO. 
See text for details 
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                   Ratio                               Plasmid DNA [µg/well]          Lipofectamin 2000 
DNA (μg): Lipofectamine 2000 (μl)                                                                 [µl/well] 
                  1 : 0.5                                              0.2                                        0.1 
                  1 : 1                                                 0.2                                        0.2 
                  1 : 2                                                 0.2                                        0.4 
                  1 : 3                                                 0.2                                        0.6 
                  1 : 5                                                 0.2                                        1.0 
 
For transfection of HepG2 cells, the value of firefly luminescence was gradually enhancing 
due to increased transfection reagent and the maximum value of firefly luminescence was 
DNA (μg): LipofectamineTM 2000 (μl) = 1: 3 (Figure 4.4A). Meanwhile, the value of Renilla 
luminescence got the maximum value as well as DNA (μg): LipofectamineTM 2000 (μl) = 1: 3 
(Figure 4.4B). However, when DNA (μg): LipofectamineTM 2000 (μl) ratio was 1: 5, the 
values of firefly luminescence and Renilla luminescence were decreased, because increased 
transfection reagent was toxic to cells and part of cells were dead. The result showed that the 
ratio of Firefly/Renilla luminescence was unchanged (Figure 4.4C), even DNA (μg): 
LipofectamineTM 2000 (μl) ratios varied from 1: 0.5 to 1: 5. Therefore, when the DNA (μg): 
LipofectamineTM 2000 (μl) ratio was 1: 3 in HepG2 cells, the transfection efficiency got the 
highest level and the values of firefly luminescence and Renilla luminescence reached the 
maximum at the same time.  
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 The ratio of DNA (μg): LipofectamineTM 2000 (μl) 
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For transfection of A549 cells, the value of firefly luminescence was gradually enhancing, 
when DNA (μg): LipofectamineTM 2000 (μl) ratio was 1: 2, the value of firefly luminescence 
reached the maximum (Figure 4.5A). Then, the value of firefly luminescence was gradually 
decreasing, because increased transfection reagent was toxic to cells and part of cells were 
dead. Meanwhile, the value of Renilla luminescence was also gradually enhancing, the 
maximum value of Renilla luminescence also appeared that DNA (μg): LipofectamineTM 
2000 (μl) ratio was 1: 2 (Figure 4.5B). The result showed that the ratio of Firefly/Renilla 
luminescence was unchanged (Figure 4.5C), even DNA (μg): LipofectamineTM 2000 (μl) 
Figure 4.4 Measurement of firefly and Renilla luciferase activities in HepG2 cells. 
(A) Firefly luciferase activity. (B) Renilla luciferase activity. (C) Ratio (Firefly/Renilla). 
(Supplement data see Appendix 7.3 Table 1) 
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ratios varied from 1: 0.5 to 1: 5. Therefore, when the DNA (μg): LipofectamineTM 2000 (μl) 
ratio was 1: 2 in A549 cells, the transfection efficiency got the highest level and the values of 
firefly luminescence and Renilla luminescence reached the maximum at the same time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Measurement of firefly and Renilla luciferase activities in A549 cells. 
(A) Firefly luciferase activity. (B) Renilla luciferase activity. (C) Ratio (Firefly/Renilla). 
(Supplement data see Appendix 7.3 Table 2) 
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However, for transfection of 3T3-L1 cells, transfection efficiency was pretty low. The values 
of firefly luminescence and Renilla luminescence were very low and close to background 
values (blank control). Therefore, the 3T3-L1 cell line was not used in the following 
experiments. 
 
4.4 MiRNAs bind to 3’UTR of HSD11B1 mRNA 
To examine the possibility of HSD11B1 regulation by miRNAs, four different miRNAs, 
namely hsa-miR-561, hsa-miR-579, hsa-miR-181b and hsa-miR-340, were selected as 
candidates for functional analysis. The plasmid, pmir-HSD11B1-3’UTR was transfected alone 
or cotransfected with negative control miRNA#2 and candidate miRNAs, hsa-miR-561, hsa-
miR-579, hsa-miR-181b and hsa-miR-340 into HepG2 cells. Relative luciferase activity was 
significantly suppressed by about 30% by hsa-miR-561 and about 40% by hsa-miR-579 and 
hsa-miR-340, but unchanged by hsa-miR-181b compared with cotransfection with negative 
control miRNA#2 (Figure 4.6A). Here, I must mention that negative control miRNA#1 was 
used as negative control miRNA at the beginning, but negative control miRNA#1 suppressed 
the firefly luciferase expression in HepG2 cells, thus another negative control miRNA#2 was 
selected as negative control miRNA in HepG2 cells.  
 
Similar experiments were carried out with A549 cells. The same plasmid, pmir-HSD11B1-
3’UTR, was transfected alone or cotransfected with negative control miRNA#1, hsa-miR-561, 
hsa-miR-579, hsa-miR-181b and hsa-miR-340 into A549 cells. Similar results were also 
obtained. Relative luciferase activity was significantly suppressed by about 20% by hsa-miR-
561 and about 40% by hsa-miR-579 and hsa-miR-340, but not significantly changed by hsa-
miR-181b compared with cotransfection with negative control miRNA#1 (Figure 4.6B). 
These results suggested that three of the selected miRNA candidates, namely hsa-miR-561, 
hsa-miR-579, and hsa-miR-340, but not hsa-miR-181b, bound to the 3’UTR of the HSD11B1 
mRNA. Therefore, to validate these results, several follow-up experiments were carried out 
with hsa-miR-561, hsa-miR-579, and hsa-miR-340.  
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Figure 4.6 Results of luciferase reporter assay for four miRNA candidates interaction with the 
3’UTR of human HSD11B1 mRNA. (A) Results of cotransfection experiments in HepG2 cells with 
the pmir-GLO vector carrying the HSD11B1-3’UTR and various miRNA precursors: negative control 
miRNA#2, hsa-miR-561, -579, -181b, and -340. (B) Results of cotransfection experiments in A549 
cells with the pmir-GLO vector carrying the HSD11B1-3’UTR and various miRNA precursors: 
negative control miRNA#1, hsa-miR-561, -579, -181b, and -340. Luciferase activities were measured 
48 hours after transfection. All results were normalized to luciferase activity in the absence of miRNA 
which was set to 100%. Results are based on three independent experiments and shown as average ± 
SD. Statistical analysis was by student’s t-test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Supplement 
data see Appendix 7.3 Table 3). 
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4.5 Deletion/mutation of the corresponding miRNA response elements 
(MREs) in the HSD11B1-3’UTR 
Two prediction tools, TargetScan Human (http://www.targetscan.org/) and MicroCosm 
Targets (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/ ) were used to predict 
the corresponding miRNA response elements in the 3’UTR of HSD11B1 mRNA. The 
predicted miRNA response elements (MREs) of the three positive miRNAs, hsa-miR-340, 
hsa-miR-561, and hsa-miR-579, in the 3’UTR of human HSD11B1 mRNA are shown in 
Figure 4.7 (A, B and C). The prediction results indicated that miRNAs-target HSD11B1 
mRNA are imperfect complementarity. To further verify whether repression by hsa-miR-561, 
hsa-miR-579, and hsa-miR-340 was due to binding to the predicted MREs, particularly in 
‘seed region’ main miRNA binding sites (red letters; Figure 4.7), luciferase reporter 
constructs were generated where the corresponding MREs were either deleted or mutated (3 
points mutation) in the seed region (Figure 4.7D). The sequences of deletion/mutation of the 
hsa-miR-561, hsa-miR-579 and hsa-miR-340 MREs in the HSD11B1-3’UTR were shown in 
Figure 4.7E.  Deletion/mutation of the hsa-miR-561, hsa-miR-579 and hsa-miR-340 MREs in 
the HSD11B1-3’UTR construct were performed using splicing by overlapping extension PCR 
(Vallejo et al., 1994). The resulting PCR fragment was purified and inserted into the pCR2.1-
TOPO vector. After sequencing, the expected fragment was subcloned into the pmir-GLO 
vector. The resulting plasmids were named pmir-561-del, pmir-561-mut, pmir-579-del, pmir-
579-mut, pmir-340-del and pmir-340-mut, respectively, for deletion/mutation of the hsa-miR-
561, hsa-miR-579 and hsa-miR-340 MREs in the HSD11B1-3’UTR. 
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Figure 4.7 Outline of luciferase reporter assay for validating the interaction of hsa-miR-340, hsa-miR-
561, and hsa-miR-579 with the 3’UTR of human HSD11B1 mRNA: The miRNA response elements 
(MREs) of (A) hsa-miR-340, (B) hsa-miR-561, and (C) hsa-miR-579 in the 3’UTR of human HSD11B1 
mRNA are shown as predicted by TargetScan (http://www.targetscan.org). Red letters indicate the ‘seed’ 
(S) region. (D) The complete 3’UTR sequence (depicted in orange) of the HSD11B1 mRNA was inserted 
into the pmir-GLO vector, immediately downstream of the firefly luciferase gene (depicted in green). In 
mutant reporter constructs, the MRE (depicted in beige, seed region in purple) was deleted or a three-
mismatch mutation (red boxes) was introduced into the seed region. (E) Sequences of deletion or mutation 
for miR-340-MRE, miR-561-MRE and miR-579-MRE in the 3’UTR of HSD11B1 mRNA. 
 
 
                                   340-mut 
                                   G  G C 
 301 UAUUAAUUAU AAUAAAGGUC ACAUAAACUU UAUAAATTCA UAACUGGUAG 
                             340-del 
 351 CUAUAACUUG AGCUUAUUCA GGAUGGUUUC UUUAAAACCA UAAACUGUAC 
                                                 
 401 AAAUGAAAUU UUUCAAUAUU UGUUUCUUA 
 
                               561-mut 
                                U G C  
 301 UAUUAAUUAU AAUAAAGGUC ACAUAAACUU UAUAAAUUCA UAACUGGUAG 
                             561-del 
 351 CUAUAACUUG AGCUUAUUCA GGAUGGUUUC UUUAAAACCA UAAACUGUAC 
                                                 
 401 AAAUGAAAUU UUUCAAUAUU UGUUUCUUA   
  
                     
 301 UAUUAAUUAU AAUAAAGGUC ACAUAAACUU UAUAAAUUCA UAACUGGUAG 
                                                                 
 351 CUAUAACUUG AGCUUAUUCA GGAUGGUUUC UUUAAAACCA UAAACUGUAC 
                                              579-del  
    579-mut 
     U G C 
 401 AAAUGAAAUU UUUCAAUAUU UGUUUCUUA                        
 
E 
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4.6 Deletion/mutation of the corresponding miRNA response elements 
(MREs) in the 3’UTR of HSD11B1 mRNA abolished the effect for hsa-miR-
561 and hsa-miR-579, but not completely for hsa-miR-340 
To further verify whether repression by hsa-miR-561, hsa-miR-579, and hsa-miR-340 was 
due to binding to the predicted MREs, the plasmid pmir-HSD11B1-3’UTR (wild type), or the 
above mentioned MRE-deleted/mutated variants, namely pmir-561-del, pmir-561-mut, pmir-
579-del, pmir-579-mut, pmir-340-del and pmir-340-mut, were transfected alone or 
cotransfected with the corresponding miRNA into HepG2 cells. Suppression of luciferase 
activity by hsa-miR-561 and hsa-miR-579 was completely abolished when the miR-561-
MREs and miR-579-MREs, respectively, were deleted from the HSD11B1-3’UTR, as well as 
when a 3-base mismatch mutation was introduced into the MREs seed region (Figure 4.8A 
and B). However, for hsa-miR-340, suppression of luciferase activity was not completely 
abolished in these experiments (Figure 4.8C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 69
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The same experiments were carried out in A549 cells, similar results were obtained. 
Suppression of luciferase activity by hsa-miR-561 and hsa-miR-579 was completely 
abolished, but not completely abolished by hsa-miR-340 (Figure 4.9). These results indicated 
that deletion/mutation of the corresponding miRNA response elements (MREs) in the 
HSD11B1-3’UTR abolished the effect for hsa-miR-561 and hsa-miR-579, but did not 
completely abolish for hsa-miR-340. Mutated luciferase constructs results showed that the 
‘seed region’ is main and valid miRNA binding sites in the 3’UTR of HSD11B1 mRNA. 
 
 
 
 
 
 
 
 
 
Figure 4.8 Deletion (3’UTR XXX del) as well as mutation (3’UTR XXX mut) of the corresponding 
MREs abolished the repression by hsa-miR-561 (A) and hsa-miR-579 (B), but did not completely 
abolish repression by hsa-miR-340 (C). The pmir-GLO vector carrying the HSD11B1-3’UTR (UTR, 
WT) or the MRE-deleted/mutated constructs were cotransfected with hsa-miR-561, hsa-miR-579, or 
hsa-miR-340 into HepG2 cells, respectively. Luciferase activities were measured 48 hours after 
transfection.  All results were normalized to luciferase activity in the absence of miRNA which was set 
to 100%. Results are based on three independent experiments and shown as average ± SD. Statistical 
analysis was by student’s t-test: *, p < 0.05; ***, p < 0.001 (Supplement data see Appendix 7.3 Table 
4). 
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To further make sure that suppression of luciferase activity is due to miRNA binding to 
3’UTR of HSD11B1 mRNA, the plasmid pmir-GLO (absence of HSD11B1-3’UTR) and 
pmir-HSD11B1-3’UTR (pmir-UTR) were transfected alone or cotransfected with miRNAs 
into A549 cells, respectively. For the plasmid pmir-GLO, the results showed that relative 
luciferase activity was unchanged by hsa-miR-561 and hsa-miR-579 compared to that without 
Figure 4.9 Deletion (3’UTR XXX del) as well as mutation (3’UTR XXX mut) of the corresponding 
MREs abolished the repression by hsa-miR-561 (A) and hsa-miR-579 (B), but did not completely 
abolish repression by hsa-miR-340 (C). The pmir-GLO vector carrying the HSD11B1-3’UTR (UTR, 
WT) or the MRE-deleted/mutated constructs were cotransfected with hsa-miR-561, hsa-miR-579, or hsa-
miR-340 into A549 cells, respectively. Luciferase activities were measured 48 hours after transfection.  
All results were normalized to luciferase activity in the absence of miRNA which was set to 100%. 
Results are based on three independent experiments and shown as average ± SD. Statistical analysis was 
by student’s t-test: *, p < 0.05; ***, p < 0.001 (Supplement data see Appendix 7.3 Table 5). 
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miRNAs (Figure 4.10A and B). For the plasmid pmir-HSD11B1-3’UTR, in agreement with 
previous results, relative luciferase activity was significantly suppressed by about 30% by 
hsa-miR-561 and about 40% by hsa-miR-579 compared to that without miRNAs (Figure 
4.10A and B). However, for the plasmid pmir-GLO (absence of HSD11B1-3’UTR) and pmir-
HSD11B1-3’UTR, relative luciferase activity was significantly suppressed by about 20% and 
about 40% by hsa-miR-340 compared to that without miRNAs (Figure 4.10C), respectively. 
These results showed that suppression of luciferase activity by hsa-miR-340 was not due to 
specific binding to the predicted MREs in the 3’UTR of HSD11B1 mRNA. Therefore, hsa-
miR-561 and hsa-miR-579 were used in the following experiments, but not including hsa-
miR-340. 
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4.7 Target mRNA levels were unchanged by hsa-miR-561 and hsa-miR-579 
In efforts to explore the underlying mechanism of miRNA-mediated suppression (either 
mRNA degradation or translational repression), levels of firefly (reporter) and Renilla 
(control) luciferase mRNA were semi-quantified after cotransfection experiments with the 
luciferase construct containing the 3’UTR of HSD11B1 mRNA and negative control 
miRNA#1, hsa-miR-561 or hsa-miR-579. The result showed that none of the miRNAs 
significantly changed the ratio of firefly/Renilla luciferase mRNAs (Figure 4.11). In fact, 
levels of both mRNAs decreased in the contransfection experiment compared to the 
experiment where miRNA was not used (Figure 4.11). 
 
 
 
 
 
Figure 4.10 Results of luciferase reporter assay for hsa-miR-561, hsa-miR-579, and hsa-miR-340 
binding to the 3’UTR of human HSD11B1 mRNA. Results of transfection experiments in A549 cells with 
the pmir-GLO or pmir-GLO vector carrying the HSD11B1-3’UTR (pmir-UTR) and various miRNA 
precursors: hsa-miR-561(A), hsa-miR-579 (B), and hsa-miR-340 (C). Luciferase activities were measured 
48 hours after transfection. All results were normalized to luciferase activity in the absence of miRNA 
(pmir-GLO) which was set to 100%. Results are based on three independent experiments and shown as 
average ± SD. Statistical analysis was by student’s t-test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 
(Supplement data see Appendix 7.3 Table 6). 
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Moreover, the levels of endogenous HSD11B1 mRNA were semi-quantified after transfection 
experiments with negative control miRNA, hsa-miR-561 or hsa-miR-579 into HepG2 cells 
and A549 cells. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as loading 
control in semi-quantitative RT-PCR. The results showed that the ratios of HSD11B1 
mRNA/GAPDH mRNA were unchanged after transfection with negative control miRNA, 
hsa-miR-561 and hsa-miR-579 in HepG2 cells (Figure 4.12A) and A549 cells (Figure 4.12 
B). 
 
 
 
 
Figure 4.11 Results of luciferase reporter assay on mRNA level. A549 cells were cotransfected with 
the pmir-GLO vector carrying the HSD11B1-3’UTR and various miRNA precursors: negative control 
(NC) miRNA#1, hsa-miR-561, and -579. Cotransfection was followed by RNA isolation (treatment 
with DNase), cDNA synthesis and finally semi-quantitative RT-PCR. Results are based on three 
independent experiments (Appendix 7.3 Figure 1). Results were semi-quantified by determination of 
band intensity using GIMP 2.6 (GNU Image Manipulation Program) and shown as average ± SD. 
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A 
Figure 4.12 The levels of endogenous HSD11B1 mRNA were analyzed by semi-quantitative 
RT-PCR. (A) HepG2 cells were transfected with the various miRNA precursors: negative control 
(NC) miRNA#2, hsa-miR-561, and -579. (B) A549 cells were transfected with the various miRNA 
precursors: negative control (NC) miRNA#1, hsa-miR-561, and -579. Transfection was followed 
by RNA isolation, cDNA synthesis and finally semi-quantitative RT-PCR. GAPDH was used as a 
loading control in semi-quantitative RT-PCR. Results are based on three independent experiments 
(Appendix 7.3 Figure 2). Results were semi-quantified by determination of band intensity using 
GIMP 2.6 (GNU Image Manipulation Program) and shown as average ± SD. 
B 
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4.8 Glucocorticoids induction of HSD11B1 expression in A549 cells 
Glucocorticoids such as dexamethasone and cortisol are important regulators of HSD11B1 
expression in human liver, lung, and many cells. To assess the relative contribution of the two 
alternative promoter usage after glucocorticoids induction of HSD11B1 expression in A549 
cells, primers were designed for specifically amplifying the two distinct HSD11B1 transcripts 
(Figure 4.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After A549 cells were induced with dexamethasone and cortisol, levels of HSD11B1 mRNA 
from P1-, P2-, and total transcript were assessed with semi-quantitative RT-PCR. The results 
showed that HSD11B1 mRNA from P1-, P2-, and total transcript were significantly increased 
by induction with dexamethasone and cortisol (Figure 4.14). HSD11B1 expression from 
Promoter 2 was much stronger than from Promoter 1 (Figure 4.14). Therefore, dexamethasone 
and cortisol induce HSD11B1 transcription in A549 cells mostly via P2 promoter.  
 
 
 
Figure 4.13 Human HSD11B1 transcripts for assessment of alternative promoter usage. The forward 
primers (primer 1 and primer 2) were designed that bind specifically to the 5’UTRs of transcript 1 and 2, 
respectively. Total transcript levels can be captured by a common forward primer (primer 3) which binds to 
the coding sequence (CDS). One common reverse primer (primer 4) was used in all RT-PCR preparations.  
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4.9 Cloning of HSD11B1-Promoter 1 or HSD11B1-Promoter 2 into pmir-
HSD11B1-3’UTR 
To explore the relative influence of 5’-regulatory elements as e.g. transcription factors versus 
3’-regulatory elements as miRNAs in HSD11B1 expression or analyze HSD11B1 promoter 
activity, the HSD11B1-Promoter 1 and the HSD11B1-Promoter 2 were cloned into the dual-
luciferase assay system. The DNA fragment of HSD11B1-Promoter 1 on upstream about 2 kb 
of transcription start sites was amplified, which contains all evolutionarily conserved regions 
as estimated by the ECR browser (http://ecrbrowser.dcode.org/) and a part of the 5’-
untranslated region (UTR). The fragment of HSD11B1-Promoter 2 was amplified the region 
designated as promoter in NCBI (http://www.ncbi.nlm.nih.gov/), which contains all 
evolutionarily conserved regions as estimated by the ECR browser and the 5’-untranslated 
region (UTR). The PGK promoter of pmir-HSD11B1-3’UTR was replaced by the Promoter 1 
or 2 fragment of HSD11B1 as follows. First, the fragment of HSD11B1-Promoter 1 and 
HSD11B1-Promoter 2 were successfully amplified from genomic DNA of A549 cells. The 
desired DNA fragments of Promoter 1 and 2 were 2.173 kb and 2.506 kb, respectively, which 
were shown correct molecular weight in an agarose gel (Figure 4.15). Then, these fragments 
were cloned into the pCR2.1-TOPO vector. The sequencing results showed that the correct 
sequences of Promoter 1 and 2 were obtained (Identical to the database entry NCBI, 
http://www.ncbi.nlm.nih.gov/; Ensembl Genome Browser, http://www.ensembl.org/, 
sequences see Appendix 7.2.2 and 7.2.3). The PGK promoter of pmir-HSD11B1-3’UTR was 
deleted and a new Xma I restriction site was introduced. Subsequently, the fragment of 
Figure 4.14 HSD11B1 expression from P1-, P2-, and total transcript were semi-quantified by RT-PCR. 
HSD11B1 transcription can be assessed in A549 cells. A549 cells were induced with dexamethasone (Dex) 
and cortisol for 48 hours, total RNA was isolated and HSD11B1 mRNA from P1-, P2-, and total transcript 
were detected by semi-quantitative RT-PCR. Results are based on three independent experiments (Appendix 
7.3 Figure 3). 
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HSD11B1-Promoter 1 or HSD11B1-Promoter 2 was digested by Xma I and subcloned into the 
deleted and modified pmir-HSD11B1-3’UTR vector (Figure 4.16). The resulting plasmids 
were named pmir-Promoter 1 and pmir-Promoter 2, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 PCR products of HSD11B1-Promoter 1 and -Promoter 2. 
M: 1kb DNA ladder 1: Promoter 1 (2.173kb) 2: Promoter 2 (2.506kb) 
Figure 4.16 Schematic overview of the cloning of HSD11B1-Promoter 1 or HSD11B1-Promoter 2 
into the dual-luciferase assay system. See text for details 
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4.10 Assessment of regulation of HSD11B1 expression by glucocorticoids 
using the pmir-Promoter constructs 
To investigate regulation of HSD11B1 expression by glucocorticoids in the dual-luciferase 
assay system, the pmir-Promoter 1 or pmir-Promoter 2 was transfected into A549 cells, 
followed by induction with dexamethasone and cortisol 4 hours after transfection. Luciferase 
activities were measured 48 hours after transfection. Relative luciferase activity of the 
Promoter 2 reporter construct was significantly increased after induction with dexamethasone 
and cortisol in A549 cells, while luciferase activity of the Promoter 1 reporter construct was 
unchanged (Figure 4.17). Therefore, the pmir-Promoter 2 plasmid was used in subsequent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Glucocorticoids regulation of HSD11B1-Promoter 1 or 2 expression in the dual-
luciferase assay system.  All results were normalized to luciferase activity in the absence of 
glucocorticoids which was set to 100%. Results are based on three independent experiments and shown as 
average ± SD. Statistical analysis was by student’s t-test: ***, p < 0.001 (Supplement data see Appendix 
7.3 Table 7). 
Results 
 79
4.11 Hsa-miR-579, but not hsa-miR-561, represses HSD11B1 expression 
after induction with glucocorticoids  
To investigate the relative influence of glucocorticoids in HSD11B1 expression versus 
miRNAs, the pmir-Promoter 2 was transfected alone or cotransfected with hsa-miR-579 or 
hsa-miR-561 into A549 cells. 4 hours after transfection, the cells were induced with 
dexamethasone or cortisol and luciferase activities were measured 48 hours after transfection. 
Relative luciferase activity was significantly decreased by transfection with hsa-miR-579 and 
increased by induction with dexamethasone or cortisol compared to the control (Figure 4.18A 
and B). After induction with dexamethasone or cortisol, the relative luciferase activity was 
still inhibited by hsa-miR-579 compared to induction with dexamethasone or cortisol and 
absence of miRNAs (Figure 4.18A and B). For hsa-miR-561, the relative luciferase activity 
was decreased by transfection with hsa-miR-561 and increased by induction with 
dexamethasone or cortisol compared to the control (Figure 4.18C and D). However, after 
induction with dexamethasone or cortisol, the relative luciferase activity could not be 
significantly repressed by hsa-miR-561 compared to induction with dexamethasone or cortisol 
and absence of miRNAs (Figure 4.18C and D). Therefore, hsa-miR-579 is a more potent 
repressor than hsa-miR-561. To some extent, hsa-miR-579 could resist the effect of 
glucocorticoids induction of HSD11B1 expression.  
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4.12 Analysis of HSD11B1 promoter activity  
As mentioned previously, HSD11B1 expression is controlled by two distinct promoters, and 
HSD11B1 expression is regulated by many regulatory factors including some 
proinflammatory cytokines (TNF-α), glucocorticoids (cortisol and dexamethasone), insulin 
and so on. To explore alternative promoter usages, luciferase constructs containing fragments 
of HSD11B1-Promoter 1 or -Promoter 2, namely the plasmid pmir-Promoter 1 and pmir-
Promoter 2 (Figure 4.16) were used in the following experiments. The pmir-Promoter 1 or 
pmir-Promoter 2 was transfected into A549 cells, 4 hours after transfection, the cells were 
induced with regulatory factors and detected regulatory factors are listed in Table 4.3. 
Luciferase activities were measured after 48 hours.  
 
 
Regulatory factors                                                              Concentration 
TNFα                                                                                  50 ng/ml 
Insulin                                                                                 1 μg/ml 
Leptin                                                                                  50 ng/ml  
Resistin                                                                                50 ng/ml 
Adiponectin                                                                         30 ng/ml 
Retinoic acid                                                                       30 ng/ml 
WY14643                                                                            300 ng/ml 
Vitamin D3                                                                                                               500 ng/ml 
Ciglitazone                                                                           30 ng/ml 
Figure 4.18 Hsa-miR-579, but not hsa-miR-561, represses HSD11B1 expression after induction with 
glucocorticoids. (A) The pmir-Promoter 2 was transfected alone or cotransfected with hsa-miR-579 into A549 
cells, 4 hours after transfection, the cells were induced with dexamethasone. (B) The pmir-Promoter 2 was 
transfected alone or cotransfected with hsa-miR-579 into A549 cells, 4 hours after transfection, the cells were 
induced with cortisol. (C) The pmir-Promoter 2 was transfected alone or cotransfected with hsa-miR-561 into 
A549 cells, 4 hours after transfection, the cells were induced with dexamethasone. (D) The pmir-Promoter 2 was 
transfected alone or cotransfected with hsa-miR-561 into A549 cells, 4 hours after transfection, the cells were 
induced with cortisol. All results were normalized to luciferase activity in the absence of miRNA and 
glucocorticoids which was set to 100%. Results are based on three independent experiments and shown as 
average ± SD. Statistical analysis was by student’s t-test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Supplement 
data see Appendix 7.3 Table 8). 
Table 4.3 List of regulatory factors used 
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Trichostatin A                                                                      30 ng/ml 
Estradiol                                                                               50 ng/ml 
 
The results show that relative luciferase activities of pmir-Promoter 1 and pmir-Promoter 2 
were not changed after induction with TNFα, Insulin, Leptin, Resistin and Adiponectin 
(Figure 4.19A and C) and Retinoic acid, WY14643, Vitamin D3, Ciglitazone, Trichostatin A, 
Estradiol (Figure 4.19B and D) compared to the control without induction. In other words, in 
A549 cells both Promoter 1 and Promoter 2 of HSD11B1 are not activated by regulatory 
factors. It is possible that the fragments of Promoter 1 and Promoter 2 do not contain related 
binding sites of the regulatory factors. Another possibility is that HSD11B1 expression is not 
influenced by absence of relative factors which react with regulatory factors in lung cells 
(A549). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 83
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 Results of luciferase reporter assay for pmir-Promoter 1 and pmir-Promoter 2. 
(A) After transfection of pmir-Promoter 1 and induction with TNFα, Insulin, Leptin, Resistin and 
Adiponectin. (B) After transfection of pmir-Promoter 1 and induction with Retinoic acid, WY14643, 
Vitamin D3, Ciglitazone, Trichostatin A and Estradiol. (C) After transfection of pmir-Promoter 2 and 
induction with TNFα, Insulin, Leptin, Resistin and Adiponectin. (D) After transfection of pmir-Promoter 2 
and induction with Retinoic acid, WY14643, Vitamin D3, Ciglitazone, Trichostatin A and Estradiol. The 
pmir-Promoter 1 or pmir-Promoter 2 was transfected into A549 cells. 4 hours after transfection, the cells 
were induced with regulatory factors. All results were normalized to luciferase activity in the absence of 
regulatory factor which was set to 100%. Results are based on three independent experiments and shown as 
average ± SD. (Supplement data see Appendix 7.3 Table 9). 
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4.13 Detection of endogenous 11β-HSD1 expression  
To investigate the regulation of endogenous human 11β-HSD1 by hsa-miR-561 and hsa-miR-
579, A549 cells (human lung adenocarcinoma cell line) and HepG2 cells (human hepatoma 
cell line) were used, which are known to express wild-type 11β-HSD1. The levels of 
endogenous 11β-HSD1 expression in A549 cells and HepG2 cells are very low, so 11β-HSD1 
protein was detected after induction with dexamethasone by Western blot analysis. Hsa-miR-
579 or hsa-miR-561 was transfected into A549 cells or HepG2 cells. 4 hours after transfection, 
A549 cells or HepG2 cells were induced with dexamethasone. The cells were harvested 48 
hours after transfection. Microsomes and total proteins were isolated from A549 and HepG2 
cells, which were used for Western blot analysis. 11β-HSD1 was detected using microsomes 
from A549 and HepG2 cells, the results showed that no band was visualized (Figure 4.20A 
and B). One possibility is that it’s difficult to completely extract 11β-HSD1 from microsomes 
of the cells. Therefore, the total proteins were used for detection of 11β-HSD1. The results 
showed that no band was observed (Figure 4.20C and D). All of Western blot results indicated 
that 11β-HSD1 protein is hardly detectable, even A549 and HepG2 cells were induced with 
dexamethasone (Figure 4.20). However, human liver microsomes (HLM) were used to purify 
11β-HSD1 and large amount of hepatic 11β-HSD1 was obtained. The purified protein was 
applied on Western blot and showed a strong signal in Figure 4.20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 Western Blot for detection of 11β-HSD1 in A549 cells and HepG2 cells. 11β-HSD1 
was detected with microsomes or total proteins using an anti-11β-HSD1 antibody. β-actin was used 
as a loading control for detection of total protein. HLM: human liver microsomes were used as 
positive control. Results are based on three independent experiments (Appendix 7.3 Figure 4). 
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4.14 Detection of miR-579 and miR-561 in HepG2 cells using the dual-
luciferase assay system 
Anti-microRNA oligonucleotides (AMOs) were used to determine the presence of miR-579 
and miR-561 in HepG2 cells and block endogenous or exogenous miRNAs function. The 
natural miR-579 and miR-561 sequences can be found in miRBase database 
(http://www.mirbase.org/). The sequences of AMOs used in the study were exactly the same 
as the antisense sequences of the natural miR-579 and miR-561. These oligonucleotide 
sequences are listed in Table 4.4.  
 
 
 
Name                        Sequence  
miR-579                    5’-UUCAUUUGGUAUAAACCGCGAUU-3’ 
AMO-579                 5’-AATCGCGGTTTATACCAAATGAA-3’ 
DNA-579                  5’-TTCATTTGGTATAAACCGCGATT-3’   
miR-561                    5’-CAAAGUUUAAGAUCCUUGAAGU-3’ 
AMO-561                 5’-ACTTCAAGGATCTTAAACTTTG-3’ 
DNA-561                 5’-CAAAGTTTAAGATCCTTGAAGT-3’   
 
The experiment was performed as follows: the plasmid pmir-HSD11B1-3’UTR was 
transfected alone or cotransfected with miR-579, miR-579/AMO-579, AMO-579 and DNA-
579, respectively. The sequence of mature miR-579, AMO-579 and DNA-579 are listed in 
Table 4.4. In agreement with previous results, relative luciferase activity was significantly 
suppressed by about 40% by miR-579 compared with absence of miRNA (Figure 4.21A). 
AMO-579 could block the repression by miR-579 due to hybridization with miR-579 (Figure 
4.21A). Moreover, the luciferase activity was significantly increased about 20% by AMO-579. 
Obviously, this was due to blocking endogenous miR-579 function (Figure 4.21A). The 
luciferase activity was unchanged by DNA-579 (Figure 4.21A). 
 
The same experiments were carried out by miR-561, and a similar result was obtained. 
Relative luciferase activity was significantly suppressed by about 20% by miR-561 compared 
with absence of miRNA (Figure 4.21B). AMO-561 could block the repression by miR-561 
(Figure 4.21B). Moreover, the luciferase activity was significantly increased about 20% by 
Table 4.4 The sequences of mature miR-579, AMO-579 and DNA-579 and mature miR-561, 
AMO-561 and DNA-561 
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AMO-561 (Figure 4.21B). The luciferase activity was unchanged by DNA-561 (Figure 
4.21B). These results indicated that miR-579 and miR-561 are present in HepG2 cells 
indirectly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 Results of luciferase reporter assay with AMOs in HepG2 cells. 
(A) The plasmid pmir-HSD11B1-3’UTR was transfected alone or cotransfected with miR-579, miR-
579/AMO-579, AMO-579 and DNA-579, respectively. (B) The plasmid pmir-HSD11B1-3’UTR was 
transfected alone or cotransfected with miR-561, miR-561/AMO-561, AMO-561 and DNA-561, 
respectively. Luciferase activities were measured 48 hours after transfection. All results were 
normalized to luciferase activity in the absence of miRNA which was set to 100%. Results are based on 
three independent experiments and shown as average ± SD. Statistical analysis was by student’s t-test: 
*, p < 0.05; **, p < 0.01; ***, p < 0.001 (Supplement data see Appendix 7.3 Table 10). 
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4.15 Detection of miR-561 and miR-579 in human hepatocytes and HepG2 
cells by Northern Blot 
To detect hsa-miR-561 or hsa-miR-579 in human hepatocytes and HepG2 cells, Northern blot 
analysis was carried out using a radioactive-labeled (γ-32P-ATP) DNA oligonucleotides as 
probe. DNA-561 and DNA-579 were used as positive controls. The sequences of DNA 
oligonucleotides used in this work are listed in the Material Table 3.4. When 10 μg of total 
RNA was loaded for each sample, both hsa-miR-561 and hsa-miR-579 remained undetected 
in human hepatocytes and HepG2 cells by Northern blot analysis (Figure 4.22). However, 20 
ng of both positive controls, DNA-561 and DNA-579, showed strong signals (Figure 4.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 Detection of miRNAs expression by Northern blot. 10 μg of total RNA of human 
hepatocytes and HepG2 cells were separated on 2% agarose/formaldehyde gel, transferred onto a nylon 
membrane and hybridized with γ-32P-ATP-radioactive-labelled probe. 1: DNA-561 (20 ng) as positive 
control; 2:- ; 3: Human hepatocytes RNA (BMI: 35.4); 4: Human hepatocytes RNA (BMI: 29.4); 5: HepG2 
cells RNA; 6: DNA-579 (20 ng) as positive control; 7:- ; 8: Human hepatocytes RNA (BMI: 35.4); 9: 
Human hepatocytes RNA (BMI: 29.4); 10: HepG2 cells RNA; Results are based on three independent 
experiments (Appendix 7.3 Figure 5). 
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4.16 Detection of miR-561 and miR-579 in human hepatocytes and HepG2 
cells by RT-PCR 
RT-PCR was used to assess the presence of hsa-miR-561 or hsa-miR-579 in human 
hepatocytes and HepG2 cells. For the detection of miRNAs by RT-PCR, a stem-loop primer 
specific to the interest miRNA for reverse transcription (RT) and a miRNA-specific forward 
primer and a specific reverse primer were used for PCR amplification (Figure 4.23). The RT-
PCR results showed that specific bands were obtained for amplifying miR-561 and miR-579 
from total RNA of human hepatocytes and HepG2 compared with negative control, no 
genomic amplification (Figure 4.24A) or no template control (Figure 4.24B). Sequences of all 
the primers are confidential in Ambion (Applied Biosystems, Germany). Therefore, the exact 
size of the expected amplicons upon RT-PCR amplification can only roughly be determined 
as being lower than 97 or 98 base pairs, which corresponds to the precursor miRNAs size of 
miR-561 and miR-579, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Schematic of RT-PCR primers design (from Ambion). 
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A 
B 
Figure 4.24 RT-PCR results.  RT-PCR was carried out by cDNA synthesis and PCR. Results are based on 
three independent experiments (Appendix 7.3 Figure 6). The bands were obtained in the 75 bp region 
correspond to the expected miR-561 (lanes 2 and 4) and miR-579 (lanes 6 and 8). 
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4.17 Potential transcription of miRNAs in hepatocytes with different BMI 
Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used to 
classify underweight, normal, overweight and obesity in adults. It is defined as the weight in 
kilograms divided by the square of the height in metres (kg/m2). The world health 
organization (WHO) regards a BMI range from 18.5 to 24.99 as normal weight, while a BMI 
between 25 and 30 is considered overweight and above 30 is considered obese. To test the 
potential transcription of miR-561 and miR-579 in hepatocytes, six different BMI hepatocyte 
samples were used, they are Female BMI 23.5 (normal weight, age 27), Male BMI 23.8 
(normal weight, age 48), Female BMI 26.1 (overweight, age 25), Male BMI 29.4 (overweight, 
age 48), Female BMI 38.2 (obese, age 37) and Male BMI 38 (obese, age 54), respectively. 
Transcriptions of miR-561, miR-579 and HSD11B1 mRNA were generated by semi-
quantitative RT-PCR. The results showed that miR-561 transcriptions were in the similar 
levels in hepatocytes with different BMI (Figure 4.25A and B). However, miR-579 
transcriptions were significantly lower in both female and male obese people (Figure 4.25A, 
arrow 1 and 2) than in the corresponding female and male of normal weight people (Figure 
4.25A and C, arrow 3 and 4). Furthermore, in five BMI hepatocyte samples, HSD11B1 
mRNA transcriptions were at the same levels, whereas the sample of female BMI 26.1 
showed a low level (Figure 4.25A and D, arrow 5). 
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4.18 Pathway enrichment analysis  
MiRNAs are characterized by considerable target multiplicity, i.e. each miRNA might 
regulate the expression of up to 100 different target mRNAs. Here, DIANA-mirPATH 
(http://diana.cslab.ece.ntua.gr/pathways/, Papadopoulos et al., 2009) was used for miRNA 
target gene-based pathway enrichment analysis. Six Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways were statistically overrepresented for both hsa-miR-561 and hsa-
miR-579, namely Ubiquitin-mediated proteolysis, Long-term potentiation, Insulin signalling 
pathway, Melanogenesis, Tight junction and Axon guidance (Table 4.5). The enrichment of 
twelve KEGG pathways were found for hsa-miR-561 alone, namely Prion disease, Colorectal 
Figure 4.25 The levels of miR-561, miR-579 and HSD11B1 mRNA transcription were semi-quantified 
by RT-PCR. (A) RT-PCR results.  (B), (C) and (D) Results were semi-quantified by determination of band 
intensity using GIMP 2.6 (GNU Image Manipulation Program) and shown as average ± SD. β-actin was 
used as a loading control in semi-quantitative RT-PCR. Results are based on three independent experiments 
(Appendix 7.3 Figure 7) 
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cancer, Long-term depression, ErbB signalling pathway, mTOR signalling pathway, Prostate 
cancer, TGF-beta signalling pathway, Renal cell carcinoma, Focal adhesion, Nicotinate and 
nicotinamide metabolism,  Neurodegenerative Disease, and finally Wnt signalling pathway 
(Table 4.5). The three enriched KEGG pathways were only found for hsa-miR-579, including 
Dorso-ventral axis formation, Calcium signalling pathway, and Methane metabolism (Table 
4.5). Mostly, at least four genes contributed to the enrichments, with the exception of 
Methane metabolism, where only two genes contributed to the enrichment (Table 4.5). 
Furthermore, HSD11B1 itself did not contribute to any enrichment. 
 
Table 4.5 Pathway Enrichment Analysis of predicted target genes of hsa-miR-561 and hsa-miR-579. The 
Pathway Enrichment Analysis was carried out using analysis of multiple miRNAs in DIANA-mirPATH with 
DIANA-microT-4.0 as target prediction software. Only results with a –ln (p-value) > 3 are shown 
(corresponding to p < 0.05). 
 
KEGG pathway (ID)      Found genes     -ln (p-value)                      Gene names 
                                                            hsa-miR-561 
Ubiquitin mediated                         18                      14.3          SOCS1, UBE2G1, UBE1, 
proteolysis (hsa04120)                                                              MAP3K1, UBE2Q2, BIRC6, 
                                                                                                  UBE2E3,UBE2E4P, UBE2I,  
                                                                                                  UBE2W, CUL4A, CUL2, 
SOCS3, UBE1L2, CBLB,  
HUWE1, UBE2D3, CUL4B, 
UBE2A 
Prion disease (hsa05060)                 4                        8.8          BCL2, PRNP, LAMC1,  
NFE2L2 
Colorectal cancer                            11                       7.45        MSH6, BCL2, PIK3CA, 
 hsa05210)                                                                                 PDGFRA, KRAS, CASP9,  
FZD1, FZD4, AKT3,  
CTNNB1, SMAD3 
Long-term depression                     10                       7.34        GNAI2, PPP2R2B, KRAS, 
(hsa04730)                                                                                GNAS, PRKG1, GRIA2,  
NOS1, GRID2, IGF1,  
PPP2CB 
Long-term potentiation 9                       7.31        RPS6KA1, KRAS, PRKX, 
(hsa04720)                                                                                ENSG00000143933, GRIA2, 
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                                                                                                  RAP1B, PPP3CA, RPS6KA3, 
EP300 
ErbB signaling pathway 11                       7.13        CDKN1B, PIK3CA, KRAS, 
(hsa04012)                                                                                PAK2, CBLB, NRG1, 
ERBB4, PAK7, RPS6KB1, 
ENSG00000109321, AKT3 
Insulin signaling pathway 14                       5.97        IRS2, PIK3CA, SOCS1,  
(hsa04910)                                                                                ENSG00000143933, PFKP,  
KRAS, SORBS1, PRKX,  
PRKAA1, SOCS3, RHOQ,  
CBLB, RPS6KB1, AKT3 
mTOR signaling pathway 7                       5.9           PIK3CA, RPS6KA1,  
(hsa04150)                                                                                 PRKAA1, RPS6KA3, IGF1,  
RPS6KB1, AKT3 
Prostate cancer                                 10                      5.26        BCL2, CDKN1B, PIK3CA, 
(hsa05215)                                                                                 PDGFRA, KRAS, CASP9,  
IGF1, EP300, AKT3,  
CTNNB1 
TGF-beta signaling                          10                      5.14        PPP2R2B, ID2, RHOA, ID3, 
pathway                                                                     ACVR1, ACVR2A, EP300, 
(hsa04350)                                                                                 RPS6KB1, PPP2CB, SMAD3 
Renal cell carcinoma                        8                       4.41         PIK3CA, KRAS, CUL2,  
(hsa05211)                                                                                 PAK2, RAP1B, PAK7,  
EP300, AKT3 
Focal adhesion                                 16                      4.25        BCL2, COL6A3, PIK3CA, 
(hsa04510)                                                                                 PDGFRA, RHOA, KDR,  
PAK2, RAP1B, COL5A2, 
ENSG00000101608, 
ARHGAP5, LAMC1, IGF1, 
PAK7, AKT3, CTNNB1 
Melanogenesis                                 10                      4.17        GNAI2, KRAS, GNAS, 
(hsa04916)                                                                                ENSG00000143933, PRKX, 
                                                                                                  KITLG, FZD1, FZD4,  
EP300, CTNNB1 
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Nicotinate and nicotinamide            4                        4.12        NADK, PBEF1, C9orf95,  
metabolism                                                                                NNT 
(hsa00760) 
Tight junction                                  12                       3.83        MYH3, GNAI2, MAGI2, 
(hsa04530)                                                                                 PPP2R2B, RHOA, KRAS, 
                                                                                                   ASH1L, CASK, AKT3, 
CTNNB1, PPP2CB,  
ENSG00000101608 
Axon guidance                                 11                      3.46         GNAI2, NTN4, SLIT1, 
(hsa04360)                                                                                 ABLIM1, UNC5C, RHOA,  
KRAS, NRP1, PAK2,  
PPP3CA, PAK7 
Neurodegenerative                           5                        3.34        BCL2, NR4A2, PRNP,  
Diseases                                                                     UCHL1, EP300 
(hsa01510) 
Wnt signaling pathway 12                       3.09         NKD1, PPP2R2B, RHOA, 
(hsa04310)                                                                                 PRKX, SFRP2, PPP3CA,  
 FZD1, FZD4, EP300,  
PPP2CB, CTNNB1, SMAD3 
 
 
 
KEGG pathway (ID)      Found genes     -ln (p-value)                      Gene names 
                                                            hsa-miR-579 
Melanogenesis                                 15                      9.66         CSDE1, FZD5, EDNRB,  
(hsa04916)                                                                                 EDN1, ENSG00000143933, 
ENSG00000198668, MITF,  
KITLG, PLCB1, PLCB4,  
FZD4, CREB1, GNAI1,  
PRKACB, FZD10 
Long-term potentiation 11                     9.1            CSDE1, GRIA1, GRIN2A, 
(hsa04720)                                                                                  ENSG00000143933,    
                ENSG00000198668,     
PPP1CC, RAP1A, PLCB1,  
PLCB4, RPS6KA3, 
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PRKACB      
Insulin signaling pathway 16                    5.92           IRS2, CSDE1, PFKP, RHEB, 
(hsa04910)                                                                                  FRAP1, ENSG00000143933, 
                                                                                                    SREBF1, SORBS1, 
                                                                                                    ENSG00000198668, RHOQ, 
PPP1CC, PPP1R3A, 
PRKAA1, PRKAB2, 
RPS6KB1, PRKACB 
Tight junction                                   15                     5.11          MAGI3, OCLN, CSDE1, 
(hsa04530)                                                                                  YES1, PPP2R3A, CLDN11,  
PTEN, PTENP1, CLDN18,  
CLDN8, CDC42, PARD6B,  
INADL, GNAI1, EPB41,  
MAGI1 
Dorso-ventral axis formation 5                      4.6            FMN2, NOTCH2, SPIRE1, 
(hsa04320)                                                                                  ETV6, ERBB4 
Axon guidance                                  13                     3.79          EFNB2, SEMA3G, CSDE1, 
(hsa04360)                                                                                  ITGB1, LRRC4C, SEMA6D, 
                                                                                                    SRGAP2, SEMA3D, NRP1, 
CDC42, NFAT5, EPHB1, 
GNAI1 
Calcium signaling pathway 16                      3.76          PDE1C, PLN, PDGFRA,  
(hsa04020)                                                                                  EDNRB, ATP2B1, HTR7,  
ENSG00000143933, PLCB1, 
 PTGER3, NTSR1, PLCB4, 
GRIN2A, PRKACB,  
ENSG00000198668,  
ERBB4, VDAC3 
Ubiquitin mediated proteolysis 13                      3.32         UBE2D1, UBE2M, UBE4A, 
(hsa04120)                                                                                 UBE3A, UBE2Z, BIRC6,  
UBE1C, FBXW7, TRIM37,  
CUL5, ITCH, BIRC4, CUL4B
Methane metabolism                         2                      3.2           PRDX6, SHMT2 
(hsa00680) 
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5 Discussion 
5.1 miRNA prediction tools  
Tissue-specific regulation of HSD11B1 expression is not fully understood. Particularly the 
mechanisms underlying hepatic downregulation of HSD11B1 expression in obese patients 
displaying increased 11β-HSD1 in adipose tissue remain an enigma. As miRNA expression is 
highly tissue-specific manner and regulation by miRNAs is predominantly negative, miRNAs 
targeting HSD11B1 are clearly interesting candidates in this context, but have till now not 
been assessed. Four different web-based tools were used for miRNA target prediction, 
searching for miRNA response elements (MREs) in the 3’UTR of human HSD11B1 mRNA. 
Finally, four candidate miRNAs, hsa-miR-561, hsa-miR-579, hsa-miR-340 and hsa-miR-
181b, were selected for functional analysis. 
 
The selection for functional analysis was based on two mains: First, every miRNA predicted 
by all four tools was included and additionally, two miRNAs predicted by three of four tools 
were included because they had been shown to be expressed in hepatocytes (Hausser et al., 
2009; Landgraf et al., 2007), a major site of HSD11B1 expression in vivo. Functional analysis 
based on a dual luciferase assay system identified two miRNAs as potential novel regulators 
of HSD11B1 expression, namely hsa-miR-561, and hsa-miR-579. Experiments using MRE-
deleted and MRE-mutated vector constructs showed that the binding of both miRNAs to the 
predicted MREs was specific. Of note, both these miRNAs had been identified initially by all 
four predicted tools used in this study (Table 4.1). In contrast, hsa-miR-181b, which was 
identified by three of four prediction tools, did not bind to the 3’UTR of HSD11B1 mRNA at 
all. Another candidate miRNA, hsa-miR-340, was also identified by three of four prediction 
tools, and suppressed luciferase activity significantly (Figure 4.6). However, experiments with 
mutant luciferase constructs showed that suppression of luciferase activity by hsa-miR-340 
was not due to specific binding to the predicted MREs in the 3’UTR of HSD11B1 mRNA 
(Figure 4.8C and 4.9C). Supplementary experiments with the original, HSD11B1-3’UTR-
deficient vector, showed that hsa-miR-340, but neither hsa-miR-561 nor hsa-miR-579, already 
leads to suppression of luciferase activity when the 3’UTR of HSD11B1 mRNA is absent in 
the vector (Figure 4.10).  
 
In summary, hsa-miR-561 and hsa-miR-579 inhibited luciferase activity due to specific 
binding to the 3’UTR of HSD11B1 mRNA, but none of the miRNAs identified by three of 
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four prediction tools only showed specific binding to the corresponding MRE in the 3’ UTR 
of HSD11B1 mRNA.  
 
Of the two miRNAs identified, hsa-miR-579 was the more potent regulator, resulting in 
repression by about 40% in the luciferase reporter assay. This is furthermore emphasized by 
the fact that, in contrast to hsa-miR-561, hsa-miR-579 is also capable of significantly 
downregulating HSD11B1 expression after induction with glucocorticoids (Figure 4.18). It is 
worth mentioning at this point that two prediction tools, namely DIANA micro-T and 
MicroCosm Targets, predicted each an additional, albeit not identical, binding site for hsa-
miR-579. By deleting as well as mutating only the best-ranked binding site here, we observed 
complete abolishment of the repression, implying that only this binding site is valid. Hsa-
miR-579 has to date been mentioned very little in the literature. One study showed 
downregulation of hsa-miR-579 and simultaneous upregulation of predicted target genes in 
fibroblasts in response to high dose X-ray radiation (Maes et al., 2008). A more recent study 
has identified hsa-miR-579 as a negative regulator of TNF-α in a monocyte line model of 
endotoxin tolerance, which provides a link between expression of hsa-miR-579 and 
inflammatory disease, where expression of HSD11B1 often is deregulated (Staab et al., 2010; 
El Gazzar et al., 2010).  
 
It is striking that only the two miRNAs identified by all four prediction tools truly bound to 
the predicted 3’UTR MREs of the HSD11B1 transcript, and none of the two additionally 
tested, both identified by only three of four tools. This validates the overall approach of 
applying several prediction tools in parallel which differ considerably in the applied search 
algorithms and criteria for ranking (Bartel, 2009). The obtained results also emphasize the 
usefulness of integrating the conservation profile of the corresponding 3’UTR into the 
scoring, as both hsa-miR-561 and -579 ranked highest in the applications DIANA-microT-
ANN and Target Scan, where conservation of the 3’UTR is a main criterion for scoring 
(Maragkakis et al., 2009; Lewis et al., 2003).  
 
5.2 Dual-luciferase assay system  
In this study, the pmir-GLO, dual-luciferase miRNA target expression vector, is used to 
quantitatively evaluate miRNA activity by the insertion of miRNA target sequence on the 
downstream of the firefly luciferase gene. Firefly luciferase is the primary reporter gene; 
decrease of firefly luciferase expression indicates that miRNAs bind to the cloned miRNA 
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target sequence. Another reporter gene, Renilla luciferase is acting as a control reporter for 
normalization. The map of pmir-GLO vector is shown in Appendix 7.1.2. Normalizing the 
expression of firefly luciferase (experimental reporter) to the expression of Renilla luciferase 
(control reporter) can differentiate between specific and non-specific cellular responses. This 
dual-luciferase assay system is mainly applied for miRNA binding site analysis, 3’UTR 
analysis, miRNA detection and miRNA function analysis through monitoring luciferase gene 
expression. The feature of this dual-luciferase assay system is quick, easy and sensitive to 
measure the function of miRNA and miRNA binding sites.  
 
How does the dual-luciferase assay system work? In this assay system, firefly and Renilla 
luciferases contain distinct evolutionary origins and have very different enzyme structures and 
need different substrates. According to these differences, two luciferases can be measured in 
succession, with firefly luciferase luminescence elicited by one reagent, while the second 
reagent simultaneously quenches the firefly luciferase and elicits Renilla luciferase 
luminescence. Luminescence of firefly luciferase requires beetle luciferin, magnesium, ATP 
and molecular oxygen, while Renilla luciferase requires only coelenterate luciferin and 
molecular oxygen (Figure 5.1; http://www.promega.com).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Bioluminescent reactions catalyzed by firefly and Renilla luciferases. 
Mono-oxygenation of beetle luciferin is catalyzed by firefly luciferase in the presence of ATP, Mg2+ and 
molecular oxygen. Unlike beetle luciferin, mono-oxygenation of coelenterazine is catalyzed by Renilla 
luciferase only requires molecular oxygen. 
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Recently, dual-luciferase assay system is extensively used to study miRNA functions. For 
example, studies by Le et al. (2009) demonstrated that miR-125b-mediated down-regulation 
of p53 in both human and zebrafish is strictly dependent on the binding of miR-125b to 
microRNA response elements (MREs), which are in the 3’UTR of p53 mRNA.  Rogler et al. 
(2009) reported that miR-23b target 3’UTR of Smad (mothers against decapentaplegic 
homolog) 3, 4 and 5. Dual luciferase reporter assays confirmed down-regulation of constructs 
containing Smad 3, 4, or 5, 3' UTRs by a mixture of miR-23b cluster mimics. Another study 
showed that miR-196 directly acts on the 3’UTR of Bach1 mRNA and translationally 
represses the expression of this protein (Hou et al., 2010). Dual-luciferase reporter assay 
demonstrated that transfection of miR-196 mimic resulted in a significant decrease in Bach1 
3’UTR-dependent luciferase activity, but not in mutant Bach1 3’UTR-dependent luciferase 
activity. Moreover, there was no detectable effect of mutant miR-196 on Bach 3’UTR-
dependent luciferase activity (Hou et al., 2010). 
 
In the present study, dual-luciferase reporter assay demonstrated that in HepG2 and A549 
cells miR-579 and miR-561 down-regulate 11β-HSD1 expression due to binding to 3’UTR of 
HSD11B1 mRNA (Figure 4.6). The effect of miR-579 and miR-561 was abolished when the 
corresponding microRNA (miR-579 and miR-561) response elements (MREs) were deleted 
or mutated in the 3’UTR of HSD11B1 mRNA (Figure 4.8 and 4.9). These data indicated that 
the predicted MREs are critical for the direct and specific binding of miR-579 and miR-561 to 
the HSD11B1 mRNA. Though luciferase assays could be used to demonstrate physical 
interaction between miRNA and mRNA, it’s not available to directly prove it by using this 
system. To investigate the regulation of endogenous human 11β-HSD1 expression by miR-
579 and miR-561, A549 and HepG2 cell lines were used, which are known to express wild-
type 11β-HSD1. Normally, the level of endogenous 11β-HSD1 is very low in A549 and 
HepG2 cell lines (Staab et al., 2011) and it is very hard to detect 11β-HSD1 by Western blot. 
HSD11B1 mRNA was increased after induction with dexamethasone (Figure 4.14) and 11β-
HSD1 was increased after induction with dexamethasone proved by dual-luciferase assay 
system (Figure 4.17). Therefore, it might be possible to detect 11β-HSD1 after induction with 
dexamethasone. However, Western blot results were very disappointing (Figure 4.20), 11β-
HSD1 was undetected using microsomes and total cell proteins from A549 and HepG2 cells, 
while 11β-HSD1 was detected using human liver microsomes as positive control. In addition, 
the homogenous time-resolved fluorescence (HTRF) assay was also used for the detection of 
cortisol activity. This method could be used to prove 11β-HSD1 activity indirectly. 
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Unfortunately, HTRF assay failed to detect the cortisol activity in microsomes from A549 and 
HepG2 cells (data not shown). In other words, it failed to detect endogenous 11β-HSD1 
expresson in A549 and HepG2 cells using Western blot and HTRF assay. The main reason is 
low expresson of 11β-HSD1 in A549 and HepG2 cells (Staab et al., 2011).  
 
5.3 Mechanism of miRNA-mediated suppression: mRNA degradation or 
translational repression 
MiRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: 
mRNA degradation or translational repression. In plants, miRNAs complement with 
corresponding mRNA targets precisely, resulting in cleavage and destruction of the target 
mRNAs. In animals, complementarity of miRNAs and target mRNAs is generally imperfect 
(Lai, 2004), but partial complementarity is sufficient to trigger target mRNA degradation 
(Bagga et al., 2005; Du et al., 2005, Lim et al., 2005) or translational repression. In animals, 
some miRNAs, such as miR-196 inhibits HOXB8 expression by cleavage of HOXB8 mRNA 
in mouse embryos (Yekta et al., 2004). However, translational repression seems to be the key 
approach in animals (Bartel, 2004). In this study, miR-561 and miR-579 bound to the 3’UTR 
of HSD11B1 mRNA with imperfect complementarity (Figure 4.7). A comparison of firefly 
(reporter) and Renilla (control) luciferase mRNA levels with the corresponding luciferase 
activities (Figures 4.11 and 4.6) demonstrated that the regulatory mechanism is mainly 
translational repression-based, which is the main mechanism for metazoan miRNAs (Bartel, 
2004). Furthermore, the levels of endogenous HSB11B1 mRNA are not affected by hsa-miR-
561 and hsa-miR-579 (Figure 4.12). Collectively, the results show that the mechanism of 
miRNA-mediated suppression of HSD11B1 expression is based on translational repression 
(Figure 5.2). 
 
Up to date, miR-579 has been mentioned very little in the literature. One study by EI Gazzar 
et al. identified that miR-579 binds to the 3’UTR of TNFα. Expression profiling revealed that 
miR-221, miR-579, and miR-125b were selectively induced in LPS-tolerant cells, and miR-
221 accelerates TNFα mRNA degradation, whereas miR-579 and miR-125b block TNFα 
translation (EI Gazzar et al., 2010). Thus, the mechanism of miR-579-mediated suppression 
of TNFα expression is the same as that in HSD11B1 expression: translational repression. For 
miR-561, there is no related report its downregulation of gene expression.  
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In the introduction section, it has been mentioned that miRNAs can repress protein expression 
in all steps of mRNA translation, including inhibition of translational initiation, inhibition of 
translational elongation, premature termination of translation (like ribosome drop-off) or 
proteolysis (degradation of nascent peptide) (Figure 1.6). In this study, the mechanism of 
miR-579 and miR-561-mediated downregulation of HSD11B1 expression was demonstrated 
to be translational repression rather than mRNA degradation, but it is still unknown which 
step of 11β-HSD1 translation is controlled by miRNAs.  
 
5.4 Glucocorticoids versus miRNAs for regulation of HSD11B1 expression 
Glucocorticoids (GCs) are a class of steroid hormones that are secreted by the adrenal cortex 
and that are regulated by adenocorticotrophic hormone (ACTH) largely under the control of 
the hypothalamic-pituitary-adrenal axis.  GCs have many diverse effects, including potentially 
harmful side effects. Chronic glucocorticoids excess causes Cushing’s syndrome, obesity, 
type 2 diabetes, insulin resistance, dyslipidemia, hypertension, heart disease and memory 
Figure 5.2 Mechanism of miR-561/-579-mediated suppression in HSD11B1 expression. 
A: mRNA degradation B: translational repression. Repression of HSD11B1 expression by miR-
561 and -579 occurs at the translational level, but not at the transcriptional level. 
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impairments (Orth, 1995; Wamil and Seckl, 2007). Glucocorticoids themselves potently 
increased HSD11B1 expression in many cells, providing a potential feed-forward system to 
pathology. Glucocorticoids such as dexamethasone and cortisol are important regulators of 
HSD11B1 expression in human lung and liver (Yang et al., 2009). HSD11B1 mRNA could be 
induced by glucocorticoids in vivo (Yang et al., 1994; Hundertmark et al., 1994; Jamieson et 
al., 1999; Michailidou et al., 2007), although the regulation is tissue-specific and complex. 
Most regulators of HSD11B1 expression are likely to act indirectly, and the only direct 
regulators of HSD11B1 transcription described to date comprise members of the 
CCAAT/enhancer binding protein (C/EBP) family of transcription factors (Williams et al., 
2007; Bruley et al., 2006). CCAAT/enhancer binding proteins (C/EBPs) are a family of 
transcription factors, which promote the expression of certain genes through interaction with 
their promoter. HSD11B1 is transcribed from two distinct promoters, the distal promoter P1 or 
the proximal promoter P2. Transcription from Promoter P2 in liver, brain, and adipose tissue 
is predominant and dependent on the transcriptin factor C/EBPα (Williams et al., 2007; 
Bruley et al., 2006). Transcription from Promoter P1 is C/EBPα independent (Bruley et al., 
2006). Sai et al. have investigated the molecular mechanisms. They proved that 
glucocorticoids regulate transcription of HSD11B1 via promoter P2 and exploit an A549 cell 
model system in which endogenous HSD11B1 is expressed and induced by dexamethasone 
(Sai et al., 2008). In this model, glucocorticoid induction of HSD11B1 expression is indirect 
and requires CCAAT/enhancer-binding protein (C/EBP). The glucocorticoid-response region 
is located between -196 and -88 with respect to the transcription start site of HSD11B1, which 
contains two binding sites for C/EBP transcription factors. These sites are essential for the 
glucocorticoid response and C/EBP binding (Figure 5.3; Sai et al., 2008). 
 
In the present study, the results show that HSD11B1 expression on the transcriptional level 
was induced by glucocorticoids (Figure 4.14). However, the miRNA suppression occurs on 
the translational level. Mature miRNA is assembled into a microribonucleoprotein (miRNP), 
which binds to the 3’UTR of HSD11B1 mRNA, leading to repression of protein synthesis 
(Figure 5.3). Due to these different regulatory mechanisms exerted by glucocorticoids and 
miRNAs in HSD11B1 expression, can be controlled at the transcriptional and translational 
level, respectively. Therefore, it is possible that miR-579 can still inhibit HSD11B1 
expression after induction with glucocorticoids proved by dual luciferase assay system 
(Figure 4.18A and B). Moreover, glucocorticoids induction of HSD11B1 expression is so 
strong that the repression by miRNA is relatively negligible, in the case of hsa-miR-561 
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(Figure 4.18C and D). In contrast, hsa-miR-579 is a more potent repressor than hsa-miR-561, 
and repression of HSD11B1 expression could be detected after glucocorticoids induction 
(Figure 4.18A and B). Therefore, miRNAs, to some extent, could resist the effect of 
HSD11B1 expression by glucocorticoids, based on this mechanism, miRNAs may be a 
promising 11β-HSD1 inhibitor for therapeutic diseases in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5 The regulation of HSD11B1 expression  
The regulation of HSD11B1 expression is controlled by two distinct promoters, namely distal 
promoter P1 and proximal promoter P2, an aspect which to date has been studied very little. 
However, studies in the mouse have shown that both promoters are active in liver, lung, 
adipose tissue and brain (Bruley et al., 2006). Currently, the human HSD11B1 promoter has 
not yet been characterized in detail. Most of research groups mainly focused on studying for 
human HSD11B1 promoter P2, little for HSD11B1 promoter P1. For instance, Williams et al. 
Figure 5.3 Regulation of HSD11B1 expression by glucocorticoids and miRNAs. After binding at the 
promoter P2, GCs promote the transcription of HSD11B1, while translation of HSD11B1 mRNA can be 
inhibited by miRNAs. P1 and P2 represent Promoter 1 and 2 of HSD11B1, respectively. 0A, 0B, 1~6 
represent exons.  
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(2000) demonstrated that C/EBPα (CCAAT/enhancer binding protein) is a potent activator of 
hepatic transcription of HSD11B1 in hepatoma cells, and mice deficient in C/EBPα have 
reduced hepatic HSD11B1 expression. In contrast, C/EBPβ is a relatively weak activator for 
HSD11B1 expression. They also showed that HSD11B1 promoter (proximal promoter P2; 
between -812 and +76) contains 10 C/EBP binding sites, and mutation of the promoter 
proximal sites decreases the C/EBP inducibility (Williams et al. 2000). To characterize some 
mechanisms which control the expression of the human HSD11B1 in preadipocytes, Gout et 
al. (2006) demonstrated that two members of the C/EBP family, C/EBPα and C/EBPβ are 
required for the basal transcriptional activity of HSD11B1 in 3T3-L1 preadipocyte cells. This 
effect depends on C/EBP binding sites. Two putative C/EBP binding sites are located in a 
region of the promoter between -48 and -178 and relatively conserved among species, human, 
baboon, rat and mouse. Indeed, mutation of C/EBP binding site led to a significant decrease in 
basal HSD11B1 promoter (proximal promoter P2) activity. A differential regulation of the 
human HSD11B1 promoter depending on the cell type was observed. Promoter fragments 
were analyzed in human HepG2 cells and undifferentiated and differentiated murine 3T3-L1 
cells. A strong repressor of the basal promoter activity was only found between -85 and -172 
in HepG2 cells, while an additional repressor appeared to be active between -342 and -823 in 
human HepG2 cells and undifferentiated and differentiated murine 3T3-L1 cells (Andres et 
al., 2007). Recently, Staab et al. (2011) demonstrated that the distal promoter P1 (HSD11B1-
Promoter P1) predominated in the human tumor cell lines A431 and HT-29 and contributed 
significantly to overall HSD11B1 expression in human lung (Staab et al., 2011). The proximal 
promoter P2 (HSD11B1-Promoter P2) predominated in most tissues and cell lines assessed, 
including human liver, human lung, human subcutaneous adipose tissue, and the cell lines 
A549, Caco-2, C2C12 and 3T3-L1 (Staab et al., 2011).  
 
In this study, glucocorticoids (cortisol and dexamethasone) increased HSD11B1 mRNA 
transcription via both distal promoter P1 and proximal promoter P2, but promoter P2 
predominated in A549 cells (Figure 4.14). To analyze the promoter activity, the two 
fragments of HSD11B1-promoter, distal promoter P1 (2.173 bp) and proximal promoter P2 
(2506 bp), were cloned into plasmids of dual-luciferase assay system. The result showed that 
11β-HSD1 expression in A549 cells is significantly increased via promoter P2 after induction 
with cortisol and dexamethasone, but not significantly changed via promoter P1 (Figure 4.17). 
Consistent with the results reported by Sai et al., they demonstrated that the promoter P2, but 
not the promoter P1, of HSD11B1 is more important in A549 cells. Dexamethasone increased 
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activity of a promoter P2-reporter construct only. Moreover, they found that the region 
between -196 and -124 is essential for glucocorticoid induction of HSD11B1 promoter P2 (Sai 
et al., 2008). Furthermore, more regulatory factors were detected using dual-luciferase assay 
system in A549 cells. However, no promoter activity is shown (Figure 4.19). It is possible 
reason that both of fragments of Promoter 1 and Promoter 2 do not contain the related binding 
sites of the regulatory factors. 
 
To date, it has been reported that many regulatory factors are involved in the regulation of 
HSD11B1 expression, including some proinflammatory cytokines (TNF-α and IL-1β), growth 
hormone, leptin, insulin, glucocorticoids (cortisol and dexamethasone), CCATT/enhancer 
binding protein (C/EBP), peroxisome proliferator-activated receptor (PPAR) agonists, sex 
hormones, thyroid hormone and other nuclear receptors (Table 1.3). The present study is the 
first report that miRNAs act as potential novel regulators of HSD11B1 expression. 
 
The regulation of HSD11B1 expression occurs in a highly tissue-specific manner (Tomlinson 
et al., 2004). For example, several studies have demonstrated that TNF-α increases 11β-HSD1 
mRNA transcription and activity of this enzyme in various cell models, such as human 
osteoblasts, adipose stromal cells, adipocytes and hepato cellular carcinoma cells (Cooper et 
al., 2001; Tomlinson et al., 2001; Friedberg et al., 2003; Iwasaki et al., 2008), but not in 
human monocytes and hepatocytes (Thieringer et al., 2001; Tomlinson et al., 2001). Leptin 
treatment of ob/ob mice markedly increased hepatic 11β-HSD1 activity and mRNA 
transcription (Liu et al., 2003). Leptin causes a borderline significant increase in 11β-HSD1 
activity in omental adipose stromal cells, but not in human hepatocytes (Tomlinson et al., 
2001). Insulin inhibits 11β-HSD1 activity in primary cultures of rat hepatocytes (Liu et al., 
1996) and 3T3-L1 cells (Napolitano et al., 1998), but not changes 11β-HSD1 activity in 
human adipose stromal cells (Bujaska et al., 1999). Retinoic acid reduces glucocorticoid 
sensitivity in C2C12 myotubes by decreasing 11β-hydroxysteroid dehydrogenase type 1 and 
glucocorticoid receptor activities (Aubry and Odermatt 2009). Human monocyte expression 
of 11β-HSD1 is induced by Vitamin D3 (Thieringer et al., 2001). Based on this kind of highly 
tissue-specific manner, it might be explained that TNF-α, Leptin, insulin and so on, did not 
influence activity of 11β-HSD1 promoter, by absence of relative factors which react with 
regulatory factors in lung cells (A549 cells, Figure 4.19). However, the underlying 
mechanism is still unknown. 
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5.6 The presence of the studied miRNAs in human liver cells 
Studies have reported that anti-microRNA oligonucleotides (AMOs) or antisense 
oligonucleotides (ASOs) have been developed to inhibit miRNAs in variety of culture cells or 
organisms (Davis et al., 2006; Esau, 2008). For instance,  AMOs have been used successfully 
to downregulate miR-21 expression in A549 cells (Fei et al., 2008) and inhibit the liver-
specific miR-122 in mice (Esau et al., 2006; Krutzfeldt et al., 2005). As mentioned in the 
introduction section, the biogenesis of miRNAs is a multistep process (as shown in Figure 
1.4). Therefore, multiple steps could be targeted with AMOs for inhibition of miRNA 
production or function (Weiler et al., 2006). The major mechanism for AMOs is believed to 
be the targeted degradation of the pri-miRNA, pre-miRNA, and mature miRNA. Therefore, 
AMOs or ASOs interference with the role of miRNA are summarized in three possible 
pathways (Figure 5.4, Weiler et al., 2006). Firstly, targeted degradation of the pri-miRNA 
transcript in the nucleus with AMOs may be feasible, and could be advantageous for 
inhibiting production of miRNA from a pri-miRNA transcript. Secondly, by pathway B, 
targeting the pre-miRNA hairpin with AMOs is also theoretically possible. The last, the most 
straightforward and apparently most effective AMOs tested so far are complementary to the 
mature miRNA, designed to block its function in miRNP complex. Targeting of mature 
miRNAs with such AMOs has been reported by many investigators in a variety of cultured 
cells and organisms (Hutvagner et al., 2004; Davis et al., 2006; Esau, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMOs or ASOs A 
B
C 
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In an initial effort to assess the presence of hsa-miR-579 and hsa-miR-561 in hepatocytes, 
AMOs (AMO-579 and AMO-561) are designed to target the mature miR-579 and miR-561 in 
HepG2 cells. These results demonstrated that AMO-579 and AMO-561 not only inhibit the 
role of exogenous miR-579 and miR-561, but also block the role of endogenous miR-579 and 
miR-561 (Figure 4.21). This is a strong indication of presence of endogeous hsa-miR-579 and 
-561 in HepG2 cells, a finding which is in agreement with web-based tissue profiling using 
the smiRNAdb miRNA expression atlas (Figure 4.1, www.mirz.unibas.ch, Hausser et al., 
2009; Landgraf et al., 2007). In this work, the dual-luciferase assay system and AMOs were 
used to detect interesting miRNAs, the advantage of this method is rapidly and easily. 
Meanwhile, AMOs are a powerful tool for uncovering new areas of miRNA biology, with the 
gradual deepening of research, AMOs inhibition of miRNA function displays a potential 
therapeutic approach for miRNA therapy of human diseases.  
 
Normally, the most straightforward RNA detection method is northern blot analysis, which is 
a widely used method for RNA analyses because it is generally a readily available technology 
for laboratories. To verify the presence of miR-561 and miR-579 in hepatocytes and HepG2 
cells, the experiment was performed by Northern blot. 20 ng of positive control (DNA 
oligonucleotides) showed a strong signal. However, we could not find any signal for miR-561 
or miR-579 with 10 μg of total RNA (Figure 4.22). Two reasons have to be considered: 
miRNAs are short, average about 21 nucleotides in length, so miRNAs are more difficult to 
detect than large RNA; On the other hand, a DNA oligonucleotide probe has been used in this 
experiment, and traditional DNA oligonucleotide probe has a poor sensitivity to complement 
to target miRNA, which is especially pronounced that investigated miRNAs are at a low 
abundance.  
 
Although Northern blot failed to detect the expected miRNAs in hepatocytes, another method 
with higher sensitivity, RT-PCR, was used to prove the presence of miRNAs. This approach 
requires small amounts of starting material and can provide accurate results. Using specific 
Figure 5.4 Interference with the miRNA pathway using synthetic oligonucleotides. 
Inhibition of miRNA activity may be achieved by introducing anti-miRNA oligonucleotides (AMOs) or 
antisense oligonucleotides (ASOs) complementary to the pri-miRNA (primary-miRNA), the pre-miRNA 
(precursor-miRNA) or the mature miRNA. A, B and C represent via pri-miRNA, pre-miRNA and mature 
miRNA pathways, respectively. 
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primers (designed and obtained by Ambion GmbH), both miR-561 and miR-579 are 
successfully amplified in both human hepatocytes and HepG2 cells (Figure 4.24). Previously, 
miR-579 has been detected in HepG2 cells and hepatocytes (www.mirz.unibas.ch, Hausser et 
al., 2009; Landgraf et al., 2007, Figure 4.1). Moreover, miR-561 is firstly detected in normal 
hepatocytes and HepG2 cells. 
 
5.7 Regulatory role of microRNAs in liver 
In obese patients, HSD11B1 expression is increased in adipose tissue, but typically decreased 
in liver, and the underlying tissue-specific mechanisms are largely unknown (Livingstone et 
al., 2000). As miRNA expression is highly tissue-specific manner and regulation by miRNAs 
is predominantly negative. In this study, two miRNAs, miR-561 and miR-579, have been 
identified to downregulate HSD11B1 expression. As shown in this study, miR-561 and miR-
579 were detected from human hepatocytes and HepG2 cells. This may explain the 
mechanism by which HSD11B1 expression is downregulated in liver tissue of obese patients. 
Up to date, we know little about the roles of miR-561 and miR-579, but it is quite sure that 
many new and unanticipated roles of miRNAs in the control of normal and abnormal liver 
functions are awaiting discovery. 
 
At the beginning, miR-561 or miR-579 transcription was expected to occur in hepatocytes 
from normal, overweight and obese people. Because the hepatocyte samples (from normal, 
overweight and obese people) were not easily obtained for this experiment, in each group 
there were only two different samples. In fact, the sample numbers were not sufficient. The 
semi-quantitative RT-PCR results showed that miR-561 transcriptions were at similar levels 
in hepatocytes with different BMI (Figure 4.25) and miR-579 transcriptions were significantly 
lower in both female and male obese people than in the corresponding female and male 
samples of normal weight people (Figure 4.25). To get more convincing results, the sample 
numbers should be expanded. Furthermore, the size of miRNA is too short and it is 
impossible to detect all miRNAs in total RNA isolated from frozen hepatocytes. Therefore, 
these reasons should be considered as well.  
 
So far, many studies have uncovered profound and unexpected roles for miRNAs, in the 
control of diverse aspects of hepatic function and dysfunction, including hepatocyte growth, 
metabolism, stress response, liver cancer, viral infection, immunity, gene expression, and 
maintenance of hepatic phenotype (Krutzfeld and Stoffel, 2006; Girard et al., 2008; Lu and 
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Liston, 2009). In hepatocellular carcinoma (HCC), miRNA dysregulation plays a key role in 
mediating the pathogenicity of several etiologic risk factors and they promote a number of 
cancer-inducing signaling pathways (Law and Wong, 2011). Moreover, another study has also 
demonstrated its potential value in the clinical management of HCC patients as some miRNAs 
may be used as prognostic or diagnostic markers (Girard et al., 2008). Many miRNAs such as 
miR-21, miR-34a, miR-106a, miR-223, and miR-224, are upregulated in hepatocellular 
carcinoma (HCC) compared to that in benign hepatocellular tumors such as adenomas or focal 
nodular hyperplasia (Meng et al., 2007; Wong et al., 2008). Many other miRNAs have been 
noted to be decreased in HCC compared to non-tumoral tissue, such as miR-122a, miR-145, 
and miR-199a, miR-422b (Kutay et al., 2006; Meng et al., 2007; Wong et al., 2008; Varnholt 
et al., 2008; Gramantieri et al., 2007). Study by Li et al. found that miR-183 was up-regulated 
in HCC tumor tissue. Moreover, they validated that miR-183 could repress the programmed 
cell death 4 (PDCD4) expression and analyzed its functions in human HCC cells (Li et al., 
2010). Furthermore, miR-122 and miR-152 have been reported in modulating the response to 
hepatitis C virus infection (Kerr et al., 2011; Girard et al., 2008). 
 
5.8 Pathway Enrichment Analysis 
In efforts to place the repression of HSD11B1 expression by the identified miRNAs in a 
broader context of molecular networks, we searched for overrepresented pathways among all 
potential targets of hsa-miR-561 and -579. Several enriched pathways were found that have 
previously been associated with metabolic disease and/or glucocorticoid signalling. A striking 
result was the finding of one signalling pathways for nutrient metabolism, the insulin 
signalling pathway, for both miRNAs. As to the insulin signalling pathway, this finding raises 
the possibility that hepatic downregulation of HSD11B1 expression might occur in the context 
of miRNA-based downregulation of multiple targets involved in insulin signalling, ultimately 
leading to the development of insulin resistance.  
 
Further overrepresented pathways with linkage to glucocorticoid metabolism are long-term 
potentiation, neurodegenerative disease, and long-term depression. Neuronal vulnerability, 
depression and age-associated cognitive impairment correlate with elevated glucocorticoid 
levels (Wamil et al., 2007; Poor et al., 2004; Rajan et al., 1996; Ajilore et al., 1999).  
Furthermore, it has been shown that 11β-HSD1 levels increase during aging and cause 
memory impairment (Holmes et al., 2010). Consistently, 11β-HSD1 knockout mice show less 
learning impairment as well as decreased corticosterone levels in the hippocampus coming 
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along with enhanced long-term potentiation (Yau et al., 2001; Yau et al., 2007). Finally, a 
rare single nucleotide polymorphism in the 5’UTR of HSD11B1 associates with increased risk 
for Alzheimer’s disease (de Quervain et al., 2004).  As to the remaining enriched pathways, 
no obvious connections with 11β-HSD1 and/or glucocorticoid metabolism/signalling have 
been reported to date.  
 
Hsa-miR-561 is located in intron 1 of GULP1 (Table 5.1). Together with its host gene 
GULP1, intronic hsa-miR-561 is overexpressed in multiple myeloma primary tumors 
(Ronchetti et al., 2008), but has not been mentioned in any other context to date. Interestingly, 
GULP1, which encodes a protein that plays a role in the engulfment of apoptotic cells as well 
as in cellular glycosphingolipid and cholesterol transport, is downregulated by activated 
glucocorticoid receptor α (Lu et al., 2007). As host genes and intronic miRNAs are typically 
co-regulated (Baskerville et al., 2005), it can be speculated that downregulation of hsa-miR-
561 in response to glucocorticoids might contribute to the fine-tuning of glucocorticoid-
induced expression of HSD11B1.  
 
Neither hsa-miR-561 nor hsa-miR-579 has so far been mentioned in the context of obesity 
and diabetes. However, as all studies on differential miRNA transcription in this regard have 
been performed with rodent model systems (Esau et al., 2004; He et al., 2007; Lovis et al., 
2008; Herrera et al., 2009; Herrera et al., 2010). A search in miRBase 
(http://www.mirbase.org/) reveals a miRNA count of 940 for Homo sapiens in contrast to 590 
in Mus musculus and 326 in Rattus norvegicus, and the rodent entries include neither miR-561 
nor miR-579. Considering their relatively well-conserved MREs in the HSD11B1 mRNA 
(Table 5.1) and 3’UTRs of other genes as found in the pathway enrichment analysis by 
DIANA mirPath (Table 4.5), it is nevertheless plausible that both miRNAs can be found in 
other mammalian species. However, as there is no experimental evidence for the existence of 
these miRNAs in rodents yet, they are not included on miRNA microarrays commonly used 
for their detection (Esau et al., 2004; He et al., 2007; Lovis et al., 2008; Herrera et al., 2009; 
Herrera et al., 2010). 
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hsa-    Genomic    Position      
miR    location1    of MRE     3’-UTR MRE       miRNA expression in4    regulation in 
                                seed in       conserved in3                                                  disease or 
                              HSD11B1                                                                        other processes5 
                               3’UTR2 
-561    Intron 1                         Chimpanzee,     human adrenocarcinoma  
               of              325-331    Rhesus, Horse      cell line SW13                       ↑ multiple 
           GULP16                         Rabbit, Cow,      human embryonic kidney       myeloma cell 
                                                  Macaque,            cell line HEK293                lines (Ronchetti 
                                                  Armadillo           human multiple myeloma         et al., 2008) 
                                                  Elephant             cell lines (Ronchetti et al., 
                                                                              2008) 
-579    Intron 11                       Chimpanzee,     human hepatoma cell line 
            of ZFR7       400-406    Mouse, Rat,       HepG2 (see Figure 4.1)          ↓ irradiation 
                                                  Guinea pig,       human teratocarcinoma   (Maes et al., 2008) 
                                                  Rabbit               cell line NT2                          negatively 
                                                                           human fibroblasts                   regulates 
                                                                           (Maes et al., 2008)                  expression of 
                                                                           human acute monocytic            TNT-α (EI 
                                                                          leukemia cell line THP-1       Gazzar et al.,  
                                                                           (EI Gazzar et al., 2010)               2010) 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Compiled information on the here described miRNAs binding to the 3’UTR of 
HSD11B1 mRNA. 
1 according to miRBase (http://www.mirbase.org/, (Griffiths-Jones, 2004; Griffiths-Jones et al., 2006; Griffiths-
Jones et al., 2008) 
2 according to TargetScan (http://www.targetscan.org/, Lewis et al., 2003; Lewis et al., 2005; Liu et al., 2003; 
Grimson et al., 2007) 
3 compiled from the results by TargetScan (http://www.targetscan.org/, Lewis et al., 2003; Lewis et al., 2005; Liu 
et al., 2003; Grimson et al., 2007) and by DIANA micro-T (http://diana.cslab.ece.ntua.gr/microT, Maragkakis et 
al., 2009) 
4 according to the smiRNAdb miRNA expression atlas (http://www.mirz.unibas.ch, Landgraf et al., 2007; Hausser 
et al., 2009) and other references as cited 
5 according to the human microRNA disease database (HMDD, http://cmbi.bjmu.edu.cn/hmdd, Lu et al., 2008) and 
the miR2 Disease Base (http://www.mir2disease.org/) 
6 GULP1: PTB domain-containing engulfment adapter protein 1, modulates cellular glycosphingolipid and 
cholesterol transport; downregulated by activated GRα 
7 ZFR: Zinc finger RNA-binding protein, involved in postimplantation and gastrulation stages of development 
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5.9 Outlook 
In this work, two human miRNAs, hsa-miR-561 and hsa-miR-579, were identified as 
potential novel regulators of HSD11B1 expression. Evidence from the literature and 
experiments, as e.g. the intronic location of hsa-miR-561 in a glucocorticoid-responsive gene, 
and both hsa-miR-561 and hsa-miR-579 have been detected in hepatocytes, as well as target 
miRNA-enriched pathways strengthen their potential role in pathological conditions 
associated with deregulated glucocorticoid metabolism/signalling. Furthermore, the obtained 
results raise the possibility that regulation of HSD11B1 expression in obesity, type 2 diabetes, 
and cognitive impairment might occur in a broader context of miRNA-based downregulation 
of entire pathways. However, the relative contribution of these miRNAs to overall regulation 
of HSD11B1 remains unclear. Nevertheless, the obtained results encourage the in depth-study 
of the miRNAs identified in the context of the aetiology of the metabolic syndrome and 
neuronal disorders in the future work. 
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7 Appendix 
7.1 Plasmid maps 
7.1.1 pCR2.1-TOPO 
The map below shows the features of pCR2.1-TOPO and the sequence surrounding the TOPO 
Cloning sites. Restriction sites are labeled to indicate the actual cleavage site. The vector is 
used for the direct insertion of Taq polymerase-amplified PCR products. 
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7.1.2 pmir-GLO 
The pmir-GLO dual-luciferase miRNA target expression vector is designed to quantitatively 
evaluate microRNAs (miRNA) activity by the insertion of miRNA target sequence on the 
downstream of the firefly luciferase gene (luc2). Firefly luciferase is the primary reporter 
gene; decrease of firefly luciferase expression indicates the binding of endogenous or 
introduced miRNAs to the cloned miRNA target sequence. The pmir-GLO vector, firefly 
luciferase (luc2) is used as the primary reporter to monitor mRNA regulation, and Renilla 
luciferase (hRluc-neo) is acting as a control reporter for normalization and selection. 
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7.2 Sequences 
7.2.1 HSD11B1-3’UTR  
Nucleotide sequence of HSD11B1-3’UTR including relevant restriction sites: 
 
              CTCGAG 
               XhoI 
       1  GAACTCCCTG AGGGCTGGGC ATGCTGAGGG ATTTTGGGAC TGTTCTGTCT             
  51  CATGTTTATC TGAGCTCTTA TCTATGAAGA CATCTTCCCA GAGTGTCCCC 
 101  AGAGACATGC AAGTCATGGG TCACACCTGA CAAATGGAAG GAGTTCCTCT 
 151  AACATTTGCA AAATGGAAAT GTAATAATAA TGAATGTCAT GCACCGCTGC 
 201  AGCCAGCAGT TGTAAAATTG TTAGTAAACA TAGGTATAAT TACCAGATAG 
 251  TTATATTAAA TTTATATCTT ATATATAATA ATATGTGATG ATTAATACAA 
 301  TATTAATTAT AATAAAGGTC ACATAAACTT TATAAATTCA TAACTGGTAG 
 351  CTATAACTTG AGCTTATTCA GGATGGTTTC TTTAAAACCA TAAACTGTAC 
 401  AAATGAAATT TTTCAATATT TGTTTCTTA  CAGCTG                      
                                                                                                SalI 
   
7.2.2 HSD11B1-Promoter 1 
Nucleotide sequence of HSD11B1-Promoter 1 including relevant restriction sites: 
 
 CCCGGG    
   XmaI   
   1  GCCCAGAAAA ATTAGGAGAC AAAGCCCCAA AGAGGCAATA GTCAGCTTCT 
  51  TTCATTGGTA AGCTAAGGCT TCAAAATAAA ATTTTAACTT GAGAATGGTC 
 101  TCTCTCAAAG ACTCTGATAC CACCTAAAAC CTACCCTCCT TTCATTTCTC 
 151  TTTCTACTCA GCTTTACCTG ACCTTCAACA TGAGACAACC GTTTCTTCTA 
 201  AGTTTTCTCT GAAAAAGAGT AATCACATTG TAAAACTGCT AAACCAGAGG 
 251  GGAGCCCTAA AAAGCTGAAT TTAAACCCTG GCCTGGAGCA AAATTAAAAG 
 301  TTATCATGAA AGATTTTCCT AAGCCTCAGG GGTGGTTGAG CAGAAATTAG 
 351  TTAACAATTC AGGATTTTAT TAGGTACTTA TTGTTCTGGA TTAAACATCT 
 401  GTACCAAATG ATTCAGTTAA TTGTTAGTCC ATCCAATAGA GAAAAAAAAT 
 451  TATAAGCAGC AGGGTAAGAA AAAAATTAAA TAACTCAGTT GTGCAAAATG 
 501  AAAAACAAAC GCCTTAAGTG GACAAGAAAA ACCTTGAAAA TCCAGTACAA 
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 551  AAAGCAATTT CAAAAAAATC TTTCTTTTAA AAGTATGTTA GACAAAGATT 
 601  AAAAATTGTA AACTAAATGA AAATGAAAAG AGACTTCAGA AAACTTTCAA 
 651  AGAGCATTCT GGAGTACACT CAACAGCTGA AATAAAAGAA ACATTGTCTT 
 701  TATTTTTTTC TATTAAAGGG CTCAAATATG AATTCAGAGA TTTAATGAGA 
 751  AAAAAGTAAT TGAAATATGA AACTGACAGC TTAGAAAATA TCCAATACAT 
 801  AGCTAGATAT TTTCAGAGAG CTCTAGAAAG TAAATAAGCT AGAAATCAAT 
 851  AGAACGTATG GTTCTCTACA TAAAAAAACT TGCCCCGAAA TAAAAACAAA 
 901  GCCAAAAAGT CTTCTATTTT CTAAGAATTG GGAACATATA GAGAGGGGTA 
 951  CTTGTAGATA TTGCAAGCAA AAGTGTCATT CAAAGAACCA ATGTTCCACA 
1001  TTGGCTAAGT AACAGAAAGA TGACTATCCA AAATCTGTCT AATGGTGTTT 
1051  CTCCAAAGGA GACATTAGTA CCCAACAATT ACAGTCCTTC CTCGGAGTTT 
1101  GTGTCCCCAA ATCTCAGAGG GGCCAGTCGC TATACTCTCC ATCAGGGCAT 
1151  AGCTACATCT AGCATGGCTT ACCACTCTAT CCCCAGCCTC TAGCCCAGTG 
1201  CCTAGCATAG AGTAGATGCT TATTAGATAT CTGTTGAACA AATGAAGAAA 
1251  TAGAGGAAGA AAGTACATTT TTGTTTTGAC ATGCTGTAGT CCCTTCCTTA 
1301  GTCCAGAGAT CACAAACCTC TGAATTGGGA TGTGACTCTC TCTGTCATTA 
1351  ATCGGCAAGA ATCATGGTAG AATTATTGTC CCTACTTACG GATTCTCTTT 
1401  CCCTTATACA TCCCATTGCA GATTCCTGTC TTCCCTTTAC ATCCACTCCA 
1451  ACATCAGCTG ATGCAGTCAC TAAAATGGTT TATAAGTCAC ATATGAGATT 
1501  CCCTAAGGAG TTTATAATTG AGAAATGTGT GGACACACAG GCCTCACAGA 
1551  ATGCACTGGA TCACTAGAGT CTCTCCTGGT GAAAAGGGAA AACCTGCCCA 
1601  AATCCAGTTT TTGTTTCAGT AACTTCCTTT GAGACAAAGT CAGGAATCTG 
1651  AGAGTAAGCA CCTGCTAAGG GTGGGACAGG GGCTCTGTCT GGTATGCCTC 
1701  TCCCATGTTA AGAGCTAACA ATAGTAATGG ATAAGTCTCC AGGGCAACCA 
1751  GGACCACTTC CAAGCATTCC TGTCTTGGGC TGCCTCGAGG GCTCCTCTGT 
1801  CCTTTGGGGA GTACTGATTG ATGCCTGATG CCCAGAACTG GCCCACTCTG 
1851  GCTTCTCTTT GGAGCTGTCT CTGCAGGCGC CTTCTGGCTG CCAGCTCGGT 
1901  CCTAGCATAA GGGACTTCTT CCTTGGCCTG GGTTTCACCT TCTTGTATCA 
1951  GGTGGCAGAC CAGCTGGTTT CAGTCCCAAA TCAGGTCTTC TGACTCCTCC 
2001  CAGAAACCAA CCAACTTCTG AGCAGGAAAT CCTGCCCCTC CCCAAAGAGT 
2051  GGGAAACCGC AAAGGAAGAG AGAGATGAAA CAGAAGGAAA GGCAGAGGAG 
2101  GAGGGAGAGA GAGAGAAGAG AAGAAAAAGA AAAAAGAACA TCAATAAAAA 
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2151  GAAGTCAGAT TTGTTCGAAA TCT CCCGGG 
                                XmaI                              
 
7.2.3 HSD11B1-Promoter 2 
Nucleotide sequence of HSD11B1-Promoter 2 including relevant restriction sites: 
 
      CCCGGG   
  XmaI 
   1  GAGAACCAGC CATGTAAATA TGGACACAAA GTGGATTAGA TGTTTATTAT 
  51  ATAATATGGT CAAAGTGTGG TCCCCATGGG TCTCTGAGAC CCTCTTGAAG 
 101  GGTTGAAAGG TCAAAACTAT TTTCATAATT ATACTAAGAC ATTACCTGAC 
 151  TTTTCCAGAG GCTACAGGAT GTATGCTAAT GCCACTGCCC TGAATGCTAA 
 201  TGGAATGTAT GCTTATGTAT TCTTGAGCTT TAGAAAAAAA TCCTCAGTCT 
 251  TAATTTCTAA TGCATAAATT GCAATAGCAA TATCAATAGG TAAAACCTAC 
 301  ACAGGCAAAA GTTCTTTGAG GTCCTTGGAA ATTATTAAGA GTATACAAGG 
 351  GTCCTGAGAC CAAAAATTTG AGAACTGGTA AGATTTAATG CATCAACTAC 
 401  CATTACACAG TGTCCTTGTT TCTCATCAAT GCATTTTATA TAGCAATTAT 
 451  TTTATCTAAT CCCATGAAAC TCACTTTATT GGATGCTTTT GCCATATCCT 
 501  TATTTTCTAG CATCGTAGCT ATTAGGTCAT CTAATTATTA ATCTGTTTGT 
 551  GTCTTTGGGT TTAAATGTGT CTTTTGAGGC CACACAATGT TGGACTTCAT 
 601  TTTTTAATGG AGCCAACAAT CAGCAATTGT TAATGCATTT GCTTTGTGTT 
 651  CTATTACTCT GCAGTTTATC TTACTCATTG TTATTTTTGC TTTCTTTAAA 
 701  TTTATGTTTT CTTAATGGAC TTTAAAATTC TTTATTTATT TTTTATGTCA 
 751  GACAATAAAC ATCCCTAGTC TGCCCATCTT TCTATCATTT CAACATCATC 
 801  ATATTTCCAA ATAACTTTTC ATTGTTTCCT ATAATTTTAC TATTAATAGT 
 851  ATAGGATTAA GAAAATAAAC CTTATCTGGG TTCTGGCTGG CACTGCCTTC 
 901  CCTCTAGGGA TGAAAATGGA GTGTAGTCTG TAATATATCC TGGTATCATA 
 951  AATATATTTA TAAAATTATA CAAATGTAGC TTGCAGTTCT AAAGGCATGT 
1001  AATCTAATTT TTACTTGAAT TTTATCTTTT TTCTCTTTTT GTCCTTCATA 
1051  GACCTCGAGC TCTGTCTAGC CCTCAACTGT TCTCAAATCT CCATTGTTTT 
1101  CTACAAGTGA CCCTCACAGC TGTGGGCCTT TGTTGACAAA TTGTTTCATC 
1151  TCCTCTGGGT CTTAAATTAT TTTCTCTTAC TCTAAAGTGA AAATTTGATG 
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1201  AATGTTTCCA GATACTGCAC TTGGAATCAT AACTTAATTT CCCTTAACCT 
1251  TGTGTAAATT CTGTCCCCCC ACTACTCCCA ACTCCTATCC CTCCTCCAAA 
1301  GCACTGATAC TTATTATCAC ATTTAAATTT TTTCCCCGCT CTACTGATAA 
1351  CTTACAGAAT GCAGGACTGC ATTGTGATGG GGTAATTTCC ATGAGTTGAT 
1401  TGGTTGGTTT TGAGTTGAAA AACTTAACAA TGATACATCT TAAATTCTTT 
1451  CTTTGAGGAT TATTCCTTAA TGAATTCGTG CTACGGACAT ACTGAGGTGG 
1501  TTATTTTTAT ATTTCCCTGA TAATAAATTC TAAATTGCTA AGGGTTTCTT 
1551  ACCACCCTCG TCCTTTTACT GTTACTAGAT CTATTTTTAG CTGGTGTGGG 
1601  CGTCCCCAGC TAGTTTCACT TGCCTAATGC TAGTTCTTTT TTCTTCTACA 
1651  TCAGGTCGCC TCTTCCTAGC ATCTTCTCCA TGTTTCTTGT TGCTCTACAG 
1701  CATTTACAAG ACCCAGTTTA ATAGTTTAGT GCCTTTTTTG TCACTCATTA 
1751  TTTCTTCTTT GTTCTCTGTT AAAATAATAA GTGTATGATC CATTGCACTT 
1801  GCCTTAGAGT CTTGAACCAG TCTTGGATTT CCCGCCATCT GGGTTCTGGC 
1851  TGGCTTGCAA TTTCTCCTTT GATGTTGTAA TACTTTTTCA TTGAACTTGA 
1901  GTGTGGGGCT TATAGAGCTT CTTTGCTTTC ATTATTTTTT CCCAAAATGT 
1951  GCACATTTTT TTTCTTAAGC TTATTTTGCT GTTTTGTGCT GTTATTTTTA 
2001  ATTGCTTCCC ACTGGGTGGG GGGGTAGGGG GACTGAGAGT GAGATTTGGC 
2051  TTGAGTTTGG CTCTCTTTGC TATTACTCAC ATTTCCCCCC AGAAGCCCTA 
2101  CATGCACTCC TCTCTCTCTG TCTTTGACAA ATTACTTTTG AAAGATCATT 
2151  GATCCCTGGC GTAAATGGTG TTAAGAGTAA GATGGACTCG GGTAGGGATG 
2201  CTCAGGAATC CAGTCCTGTA CAGTCATGAG CTTGGCCATC TGGAAGTCTC 
2251  CTCTTGCTCA ATGAAATGGA GTAAACATTG TCCATTATGA AATCCACCAC 
2301  ACAGGCTGCC AGGGACGAAT GGGATCCCAC CCAAAGCCAA TCGCTGCTCT 
2351  GACAGGGAAA TTGGCTAGCA CTGCCTGAGA CTACTCCAGC CTCCCCCGTC 
2401  CCTGATGTCA CAATTCAGAG GCTGCTGCCT GCTTAGGAGG TTGTAGAAAG 
2451  CTCTGTAGGT TCTCTCTGTG TGTCCTACAG GAGTCTTCAG GCCAGCTCCC 
2501  TGTCGG CCCGGG 
             XmaI                              
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7.3 Supplement data 
 
Table 1 (Figure 4.4) 
 
               Ratio  
(DNA/Lipofectamine)                                                                                    average ± SD  
1: 0.5                           Firefly  (RLU)       74157       82479     90053          82230 ± 7950.93 
                                    Renilla (RLU)        15326      18327     15013          16222 ± 1829.69 
                                    Ratio (F/R)              4.84         4.50        6.00                 5.11 ± 0.79           
1: 1                              Firefly  (RLU)      142895    167184    187583        165887 ± 22372.20 
                                    Renilla (RLU)        27201      30175      35654           31010 ± 4287.92 
                                    Ratio (F/R)              5.25         5.54          5.26                5.35 ± 0.16 
1: 2                              Firefly  (RLU)      376870    428718    458806        421465 ± 41446.78 
                                    Renilla (RLU)        80257      84526      93657        86146.67 ± 6845.43 
                                    Ratio (F/R)              4.70        5.07         4.90                   4.89 ± 0.19 
1: 3                              Firefly  (RLU)      646552    689104    733943        689866 ± 43700.49 
                                    Renilla (RLU)       138546    125864    143698         136036 ± 9178.12 
                                    Ratio (F/R)              4.67          5.47        5.11                  5.08 ± 0.40 
1: 5                              Firefly  (RLU)      437452    391625    445084        424720 ± 28914.32   
                                    Renilla (RLU)        78241      89654      84215           84036 ± 5708.59 
                                    Ratio (F/R)              5.59          4.37       5.29                   5.08 ± 0.64 
 
 
Note: F and R represent Firefly and Renilla. 
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Table 2 (Figure 4.5) 
 
 
               Ratio  
(DNA/Lipofectamine)                                                                                  average ± SD  
1: 0.5                          Firefly  (RLU)       45750     61486     59710           55649 ± 8618.37 
                                   Renilla (RLU)        26593     31231    28480           28768 ± 2332.37 
                                   Ratio (F/R)             1.72        1.97       2.10                 1.93 ± 0.19 
1: 1                             Firefly  (RLU)       154571  155997   114844          141804 ± 23358.93 
                                   Renilla (RLU)        77159    74553    65804             72505 ± 5948.00 
                                   Ratio (F/R)             2.00        2.09       1.75                  1.95 ± 0.18 
1: 2                             Firefly  (RLU)        376221  343759  334621         351534 ± 21862.62 
                                   Renilla (RLU)        171049  181581  177924          176851 ± 5347.31 
                                   Ratio (F/R)              2.20      1.89         1.88                 1.99 ± 0.18 
1: 3                             Firefly  (RLU)        289088 386458  307344           327630 ± 51757.81      
                                   Renilla (RLU)        153133  178129  157982            163081 ± 13255.28 
                                   Ratio (F/R)             1.89         2.17      1.95                  2.00 ± 0.15 
1: 5                             Firefly  (RLU)         245492 215857  184429           215259 ± 30535.89 
                                   Renilla (RLU)         109026  125384  108228            114213 ± 9682.88 
                                   Ratio (F/R)               2.25           1.72      1.70                  1.89 ± 0.31 
 
 
Note: F and R represent Firefly and Renilla. 
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Table 3 (Figure 4.6)                                                                                                                   
 
                                                                                                              Relative luciferase activity (%)   
                                                                                                                      n=1  average ± SD (n=3)* 
                                                                                                                                        (Figure 4.6A)     
no miRNA        Firefly  (RLU)     29267   32552  44423   42327   31768 
                          Renilla (RLU)       5345     6215    8634     8464     6554  
                          Ratio (F/R)             5.48      5.24     5.15      5.00     4.85   100          100 ± 3.26 
negative control Firefly  (RLU)   13820   12657  14282   14087   14127 
                          Renilla (RLU)      3105     2378     2845     2603    2709 
                          Ratio (F/R)            4.45      5.32      5.02      5.41     5.21   98.89       98.02 ± 11.88 
miR-561            Firefly  (RLU)     8956      9653    8697     9218    9475 
                          Renilla (RLU)      2305      2623    2507     2403    2825 
                          Ratio (F/R)            3.89      3.68     3.47     3.84     3.35     70.90       72.28 ± 6.69 
miR-579            Firefly  (RLU)     7015      6826    6932     6038   6398     
                          Renilla (RLU)      2628      2417   2098     1925    1764 
                          Ratio (F/R)           2.67      2.82     3.30      3.14      3.63     60.53      57.34 ± 4.04 
miR-181b          Firefly  (RLU)    13026   12036  13102   12761  10019 
                          Renilla (RLU)      3125      2735   3630     2105    1996 
                          Ratio (F/R)           4.17       4.40    3.61      6.06     5.02       90.48      87.61 ± 4.98 
miR-340            Firefly  (RLU)     6863     6674    5454     6458    6455    
                          Renilla (RLU)     2063     1877     1539    1827    2683 
                          Ratio (F/R)          3.33      3.56     3.54      3.53     2.41       63.67       56.57 ± 2.58 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                       (Figure 4.6B)     
no miRNA       Firefly  (RLU)        8032  11527 11030 10085 8904 
                         Renilla (RLU)        3595  4928   5308    5325  5515 
                         Ratio (F/R)             2.23   2.34    2.08    1.89    1.61         100             100 ± 4.52 
negative control Firefly  (RLU)      8979  11091  15226  15883 14589   
                         Renilla (RLU)        4728   5437    8346   7517   6456     
                         Ratio (F/R)             1.90    2.04     1.82    2.11    2.26      99.77           96.32 ± 7.46 
miR-561          Firefly  (RLU)         7356   6229   6396  6969  6436 
                         Renilla (RLU)         5409  4456   4014   4607  4997 
                         Ratio (F/R)              1.36   1.40    1.59   1.51   1.29         70.40           77.74 ± 11.07 
miR-579           Firefly  (RLU)        2730   2199  3856  2287  2508  
                         Renilla (RLU)         2281   2093  3546  2185  2004 
                         Ratio (F/R)              1.20    1.05   1.09    1.05   1.25        55.45          59.73 ± 3.29 
miR-181b          Firefly  (RLU)        8265  6544  7912  5583  9337 
                         Renilla (RLU)         4597  2993  4573  2809  4518 
                         Ratio (F/R)              1.80    2.19   1.73  1.99   2.07          96.15          92.70 ± 13.12 
miR-340           Firefly  (RLU)         6166   5428  4300  3754  6365 
                         Renilla (RLU)         5074   4954   3622  2239  5363 
                         Ratio (F/R)              1.22    1.10   1.19   1.68   1.19         62.62           60.15 ± 15.06 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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Table 4 (Figure 4.8)                                                                                                                   
 
                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                       (Figure 4.8A)    
UTR, WT         Firefly  (RLU)   36602  33074  33509  36953  40859    
                         Renilla (RLU)    3365    3968    3793    3369    3455     
                         Ratio (F/R)         10.88    8.34     8.83   10.97   11.83        100            100 ± 4.69 
UTR, WT         Firefly  (RLU)   13397  12650   9569   8840    9672 
+ miR-561        Renilla (RLU)    1817    1721    1253   1281   1013  
                         Ratio (F/R)          7.37     7.35     7.64    6.90    9.55          76.33         78.91 ± 1.74 
561-del             Firefly  (RLU)    96590  88866  84949 53948  59675 
                         Renilla (RLU)     9121    9767    7778   5674    6103 
                         Ratio (F/R)          10.59    9.10     10.92   9.51    9.78         100            100 ± 7.42 
561-del             Firefly  (RLU)    38876  31450   27758  28834  26800 
+ miR-561        Renilla (RLU)    3757    3102      2281    3049    2292   
                         Ratio (F/R)         10.35    10.14    12.17   9.46     11.69     107.83      106.29 ± 6.99 
561-mut            Firefly  (RLU)  122023  141200  132882  112010  120372 
                         Renilla (RLU)   11793    14512     12331    10903   12825      
                         Ratio (F/R)        10.35      9.73      10.78     10.27      9.39    100           100 ± 5.91 
561-mut            Firefly  (RLU)   67171    56991    57909    53414   61990 
+ miR-561        Renilla (RLU)    6764     5429       5717      5468     7576 
                         Ratio (F/R)          9.93     10.50      10.13      9.77      8.18     96.03      96.24 ± 1.39 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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                                                                                                            Relative luciferase activity (%)   
                                                                                                                    n=1  average ± SD (n=3)* 
                                                                                                                                      (Figure 4.8B)     
UTR, WT         Firefly  (RLU)     30954  38393  28572  44908  39541   
                         Renilla (RLU)      3243    3598    2897    4576   4063   
                         Ratio (F/R)            9.54    10.67   9.86     9.81    9.73        100          100 ± 5.36 
UTR, WT         Firefly  (RLU)     5416   7715   11074   10388  11046 
+ miR-579        Renilla (RLU)     1039   1247     1770     1641   1874  
                         Ratio (F/R)           5.21   6.19      6.26      6.33    5.89        60.21      57.93 ± 8.25 
579-del             Firefly  (RLU)    90968  86902  80265  107027 89725    
                         Renilla (RLU)     8079     8602    7424     8176    9060    
                         Ratio (F/R)           11.26   10.10    10.81   13.09   9.90        100          100 ± 2.69 
579-del             Firefly  (RLU)     40453  43805  37615   40932  45383 
+ miR-579       Renilla (RLU)      3853    3585    3395     3866    3948  
                         Ratio (F/R)          10.50   12.22   11.08    10.59   11.50       101.29   105.98 ± 6.69 
579-mut            Firefly  (RLU)    133394  116429  100704  118749  104513 
                         Renilla (RLU)     12627    11666     9037     9931     9400 
                         Ratio (F/R)           10.56      9.98     11.14    11.96    11.12     100        100 ± 8.26 
579-mut            Firefly  (RLU)    62339   56523  46612  51807  56134  
+ miR-579        Renilla (RLU)      5428     4972    4830    5362   4834   
                         Ratio (F/R)            11.48   11.37    9.65     9.66   11.61          98.20     100.78 ± 3.30 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                       (Figure 4.8C)     
UTR, WT         Firefly  (RLU)      35812  33460  25750  25438 28241  
                         Renilla (RLU)       3482    3017    2890    2428   2625 
                         Ratio (F/R)           10.28    11.09    8.91   10.48  10.76      100             100 ± 7.32  
UTR, WT         Firefly  (RLU)      6863    6674    5454   6458   6455 
+ miR-340       Renilla (RLU)       1056     1277   1078   1127   1036 
                         Ratio (F/R)            6.50      5.23     5.06   5.73    6.23         55.79        56.57 ± 2.58 
340-del             Firefly  (RLU)      63194  47407  60647  48888  34429   
                         Renilla (RLU)       5279    4245     4706   4588    2853 
                         Ratio (F/R)           11.97    11.17   12.89  10.66   12.07       100          100 ± 3.67 
340-del             Firefly  (RLU)      12499  16751  11508  9532  12999   
+ miR-340        Renilla (RLU)      1292   1497      944    1054   1102   
                         Ratio (F/R)            9.67   11.19    12.19   9.04   11.80        91.74        86.22 ± 6.32 
340-mut            Firefly  (RLU)      28185  20701  21438  16782  16741  
                         Renilla (RLU)        2820   1711     2324   1343    1624 
                         Ratio (F/R)             9.99    12.10    9.22    12.50   10.31      100          100 ± 4.17 
340-mut            Firefly  (RLU)      11510    9377    9839    9208    8481 
+ miR-340        Renilla (RLU)        1270     1007   1188     1217    921   
                         Ratio (F/R)              9.06      9.31    8.28     7.57     9.21       80.25       75.33 ± 9.69 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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Table 5 (Figure 4.9)                                                                                                                   
 
                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                     (Figure 4.9A)      
UTR, WT         Firefly  (RLU)     4567   2163   2277   2999   3017  
                         Renilla (RLU)     1571    920    1032   1204   1382 
                         Ratio (F/R)           2.91    2.35    2.21    2.49   2.18           100             100 ± 9.12  
UTR, WT         Firefly  (RLU)    2852    3537   4375   2283   4507 
+ miR-561       Renilla (RLU)     1504    1768    2496  1192   2229 
                         Ratio (F/R)          1.90     2.00    1.75   1.92     2.02          78.98         83.11 ± 6.11 
561-del             Firefly  (RLU)     4610   5394   7116   5060   3243   
                         Renilla (RLU)     2505   2122    2503   1770   1359 
                         Ratio (F/R)          1.84    2.54      2.84    2.86    2.39         100            100 ± 4.36 
561-del             Firefly  (RLU)     5745   6568   5670   6881   4845  
+ miR-561       Renilla (RLU)      1876   3423    1876  2193   1910     
                         Ratio (F/R)           3.06   1.92      3.02   3.14    2.54          109.68      112.85 ± 33.01 
561-mut           Firefly  (RLU)      4595   4726    3025   3493   2693  
                         Renilla (RLU)      1797   1910    1379   1373   1016       
                         Ratio (F/R)            2.56    2.47     2.19   2.54    2.65          100             100 ± 5.17 
561-mut            Firefly  (RLU)     5387    3709    6357   5142   3314     
+ miR-561        Renilla (RLU)      2648   1508    1912   2432   1384    
                         Ratio (F/R)            2.03    2.46     3.32   2.11     2.39         99.26         92.08 ± 8.26 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 147
 
                                                                                                            Relative luciferase activity (%)   
                                                                                                                  n=1    average ± SD (n=3)* 
                                                                                                                                      (Figure 4.9B)     
UTR, WT         Firefly  (RLU)     6436   5076   3688   2621   2339 
                         Renilla (RLU)      2506   1988   1926   1312   1119  
                         Ratio (F/R)           2.57     2.55    1.91   2.00    2.09         100         100 ± 7.64 
UTR, WT         Firefly  (RLU)     1761    1634   1937   1365  1875 
+ miR-579       Renilla (RLU)      1436    1383   1648    1345  1019 
                         Ratio (F/R)          1.23     1.18    1.18    1.01    1.84         57.87      60.64 ± 10.80 
579-del             Firefly  (RLU)     2395   2423   1387   2542   2463  
                         Renilla (RLU)     1194   1206    821   1061   1032 
                         Ratio (F/R)            2.01    2.01    1.69   2.40   2.39          100          100 ± 5.27  
579-del             Firefly  (RLU)     2857   3597    2840   2963   3453 
+ miR-579       Renilla (RLU)      1422   1867    1271   1057   1623 
                         Ratio (F/R)            2.01   1.93     2.23    2.80    2.13       105.86     103.12 ± 23.57 
579-mut           Firefly  (RLU)      5387   3709   6357   5142   3314 
                         Renilla (RLU)      2648   1508   3912   2432   1384 
                         Ratio (F/R)           2.03   2.46    1.62    2.11     2.39        100          100 ± 9.04  
579-mut            Firefly  (RLU)      2472   3028   1928   1693   3542    
+ miR-579        Renilla (RLU)      1420   1346    961     771   1879   
                         Ratio (F/R)            1.74     2.25    2.01    2.20   1.89          94.82      96.62 ± 17.62 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                  n=1    average ± SD (n=3)*  
                                                                                                                                   (Figure 4.9C)         
UTR, WT         Firefly  (RLU)     4084   4460  4683  4933  4380  
                         Renilla (RLU)     1719   1999   1919  2140  1963 
                         Ratio (F/R)           2.38    2.23    2.44  2.31   2.23           100           100 ± 3.27 
UTR, WT         Firefly  (RLU)     2111   2404   1875  1924  1698 
+ miR-340       Renilla (RLU)      1789   1928   1297  1391  1154 
                         Ratio (F/R)           1.18    1.25    1.45   1.38   1.47          58.07       60.01 ± 10.88 
340-del             Firefly  (RLU)      6880  7041   10255  8711  7910  
                         Renilla (RLU)      3398  3324    4651   3565   3369 
                         Ratio (F/R)           2.02   2.12     2.20    2.44   2.35         100           100 ± 5.89 
340-del             Firefly  (RLU)      5415   4588   4968   4906   3975 
+ miR-340       Renilla (RLU)       2974   2209   2521   2386   2069 
                         Ratio (F/R)           1.82    2.08    1.97    2.06    1.92        88.39         85.93 ± 6.14 
340-mut            Firefly  (RLU)      6491   6982   6552   6742   6644  
                         Renilla (RLU)       3365   3440   2837   3244   2854 
                         Ratio (F/R)            1.93    2.03    2.31   2.08    2.33        100           100 ± 8.14 
340-mut            Firefly  (RLU)      3548   3508   3281   2874   3044 
+ miR-340        Renilla (RLU)       2002   2221   1741   2213   1740    
                         Ratio (F/R)            1.77    1.58    1.88    1.30    1.75        77.61        74.31 ± 1.37 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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Table 6 (Figure 4.10)                                                                                                                   
 
                                                                                                            Relative luciferase activity (%)   
                                                                                                                  n=1    average ± SD (n=3)* 
                                                                                                                                    (Figure 4.10A)     
pmir-GLO        Firefly  (RLU)     8421   9014   9672   9115   10372   
                         Renilla (RLU)      5455   4833   5862   5808   6641  
                         Ratio (F/R)           1.54    1.87    1.65    1.57    1.56        100              100 ± 3.25 
pmir-UTR       Firefly  (RLU)       6370   7310   7477   7552   7732  
                        Renilla (RLU)       4404    4962   4638  4554   5121 
                         Ratio (F/R)            1.45    1.47    1.61   1.66    1.51        94.01           95.47 ± 6.23 
pmir-GLO        Firefly  (RLU)      8547   8230   9566   8191  9304 
+ miR-561        Renilla (RLU)      5345   4923   5463   5744  5735    
                         Ratio (F/R)            1.60    1.67   1.75    1.43    1.62         98.54           95.18 ± 5.08 
pmir-UTR        Firefly  (RLU)      3504   3673   3691   3744   3502   
+ miR-561       Renilla (RLU)       2758   3092   3496   3084   2923   
                         Ratio (F/R)            1.27    1.19    1.06    1.21   1.20         72.36           68.08 ± 4.52 
 
 
                                                                                                            Relative luciferase activity (%)   
                                                                                                                   n=1   average ± SD (n=3)* 
                                                                                                                                     (Figure 4.10B)    
pmir-GLO        Firefly  (RLU)      10635   10444   9589  9401  10168  
                         Renilla (RLU)       5358    5178     5314  5219   5137 
                         Ratio (F/R)            1.98      2.02     1.80    1.80   1.98       100            100 ± 3.25 
pmir-UTR        Firefly  (RLU)       5713    7885    3613    5224  4961 
                         Renilla (RLU)       3062     4106   1821    2627   2853  
                         Ratio (F/R)             1.87     1.92    1.98     1.99   1.74        99.07        99.41 ± 5.03 
pmir-GLO        Firefly  (RLU)       8420    10259  10176  9183   9213 
+ miR-579       Renilla (RLU)        4214     5180    5898   5110   5196 
                         Ratio (F/R)             2.00      1.98    1.73    1.80     1.77      96.74        98.68 ± 5.91 
pmir-UTR        Firefly  (RLU)       1590     2360    2660   2625    2630   
+ miR-579       Renilla (RLU)        1362     1953    2303   2484    2340         
                         Ratio (F/R)             1.17     1.21      1.16    1.06     1.12     59.58         55.15 ± 6.79 
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                                                                                                            Relative luciferase activity (%)   
                                                                                                                    n=1  average ± SD (n=3)* 
                                                                                                                                      (Figure 4.10C)   
pmir-GLO        Firefly  (RLU)      11421   13144   9672   9511   10372 
                         Renilla (RLU)       6453     7833    6162   5808    6641 
                         Ratio (F/R)            1.77       1.68    1.57    1.64     1.56       100          100 ± 4.99 
pmir-UTR       Firefly  (RLU)        6370     8310    7477   8552    9732 
                         Renilla (RLU)       4404     5262    4638   5154    6121 
                         Ratio (F/R)            1.45     1.58      1.61     1.66     1.59       95.99        95.47 ± 6.23 
pmir-GLO        Firefly  (RLU)       8925     7585   8711    8431    8825 
+ miR-340       Renilla (RLU)        6748     5925   6317    5938    6453 
                         Ratio (F/R)            1.32      1.28     1.38    1.42     1.37       82.38        78.45 ± 4.38  
pmir-UTR        Firefly  (RLU)        4321    5263    4574   3973    5042  
+ miR-340       Renilla (RLU)         4549    5071    4792   5312    5307 
                         Ratio (F/R)              0.95     1.04     0.95    0.75     0.95      56.47       53.89 ±  3.85 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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Table 7 (Figure 4.17)                                                                                                                   
 
                                                                                                             Relative luciferase activity (%)   
                                                                                                                   n=1    average ± SD (n=3)*  
Pmir-P1                Firefly  (RLU)       565       365    560     628     745   
                             Renilla (RLU)      3052    2305  2584   2768   2632  
                             Ratio (F/R)            0.19    0.16   0.22     0.23    0.28     100        100 ± 8.36 
Pmir-P1                Firefly  (RLU)       901     871     982      805     765 
+ Dexmethasone  Renilla (RLU)      4156    4212   5005   3921   3400 
                             Ratio (F/R)            0.22    0.21     0.20    0.21    0.23    98.13      96.85 ± 2.94 
Pmir-P1               Firefly  (RLU)       699      584     756      852     862       
+ Cortisol            Renilla (RLU)       3658   2904    3773    3944   4066 
                            Ratio (F/R)              0.19   0.20    0.20     0.22    0.21    95.37       93.43 ± 4.96 
Pmir-P2               Firefly  (RLU)        675     950     764      752      756 
                             Renilla (RLU)      2287   2778    2506    2871    3578    
                             Ratio (F/R)            0.30     0.34   0.30     0.26     0.21    100        100 ± 5.23 
Pmir-P2               Firefly  (RLU)      1784   1534    1687    1619    1894  
 + Dexmethasone Renilla (RLU)      4319   4094    4245    4410    3930      
                             Ratio (F/R)           0.41    0.37     0.40     0.37     0.48     143.74    140.71 ± 6.36 
Pmir-P2                Firefly  (RLU)     1454    1408   1551     2336    1626 
+ Cortisol             Renilla (RLU)      4360    3071   3672    5084    3905     
                             Ratio (F/R)            0.33     0.46    0.42     0.46     0.42    147.70     143.58 ± 3.55 
 
 
n=2 and n=3 are not shown. 
     Note: F and R represent Firefly and Renilla. 
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Table 8 (Figure 4.18)                                                                                                                   
 
                                                                                                             Relative luciferase activity (%)  
                                                                                                                   n=1    average ± SD (n=3)* 
                                                                                                                                     (Figure 4.18A)    
Control                 Firefly  (RLU)       796     714     838     735     703   
                             Renilla (RLU)      3728   3148   3474    3289   2922 
                             Ratio (F/R)            0.21     0.23   0.24    0.22    0.24      100           100 ± 7.64  
miR-579               Firefly  (RLU)        221     311      461     463    382 
                             Renilla (RLU)       1983   2841    3543  3200   2201 
                             Ratio (F/R)            0.11    0.11     0.13    0.14   0.17      58.42         54.62 ± 6.36 
Dex                       Firefly  (RLU)      1965    2421    3229   2391  3518 
                             Renilla (RLU)      5571    7136    8947   6435  8864 
                             Ratio (F/R)           0.35     0.34     0.36    0.37  0.40      158.98        159.13 ± 8.53 
miR-579/Dex        Firefly  (RLU)    1513     1386   1455   1606   1959    
                              Renilla (RLU)     5841     6561   6147   7108   7071 
                              Ratio (F/R)           0.26     0.211   0.24   0.23   0.28     105.62        108.09 ± 9.92 
 
 
                                                                                                             Relative luciferase activity (%)   
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                      (Figure 4.18B)    
Control                 Firefly  (RLU)        888    728    955    918     892   
                             Renilla (RLU)       3499  2727  2969  2584   3833 
                             Ratio (F/R)             0.25   0.27   0.32   0.36   0.23        100           100 ± 8.31 
miR-579               Firefly  (RLU)        434    509    525    512     408 
                             Renilla (RLU)       2669   3534  3084  3479   2110 
                             Ratio (F/R)             0.16   0.14    0.17   0.15   0.19        57.15       56.49 ± 10.21 
Cortisol                Firefly  (RLU)        1858   1740   1969   2013  2045 
                             Renilla (RLU)        4587    4296   4473  4466  4502 
                             Ratio (F/R)             0.41     0.41    0.44   0.45    0.45    150.68      148.95 ± 13.75 
miR-579/Cortisol  Firefly  (RLU)      1182    1833    1176   1551   1775 
                              Renilla (RLU)       4333    5421    4506   4832   6557 
                              Ratio (F/R)            0.27     0.34    0.26     0.32    0.27    102.32     105.46 ± 6.39 
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n=2 and n=3 are not shown.     Note: F and R represent Firefly and Renilla. 
 
                                                                                                              Relative luciferase activity (%)   
                                                                                                                    n=1   average  ± SD (n=3)* 
                                                                                                                                       (Figure 4.18C)    
Control                 Firefly  (RLU)    1410    1867   2371   2414   2203   
                             Renilla (RLU)     6713    8340   8473   8202   8032 
                             Ratio (F/R)           0.21    0.22    0.28    0.29    0.27           100            100 ± 4.26   
miR-561               Firefly  (RLU)     1074    1597   1078   1358  1931   
                             Renilla (RLU)      5101    7860   6659   6888  8991 
                             Ratio (F/R)           0.21     0.20     0.16   0.20   0.21           77.01          74.66 ± 4.03 
Dex                       Firefly  (RLU)     4998     4374     4526    5739   5771    
                             Renilla (RLU)     12133   11902  12019  13748  14299 
                             Ratio (F/R)            0.41       0.37    0.38     0.42      0.40    154.18    158.40 ± 13.02 
miR-561/Dex        Firefly  (RLU)    3352      4247     4846     5310    4604   
                              Renilla (RLU)    9138     12231   11994   13202  12799 
                              Ratio (F/R)          0.37      0.35      0.40      0.40     0.36     146.61   143.34 ± 10.46 
                                                                                                              Relative luciferase activity (%)   
                                                                                                                    n=1   average  ± SD (n=3)* 
                                                                                                                                      (Figure 4.18D)     
Control                 Firefly  (RLU)     1240    1548    1657   1390   1459  
                             Renilla (RLU)      4655    5603    5777   4399   4205 
                             Ratio (F/R)           0.27     0.28      0.29   0.32    0.35     100          100 ± 9.36 
miR-561               Firefly  (RLU)      702      671       709     682     763 
                             Renilla (RLU)      2875    3034    3110   2748   3312 
                             Ratio (F/R)           0.24      0.22     0.23    0.25   0.23     78.52       77.99 ± 10.35 
Cortisol                Firefly  (RLU)      4785    4333    5294    3603   4816 
                             Renilla (RLU)      9899    9958     9553   8599   9447 
                             Ratio (F/R)           0.48     0.44      0.55    0.42    0.51    160.91      156.28 ± 7.11 
miR-561/Cortisol  Firefly  (RLU)    3942     4002    4892   3857   3913 
                              Renilla (RLU)     8679    9097    10750  9011   9027 
                              Ratio (F/R)          0.45     0.44      0.46    0.43    0.43    148.13    145.67 ± 14.76 
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Table 9 (Figure 4.19)                                                                                                                   
 
                                                                                                            Relative luciferase activity (%)   
                                                                                                                   n=1   average ± SD (n=3)* 
                                                                                                                                     (Figure 4.19A)    
Control             Firefly  (RLU)      960      935    1034     831    901    
                         Renilla (RLU)     5519    5846    5749   5157  5205 
                         Ratio (F/R)           0.17    0.16      0.18   0.16    0.17         100           100 ± 3.57 
TNFalpha         Firefly  (RLU)      939     1078    1041     981    983 
                         Renilla (RLU)     5038    6609    6074   5885   5991  
                         Ratio (F/R)           0.19     0.16     0.17   0.17    0.16        100.43       108.21 ± 7.62 
Insulin              Firefly  (RLU)      871      809     1011     907    1102 
                         Renilla (RLU)      5593   5474     6089   5622    6593 
                         Ratio (F/R)           0.16     0.15    0.17     0.16     0.17       94.11         96.34 ± 10.74 
Leptin              Firefly  (RLU)      794       908     1096    932      933 
                         Renilla (RLU)     4922    5083     6524   5170    5077 
                         Ratio (F/R)           0.16    0.18      0.17     0.18    0.18      102.83        102.33 ± 5.72 
Resistin            Firefly  (RLU)      837    1072        803    1096     948 
                         Renilla (RLU)     5405    6172      5088    6284   5124   
                         Ratio (F/R)           0.15     0.17      0.16      0.17    0.19     99.74          106.67 ± 8.63 
Adiponectin      Firefly  (RLU)     846     948        824      873      855    
                         Renilla (RLU)      5314   5350      4676    5217    4925        
                         Ratio (F/R)          0.16     0.18      0.18      0.17     0.17     100.66         99.01 ± 7.78 
 
      
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                   n=1    average ± SD (n=3)* 
                                                                                                                                     (Figure 4.19B)     
Control             Firefly  (RLU)       996     865    792    1001     779 
                         Renilla (RLU)     5069    5086   4269   4661   4195 
                         Ratio (F/R)            0.20   0.17     0.19   0.21     0.19        100            100 ± 5.06 
Retinoic acid    Firefly  (RLU)      846      961    971     899      867 
                         Renilla (RLU)      4308   4806   5148   5151   5031 
                         Ratio (F/R)            0.20    0.20   0.19    0.17    0.17        97.82         95.33 ± 7.49 
WY14643        Firefly  (RLU)       810     916     720      797     985    
                         Renilla (RLU)      4653   5397   4070    4413   5488   
                         Ratio (F/R)            0.17    0.17    0.18    0.18    0.18       92.47         94.17 ± 9.61 
Vitamin D3       Firefly  (RLU)      966     809     903     1069    982 
                         Renilla (RLU)      5061   4093    5094   4978   4529    
                         Ratio (F/R)            0.19    0.20    0.18    0.21   0.22        104.71       106.04 ± 11.66 
Ciglitazone      Firefly  (RLU)        731     730     759     1145    910 
                         Renilla (RLU)       4228   3710   4424    5350   4017   
                         Ratio (F/R)             0.17    0.20    0.17    0.21     0.23     103.07        99.47 ± 5.77 
Trichostatin A  Firefly  (RLU)       904      867    767       914     995 
                         Renilla (RLU)       4154    4741  4617     5347   4845   
                         Ratio (F/R)             0.22    0.18     0.17    0.17    0.21       98.99        95.74 ± 14.76 
Estradiol           Firefly  (RLU)       917     1083    1079    916    1085 
                         Renilla (RLU)       4226    5862    4784   4574   5842 
                         Ratio (F/R)             0.22    0.18      0.23    0.20    0.19      106.37      104.69 ± 6.43 
 
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
 
 
 
 
 
 
 
 
 
Appendix 
 156
 
                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                      (Figure 4.19C)    
Control             Firefly  (RLU)      733    1063    1012     636     851  
                         Renilla (RLU)      5050   6710    6907   5016   6492  
                         Ratio (F/R)            0.15    0.16    0.15     0.13    0.13           100          100 ± 6.02 
TNFalpha         Firefly  (RLU)     1024     820    1011     863    1070 
                         Renilla (RLU)      6393   6429    6289    6286   7314 
                         Ratio (F/R)            0.16    0.13    0.16      0.14   0.15         103.40       110.13 ± 8.72 
Insulin              Firefly  (RLU)      1016     951    1156    1102   1055 
                         Renilla (RLU)       6372    7427   7627    6846   7702 
                         Ratio (F/R)             0.16    0.13     0.15    0.16    0.14        104.10       93.33 ± 12.97 
Leptin              Firefly  (RLU)       696      883     1117     900      969  
                         Renilla (RLU)      5685    6576    7307    5942    6952 
                         Ratio (F/R)            0.12     0.13     0.15    0.15     0.14        98.93        108.22 ± 6.43 
Resistin            Firefly  (RLU)       692      629      929      848      750 
                         Renilla (RLU)      5042    5087    7024    6389    5258 
                         Ratio (F/R)           0.14      0.12     0.13    0.13     0.14         94.43        99.45 ± 8.87 
Adiponectin      Firefly  (RLU)      800      831       887      930     585 
                         Renilla (RLU)      5718    5814     5815    6429    4278  
                         Ratio (F/R)           0.14     0.14      0.15    0.14      0.14        101.24      103.67 ± 4.95 
 
 
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                    n=1   average ± SD (n=3)* 
                                                                                                                                     (Figure 4.19D)    
Control             Firefly  (RLU)      865     965      960    928    1045 
                         Renilla (RLU)     4552   4305    4584   4768   4632   
                         Ratio (F/R)            0.19   0.22     0.21    0.19    0.23          100           100 ± 8.23  
Retinoic acid    Firefly  (RLU)      977      828     1033    865    1175 
                         Renilla (RLU)      4889   4303     5298   4734   5341  
                         Ratio (F/R)            0.20    0.19     0.19    0.18    0.22          94.84         92.65 ± 11.84 
WY14643        Firefly  (RLU)      1016     998      897     1096    938 
                         Renilla (RLU)      5061    4683    5084    5235  5271 
                         Ratio (F/R)            0.20     0.21     0.18    0.21   0.18          93.66         96.58 ± 6.87  
Vitamin D3       Firefly  (RLU)     928     1122     979      925     1008 
                         Renilla (RLU)     4219     5149    4563    4486   4235 
                         Ratio (F/R)          0.22      0.22     0.21     0.21    0.24        105.06       107.34 ± 9.68 
Ciglitazone      Firefly  (RLU)     1074     977     1248       981      914 
                         Renilla (RLU)     5044    4584     5129    4830    3758 
                         Ratio (F/R)          0.21    0.21      0.24     0.20     0.24         106.88       105.39 ± 5.86  
Trichostatin A  Firefly  (RLU)      924     1232    1068      958    1290 
                         Renilla (RLU)     4569     5763    5260    5629    5500   
                         Ratio (F/R)           0.20     0.21      0.20     0.17     0.23        98.08        96.47 ± 8.76 
Estradiol           Firefly  (RLU)    1128      954     1062      924     1028   
                         Renilla (RLU)      4951    5009    4330      4383    5550   
                         Ratio (F/R)           0.23      0.19     0.25       0.21    0.19       101.51     104.33 ± 5.64 
 
 
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
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Table 10 (Figure 4.21)                                                                                                                   
 
                                                                                                            Relative luciferase activity (%)   
                                                                                                                  n=1    average ± SD (n=3)* 
                                                                                                                                    (Figure 4.21A)     
Control            Firefly  (RLU)     11532  10776  13521  9355  13768  
                         Renilla (RLU)       2540    2066    2429   2176  3119 
                         Ratio (F/R)             4.54     5.22    5.57    4.30   4.41        100           100 ± 14.92  
miR-579           Firefly  (RLU)      4179    4291    4687   5151   3251 
                         Renilla (RLU)       1423   1554     1412   1590   1534 
                         Ratio (F/R)             2.94    2.76      3.32    3.24    2.12      59.81         57.53 ± 10.03 
miR-579           Firefly  (RLU)     5016    6673     6564    6190   6829     
/AMO-579       Renilla (RLU)      1234    1430     1584    1401   1553  
                         Ratio (F/R)            4.06     4.67      4.14    4.39    4.40      90.13         90.00 ± 13.29 
AMO-579         Firefly  (RLU)     7097   8352     7787    6968   7514 
                         Renilla (RLU)      1283   1347     1280    1330   1419 
                         Ratio (F/R)            5.53    6.20     6.08     5.24    5.30       117.95        121.69 ± 8.25 
DNA-579         Firefly  (RLU)      7852   11355   8842   8843   7656 
                         Renilla (RLU)      1870   2332    1862   1893   1575 
                         Ratio (F/R)            4.20    4.87     4.75    4.67    4.86         97.14        99.43 ± 15.40 
 
 
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
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                                                                                                             Relative luciferase activity (%)  
                                                                                                                   n=1    average ± SD (n=3)* 
                                                                                                                                      (Figure 4.21B)    
Control             Firefly  (RLU)     48303  55435  61226 33861  59928 
                         Renilla (RLU)      7979     8008    8717   6827   8593   
                         Ratio (F/R)           6.05      6.92     7.02    4.96    6.97        100          100 ± 5.71 
miR-561           Firefly  (RLU)    18129   8733   13463   17573  14702   
                         Renilla (RLU)     3870   1798     2729     3358    3296 
                         Ratio (F/R)           4.68    4.86     4.93      5.23     4.46       75.68        75.57 ± 4.59 
miR-561           Firefly  (RLU)    14083   14727  15274  13583  14149    
/AMO-561       Renilla (RLU)      2383    2689     2332    2243    2560 
                         Ratio (F/R)           5.91     5.48       6.55    6.06     5.53      92.44       95.46 ± 5.53 
AMO-561         Firefly  (RLU)     46106  47122  42466  40306  39517  
                         Renilla (RLU)      6074     6593    5580    5436    5040 
                          Ratio (F/R)           7.59     7.15      7.61    7.41     7.84       117.75      120.87 ± 5.53 
DNA-561         Firefly  (RLU)      28705  20276  29041 17458   35180 
                         Renilla (RLU)       4517    3565    4230   3373     5104   
                         Ratio (F/R)            6.35      5.69    6.87    5.18       6.89      97.00      104. 99 ± 4.34 
 
 
      n=2 and n=3 are not shown.      
     Note: F and R represent Firefly and Renilla. 
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